

Form **990**

Return of Organization Exempt From Income Tax

OMB No. 1545-0047

Under section 501(c), 527, or 4947(a)(1) of the Internal Revenue Code (except private foundations)

2022

Do not enter social security numbers on this form as it may be made public.

Open to Public Inspection

Department of the Treasury
Internal Revenue Service

Go to www.irs.gov/Form990 for instructions and the latest information.

A For the **2022** calendar year, or tax year beginning **APR 1, 2022** and ending **MAR 31, 2023**

B Check if applicable: Address change Name change Initial return Final return/terminated Amended return Application pending	C Name of organization BRIGHTFOCUS FOUNDATION		D Employer identification number 23-7337229	
	Doing business as		E Telephone number (301) 948-3244	
	Number and street (or P.O. box if mail is not delivered to street address)	Room/suite	G Gross receipts \$ 59,269,829.	
	22512 GATEWAY CENTER DRIVE		H(a) Is this a group return for subordinates? Yes <input checked="" type="checkbox"/> No	
City or town, state or province, country, and ZIP or foreign postal code CLARKSBURG, MD 20871		H(b) Are all subordinates included? Yes No		
F Name and address of principal officer: STACY PAGOS HALLER SAME AS C ABOVE		If "No," attach a list. See instructions		
I Tax-exempt status: <input checked="" type="checkbox"/> 501(c)(3) 501(c) () (insert no.) 4947(a)(1) or 527				
J Website: WWW.BRIGHTFOCUS.ORG				
K Form of organization: <input checked="" type="checkbox"/> Corporation Trust Association Other				
L Year of formation: 1973			M State of legal domicile: DC	

Part I Summary

Activities & Governance	1 Briefly describe the organization's mission or most significant activities: BRIGHTFOCUS FOUNDATION (BRIGHTFOCUS) SEEKS A WORLD FREE FROM DISEASES OF MIND AND SIGHT.		
	2 Check this box if the organization discontinued its operations or disposed of more than 25% of its net assets.		
	3 Number of voting members of the governing body (Part VI, line 1a)	3	10
	4 Number of independent voting members of the governing body (Part VI, line 1b)	4	10
	5 Total number of individuals employed in calendar year 2022 (Part V, line 2a)	5	68
	6 Total number of volunteers (estimate if necessary)	6	60
	7 a Total unrelated business revenue from Part VIII, column (C), line 12	7a	0.
b Net unrelated business taxable income from Form 990-T, Part I, line 11	7b	0.	
Revenue	8 Contributions and grants (Part VIII, line 1h)	Prior Year	Current Year
	9 Program service revenue (Part VIII, line 2g)	46,522,410.	43,451,535.
	10 Investment income (Part VIII, column (A), lines 3, 4, and 7d)	0.	0.
	11 Other revenue (Part VIII, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e)	3,244,235.	-268,284.
	12 Total revenue - add lines 8 through 11 (must equal Part VIII, column (A), line 12)	991,083.	710,546.
		50,757,728.	43,893,797.
Expenses	13 Grants and similar amounts paid (Part IX, column (A), lines 1-3)	23,651,211.	14,321,603.
	14 Benefits paid to or for members (Part IX, column (A), line 4)	0.	0.
	15 Salaries, other compensation, employee benefits (Part IX, column (A), lines 5-10)	5,534,304.	6,392,782.
	16a Professional fundraising fees (Part IX, column (A), line 11e)	798,203.	942,971.
	b Total fundraising expenses (Part IX, column (D), line 25)	11,417,976.	
	17 Other expenses (Part IX, column (A), lines 11a-11d, 11f-24e)	24,073,639.	26,850,858.
	18 Total expenses. Add lines 13-17 (must equal Part IX, column (A), line 25)	54,057,357.	48,508,214.
19 Revenue less expenses. Subtract line 18 from line 12	-3,299,629.	-4,614,417.	
Net Assets or Fund Balances	20 Total assets (Part X, line 16)	Beginning of Current Year	End of Year
	21 Total liabilities (Part X, line 26)	65,540,964.	58,626,477.
	22 Net assets or fund balances. Subtract line 21 from line 20	36,521,089.	35,064,709.
		29,019,875.	23,561,768.

Part II Signature Block

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

Sign Here	Signature of officer: <i>Stacy Pagos Haller</i>		Date: August 9, 2023		
	Type or print name and title: STACY PAGOS HALLER, PRESIDENT/CEO				
Paid Preparer Use Only	Print/Type preparer's name	Preparer's signature	Date	Check if self-employed	PTIN
	FRANK H. SMITH	FRANK H. SMITH	08/09/23	<input type="checkbox"/>	P00639053
Firm's name: MARCUM, LLP			Firm's EIN: 11-1986323		
Firm's address: 1899 L STREET, NW, SUITE 850 WASHINGTON, DC 20036			Phone no. (202) 227-4000		

May the IRS discuss this return with the preparer shown above? See instructions Yes No

Part III Statement of Program Service Accomplishments

Check if Schedule O contains a response or note to any line in this Part III [X]

1 Briefly describe the organization's mission: BRIGHTFOCUS FOUNDATION FUNDS EXCEPTIONAL RESEARCH WORLDWIDE TO DEFEAT ALZHEIMER'S DISEASE, MACULAR DEGENERATION, AND GLAUCOMA AND PROVIDES EXPERT INFORMATION ON THESE HEARTBREAKING DISEASES. PLEASE REFER TO SCHEDULE O FOR A COMPLETE OVERVIEW OF OUR MISSION.

2 Did the organization undertake any significant program services during the year which were not listed on the prior Form 990 or 990-EZ? [] Yes [X] No If "Yes," describe these new services on Schedule O.

3 Did the organization cease conducting, or make significant changes in how it conducts, any program services? [] Yes [X] No If "Yes," describe these changes on Schedule O.

4 Describe the organization's program service accomplishments for each of its three largest program services, as measured by expenses. Section 501(c)(3) and 501(c)(4) organizations are required to report the amount of grants and allocations to others, the total expenses, and revenue, if any, for each program service reported.

4a (Code:) (Expenses \$ 19,544,776. including grants of \$ 7,755,537.) (Revenue \$) ALZHEIMER'S DISEASE RESEARCH (ADR)

PLEASE REFER TO SCHEDULE O FOR A COMPLETE DESCRIPTION OF THE ACCOMPLISHMENTS FOR ALZHEIMER'S DISEASE RESEARCH.

4b (Code:) (Expenses \$ 9,259,355. including grants of \$ 4,039,275.) (Revenue \$) MACULAR DEGENERATION RESEARCH (MDR)

PLEASE REFER TO SCHEDULE O FOR A COMPLETE DESCRIPTION OF THE ACCOMPLISHMENTS FOR MACULAR DEGENERATION RESEARCH.

4c (Code:) (Expenses \$ 3,630,550. including grants of \$ 2,526,790.) (Revenue \$) NATIONAL GLAUCOMA RESEARCH (NGR)

PLEASE REFER TO SCHEDULE O FOR A COMPLETE DESCRIPTION OF THE ACCOMPLISHMENTS FOR NATIONAL GLAUCOMA RESEARCH.

4d Other program services (Describe on Schedule O.) (Expenses \$ including grants of \$) (Revenue \$)

4e Total program service expenses 32,434,681.

Part IV Checklist of Required Schedules

Table with 3 columns: Question ID, Yes, No. Rows include questions 1 through 21 regarding organizational requirements and schedules A through I.

Part IV Checklist of Required Schedules (continued)

Table with 3 columns: Question, Yes, No. Rows 22-38 covering various organizational requirements.

Part V Statements Regarding Other IRS Filings and Tax Compliance

Check if Schedule O contains a response or note to any line in this Part V

Table with 3 columns: Question, Yes, No. Rows 1a-1c regarding Form 1096, Forms W-2G, and backup withholding rules.

Part V Statements Regarding Other IRS Filings and Tax Compliance (continued)

Table with columns for question number, question text, and Yes/No columns. Includes questions 2a through 17 regarding employee counts, tax returns, unrelated business income, foreign accounts, prohibited transactions, and various organizational requirements.

Part VI Governance, Management, and Disclosure. For each "Yes" response to lines 2 through 7b below, and for a "No" response to line 8a, 8b, or 10b below, describe the circumstances, processes, or changes on Schedule O. See instructions.

Check if Schedule O contains a response or note to any line in this Part VI [X]

Section A. Governing Body and Management

Table with 3 columns: Question, Yes, No. Rows include: 1a Enter the number of voting members... 10; 1b Enter the number of voting members included... 10; 2 Did any officer, director, trustee, or key employee have a family relationship... X; 3 Did the organization delegate control over management duties... X; 4 Did the organization make any significant changes to its governing documents... X; 5 Did the organization become aware during the year of a significant diversion of the organization's assets... X; 6 Did the organization have members or stockholders... X; 7a Did the organization have members, stockholders, or other persons who had the power to elect or appoint one or more members of the governing body... X; 7b Are any governance decisions of the organization reserved to (or subject to approval by) members, stockholders, or persons other than the governing body... X; 8 Did the organization contemporaneously document the meetings held or written actions undertaken during the year by the following: a The governing body? X; b Each committee with authority to act on behalf of the governing body? X; 9 Is there any officer, director, trustee, or key employee listed in Part VII, Section A, who cannot be reached at the organization's mailing address? If "Yes," provide the names and addresses on Schedule O... X

Section B. Policies (This Section B requests information about policies not required by the Internal Revenue Code.)

Table with 3 columns: Question, Yes, No. Rows include: 10a Did the organization have local chapters, branches, or affiliates? X; 10b If "Yes," did the organization have written policies and procedures governing the activities of such chapters, affiliates, and branches to ensure their operations are consistent with the organization's exempt purposes?; 11a Has the organization provided a complete copy of this Form 990 to all members of its governing body before filing the form? X; 11b Describe on Schedule O the process, if any, used by the organization to review this Form 990.; 12a Did the organization have a written conflict of interest policy? If "No," go to line 13... X; 12b Were officers, directors, or trustees, and key employees required to disclose annually interests that could give rise to conflicts? X; 12c Did the organization regularly and consistently monitor and enforce compliance with the policy? If "Yes," describe on Schedule O how this was done... X; 13 Did the organization have a written whistleblower policy? X; 14 Did the organization have a written document retention and destruction policy? X; 15 Did the process for determining compensation of the following persons include a review and approval by independent persons, comparability data, and contemporaneous substantiation of the deliberation and decision? a The organization's CEO, Executive Director, or top management official... X; b Other officers or key employees of the organization... X; If "Yes" to line 15a or 15b, describe the process on Schedule O. See instructions.; 16a Did the organization invest in, contribute assets to, or participate in a joint venture or similar arrangement with a taxable entity during the year? X; 16b If "Yes," did the organization follow a written policy or procedure requiring the organization to evaluate its participation in joint venture arrangements under applicable federal tax law, and take steps to safeguard the organization's exempt status with respect to such arrangements?

Section C. Disclosure

- 17 List the states with which a copy of this Form 990 is required to be filed AK, AL, AR, CA, CT, FL, GA, HI, IL, KS, KY, ME
18 Section 6104 requires an organization to make its Forms 1023 (1024 or 1024-A, if applicable), 990, and 990-T (section 501(c)(3)s only) available for public inspection. Indicate how you made these available. Check all that apply. [X] Own website [X] Another's website [X] Upon request [] Other (explain on Schedule O)
19 Describe on Schedule O whether (and if so, how) the organization made its governing documents, conflict of interest policy, and financial statements available to the public during the tax year.
20 State the name, address, and telephone number of the person who possesses the organization's books and records
DAVID F. MARKS, CPA, CMA - (301) 948-3244
22512 GATEWAY CENTER DRIVE, CLARKSBURG, MD 20871

Part VII Compensation of Officers, Directors, Trustees, Key Employees, Highest Compensated Employees, and Independent Contractors

Check if Schedule O contains a response or note to any line in this Part VII

Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees

1a Complete this table for all persons required to be listed. Report compensation for the calendar year ending with or within the organization's tax year.

- List all of the organization's **current** officers, directors, trustees (whether individuals or organizations), regardless of amount of compensation. Enter -0- in columns (D), (E), and (F) if no compensation was paid.
 - List all of the organization's **current** key employees, if any. See the instructions for definition of "key employee."
 - List the organization's five **current** highest compensated employees (other than an officer, director, trustee, or key employee) who received reportable compensation (box 5 of Form W-2, box 6 of Form 1099-MISC, and/or box 1 of Form 1099-NEC) of more than \$100,000 from the organization and any related organizations.
 - List all of the organization's **former** officers, key employees, and highest compensated employees who received more than \$100,000 of reportable compensation from the organization and any related organizations.
 - List all of the organization's **former directors or trustees** that received, in the capacity as a former director or trustee of the organization, more than \$10,000 of reportable compensation from the organization and any related organizations.
- See the instructions for the order in which to list the persons above.

Check this box if neither the organization nor any related organization compensated any current officer, director, or trustee.

(A) Name and title	(B) Average hours per week (list any hours for related organizations below line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)						(D) Reportable compensation from the organization (W-2/1099-MISC/1099-NEC)	(E) Reportable compensation from related organizations (W-2/1099-MISC/1099-NEC)	(F) Estimated amount of other compensation from the organization and related organizations
		Individual trustee or director	Institutional trustee	Officer	Key employee	Highest compensated employee	Former			
(1) STACY PAGOS HALLER PRESIDENT/CEO	45.00			X			440,796.	0.	52,228.	
(2) NANCY LYNN SR. VP STRATEGIC PARTNERSHIPS	45.00			X			250,394.	0.	55,303.	
(3) R. BRIAN ELDETON SR. VP, DEVELOPMENT	45.00			X			243,178.	0.	46,740.	
(4) DAVID F. MARKS, CPA, CMA VP, FINANCE & ADMINISTRATION	45.00			X			166,931.	0.	58,076.	
(5) DIANE BOVENKAMP, PHD VP, SCIENTIFIC AFFAIRS	45.00			X			182,082.	0.	21,178.	
(6) AYO ABRAHAM, CPA, CGMA CONTROLLER	40.00				X		141,525.	0.	15,244.	
(7) LISA MORGAN DIRECTOR OF ANNUAL GIVING	40.00				X		120,019.	0.	33,191.	
(8) SHARYN ROSSI, PHD, DIR. OF SCIENT. PROGRAMS, NEUROSCIENCE	40.00				X		117,521.	0.	34,655.	
(9) KACI BAEZ VP, INTEGRATED MARKETING & COMMS	45.00				X		121,016.	0.	18,929.	
(10) PREETI SUBRAMANIAN, PHD, DIR. OF SCIENT. PROGRAMS, VISION SCIENCE	40.00				X		125,051.	0.	14,295.	
(11) PATRICIA M. STEWART CHAIR	10.00	X		X			0.	0.	0.	
(12) CECILIA ARRADAZA VICE CHAIR	6.00	X		X			0.	0.	0.	
(13) MADDY DYCHTOWALD SECRETARY	6.00	X		X			0.	0.	0.	
(14) ETHAN TREESE TREASURER - UNTIL 06/2022	2.00	X		X			0.	0.	0.	
(15) EDWARD FINLEY, DIRECTOR, TREASURER - AS OF 06/2022	8.00	X		X			0.	0.	0.	
(16) PAUL CAMPBELL DIRECTOR	5.00	X					0.	0.	0.	
(17) SHAWA GOTTLIEB DIRECTOR	5.00	X					0.	0.	0.	

Part VII Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees (continued)

(A) Name and title	(B) Average hours per week (list any hours for related organizations below line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)						(D) Reportable compensation from the organization (W-2/1099-MISC/1099-NEC)	(E) Reportable compensation from related organizations (W-2/1099-MISC/1099-NEC)	(F) Estimated amount of other compensation from the organization and related organizations
		Individual trustee or director	Institutional trustee	Officer	Key employee	Highest compensated employee	Former			
(18) DANA GRIFFIN DIRECTOR	5.00	X						0.	0.	0.
(19) SCOTT KAISER, MD DIRECTOR	5.00	X						0.	0.	0.
(20) TONYA MATTHEWS, PHD DIRECTOR	5.00	X						0.	0.	0.
(21) ERIC SIEMERS, MD DIRECTOR - UNTIL 06/2022	2.00	X						0.	0.	0.
(22) JAN M. STOUFFER, PHD DIRECTOR	6.00	X						0.	0.	0.
1b Subtotal								1,908,513.	0.	349,839.
c Total from continuation sheets to Part VII, Section A								0.	0.	0.
d Total (add lines 1b and 1c)								1,908,513.	0.	349,839.

2 Total number of individuals (including but not limited to those listed above) who received more than \$100,000 of reportable compensation from the organization 11

	Yes	No
3 Did the organization list any former officer, director, trustee, key employee, or highest compensated employee on line 1a? <i>If "Yes," complete Schedule J for such individual</i>	3	X
4 For any individual listed on line 1a, is the sum of reportable compensation and other compensation from the organization and related organizations greater than \$150,000? <i>If "Yes," complete Schedule J for such individual</i>	4	X
5 Did any person listed on line 1a receive or accrue compensation from any unrelated organization or individual for services rendered to the organization? <i>If "Yes," complete Schedule J for such person</i>	5	X

Section B. Independent Contractors

1 Complete this table for your five highest compensated independent contractors that received more than \$100,000 of compensation from the organization. Report compensation for the calendar year ending with or within the organization's tax year.

(A) Name and business address	(B) Description of services	(C) Compensation
RKD GROUP, 35 PARKWOOD DRIVE, SUITE 160, HOPKINTON, MA 01748	PUBLIC AWARENESS CONSUL. & MATERIALS	9,849,026.
ALLEGIANCE GROUP, 2300 CLARENDON BLVD., SUITE 925, ARLINGTON, VA 22201	ONLINE PUBLIC AWARENESS CONSULTING	1,890,997.
ADSTRA LLC, 750 COLLEGE ROAD EAST, SUITE 201, PRINCETON, NJ 08540	LIST RENTAL	1,174,435.
DATA MANAGEMENT, INC. 160 STONE STREET, STONEVILLE, NC 27048	DATABASE MANAGEMENT	298,773.
GOOGLE LLC, 1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW, CA 94043	PUBLIC AWARENESS ADVERTISING	222,954.

2 Total number of independent contractors (including but not limited to those listed above) who received more than \$100,000 of compensation from the organization 14

Part VIII Statement of Revenue

Check if Schedule O contains a response or note to any line in this Part VIII

			(A)	(B)	(C)	(D)	
			Total revenue	Related or exempt function revenue	Unrelated business revenue	Revenue excluded from tax under sections 512 - 514	
Contributions, Gifts, Grants and Other Similar Amounts	1 a	Federated campaigns	1a 257,616.				
	b	Membership dues	1b				
	c	Fundraising events	1c 242,498.				
	d	Related organizations	1d				
	e	Government grants (contributions)	1e				
	f	All other contributions, gifts, grants, and similar amounts not included above	1f 42951421.				
	g	Noncash contributions included in lines 1a-1f	1g \$ 468,968.				
	h	Total. Add lines 1a-1f		43451535.			
Program Service Revenue	2 a	_____	Business Code				
	b	_____					
	c	_____					
	d	_____					
	e	_____					
	f	All other program service revenue					
	g	Total. Add lines 2a-2f					
Other Revenue	3	Investment income (including dividends, interest, and other similar amounts)		882,169.		882,169.	
	4	Income from investment of tax-exempt bond proceeds					
	5	Royalties		495,958.		495,958.	
	6 a	Gross rents	(i) Real	6a 594,742.			
			(ii) Personal	6b 70,900.			
				6c 523,842.			
	d	Net rental income or (loss)		523,842.		523,842.	
	7 a	Gross amount from sales of assets other than inventory	(i) Securities	7a 13781625			
			(ii) Other	7b 14932078			
				7c -1150453			
	d	Net gain or (loss)		-1150453.		-1150453.	
	8 a	Gross income from fundraising events (not including \$ 242,498. of contributions reported on line 1c). See Part IV, line 18		8a 63,800.			
				8b 373,054.			
	c	Net income or (loss) from fundraising events		-309,254.		-309,254.	
9 a	Gross income from gaming activities. See Part IV, line 19		9a				
			9b				
c	Net income or (loss) from gaming activities						
10 a	Gross sales of inventory, less returns and allowances		10a				
			10b				
c	Net income or (loss) from sales of inventory						
Miscellaneous Revenue	11 a	_____	Business Code				
	b	_____					
	c	_____					
	d	All other revenue					
	e	Total. Add lines 11a-11d					
12	Total revenue. See instructions		43893797.	0.	0.	442,262.	

Part IX Statement of Functional Expenses

Section 501(c)(3) and 501(c)(4) organizations must complete all columns. All other organizations must complete column (A).

Check if Schedule O contains a response or note to any line in this Part IX

Do not include amounts reported on lines 6b, 7b, 8b, 9b, and 10b of Part VIII.	(A) Total expenses	(B) Program service expenses	(C) Management and general expenses	(D) Fundraising expenses
1 Grants and other assistance to domestic organizations and domestic governments. See Part IV, line 21	11,712,740.	11,712,740.		
2 Grants and other assistance to domestic individuals. See Part IV, line 22	6,000.	6,000.		
3 Grants and other assistance to foreign organizations, foreign governments, and foreign individuals. See Part IV, lines 15 and 16	2,602,863.	2,602,863.		
4 Benefits paid to or for members				
5 Compensation of current officers, directors, trustees, and key employees	1,517,616.	880,227.	341,164.	296,225.
6 Compensation not included above to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B)				
7 Other salaries and wages	3,630,029.	1,993,650.	1,131,056.	505,323.
8 Pension plan accruals and contributions (include section 401(k) and 403(b) employer contributions)	206,463.	113,392.	64,330.	28,741.
9 Other employee benefits	696,236.	382,380.	216,935.	96,921.
10 Payroll taxes	342,438.	188,071.	106,697.	47,670.
11 Fees for services (nonemployees):				
a Management				
b Legal	107,489.	51,197.	56,292.	
c Accounting	102,567.	55,371.	35,038.	12,158.
d Lobbying				
e Professional fundraising services. See Part IV, line 17	942,971.			942,971.
f Investment management fees	327,036.		327,036.	
g Other. (If line 11g amount exceeds 10% of line 25, column (A), amount, list line 11g expenses on Sch O.)	2,129,159.	1,952,570.	146,845.	29,744.
12 Advertising and promotion	889,360.	364,825.		524,535.
13 Office expenses	1,485,870.	699,697.	401,524.	384,649.
14 Information technology	970,074.	686,028.	189,425.	94,621.
15 Royalties				
16 Occupancy	480,975.	281,749.	154,310.	44,916.
17 Travel	421,586.	276,164.	98,187.	47,235.
18 Payments of travel or entertainment expenses for any federal, state, or local public officials				
19 Conferences, conventions, and meetings	513,887.	493,989.	13,435.	6,463.
20 Interest	2,624.	1,537.	842.	245.
21 Payments to affiliates				
22 Depreciation, depletion, and amortization	449,785.	258,679.	135,126.	55,980.
23 Insurance	108,539.	40,215.	57,615.	10,709.
24 Other expenses. Itemize expenses not covered above. (List miscellaneous expenses on line 24e. If line 24e amount exceeds 10% of line 25, column (A), amount, list line 24e expenses on Schedule O.)				
a PUB. AWARENESS POSTAGE	7,867,415.	3,904,619.	533,044.	3,429,752.
b PUB. AWARENESS PRINTING	7,290,443.	3,640,583.	445,165.	3,204,695.
c PUB. AWARENESS COMP.	2,121,383.	1,069,157.	115,067.	937,159.
d LIST RENTAL	1,582,666.	778,978.	86,424.	717,264.
e All other expenses				
25 Total functional expenses. Add lines 1 through 24e	48,508,214.	32,434,681.	4,655,557.	11,417,976.
26 Joint costs. Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation. Check here <input checked="" type="checkbox"/> if following SOP 98-2 (ASC 958-720)	18,131,282.	8,101,074.	1,241,396.	8,788,812.

Part X Balance Sheet

Check if Schedule O contains a response or note to any line in this Part X

		(A)		(B)	
		Beginning of year		End of year	
Assets	1	Cash - non-interest-bearing	138,432.	1	205,653.
	2	Savings and temporary cash investments	4,940,634.	2	3,889,254.
	3	Pledges and grants receivable, net	6,568,692.	3	6,522,988.
	4	Accounts receivable, net	0.	4	165,585.
	5	Loans and other receivables from any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons		5	
	6	Loans and other receivables from other disqualified persons (as defined under section 4958(f)(1)), and persons described in section 4958(c)(3)(B)		6	
	7	Notes and loans receivable, net		7	
	8	Inventories for sale or use	37,046.	8	51,738.
	9	Prepaid expenses and deferred charges	322,345.	9	50,244.
	10a	Land, buildings, and equipment: cost or other basis. Complete Part VI of Schedule D	10a 13,067,892.		
	b	Less: accumulated depreciation	10b 4,939,613.	10c	8,128,279.
	11	Investments - publicly traded securities	45,203,665.	11	39,542,541.
	12	Investments - other securities. See Part IV, line 11		12	
	13	Investments - program-related. See Part IV, line 11		13	
	14	Intangible assets		14	
	15	Other assets. See Part IV, line 11	169,035.	15	70,195.
16	Total assets. Add lines 1 through 15 (must equal line 33)	65,540,964.	16	58,626,477.	
Liabilities	17	Accounts payable and accrued expenses	862,205.	17	1,112,727.
	18	Grants payable	34,865,851.	18	33,119,925.
	19	Deferred revenue	0.	19	116,500.
	20	Tax-exempt bond liabilities		20	
	21	Escrow or custodial account liability. Complete Part IV of Schedule D		21	
	22	Loans and other payables to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons		22	
	23	Secured mortgages and notes payable to unrelated third parties		23	
	24	Unsecured notes and loans payable to unrelated third parties		24	
	25	Other liabilities (including federal income tax, payables to related third parties, and other liabilities not included on lines 17-24). Complete Part X of Schedule D	793,033.	25	715,557.
	26	Total liabilities. Add lines 17 through 25	36,521,089.	26	35,064,709.
Net Assets or Fund Balances	Organizations that follow FASB ASC 958, check here <input checked="" type="checkbox"/>				
	and complete lines 27, 28, 32, and 33.				
	27	Net assets without donor restrictions	13,864,090.	27	10,360,299.
	28	Net assets with donor restrictions	15,155,785.	28	13,201,469.
	Organizations that do not follow FASB ASC 958, check here <input type="checkbox"/>				
	and complete lines 29 through 33.				
	29	Capital stock or trust principal, or current funds		29	
	30	Paid-in or capital surplus, or land, building, or equipment fund		30	
31	Retained earnings, endowment, accumulated income, or other funds		31		
32	Total net assets or fund balances	29,019,875.	32	23,561,768.	
33	Total liabilities and net assets/fund balances	65,540,964.	33	58,626,477.	

Part XI Reconciliation of Net Assets

Check if Schedule O contains a response or note to any line in this Part XI

1	Total revenue (must equal Part VIII, column (A), line 12)	1	43,893,797.
2	Total expenses (must equal Part IX, column (A), line 25)	2	48,508,214.
3	Revenue less expenses. Subtract line 2 from line 1	3	-4,614,417.
4	Net assets or fund balances at beginning of year (must equal Part X, line 32, column (A))	4	29,019,875.
5	Net unrealized gains (losses) on investments	5	-2,139,406.
6	Donated services and use of facilities	6	
7	Investment expenses	7	
8	Prior period adjustments	8	
9	Other changes in net assets or fund balances (explain on Schedule O)	9	1,295,716.
10	Net assets or fund balances at end of year. Combine lines 3 through 9 (must equal Part X, line 32, column (B))	10	23,561,768.

Part XII Financial Statements and Reporting

Check if Schedule O contains a response or note to any line in this Part XII

- 1 Accounting method used to prepare the Form 990: Cash Accrual Other _____
If the organization changed its method of accounting from a prior year or checked "Other," explain on Schedule O.
- 2a Were the organization's financial statements compiled or reviewed by an independent accountant?
If "Yes," check a box below to indicate whether the financial statements for the year were compiled or reviewed on a separate basis, consolidated basis, or both:
 Separate basis Consolidated basis Both consolidated and separate basis
- b Were the organization's financial statements audited by an independent accountant?
If "Yes," check a box below to indicate whether the financial statements for the year were audited on a separate basis, consolidated basis, or both:
 Separate basis Consolidated basis Both consolidated and separate basis
- c If "Yes" to line 2a or 2b, does the organization have a committee that assumes responsibility for oversight of the audit, review, or compilation of its financial statements and selection of an independent accountant?
If the organization changed either its oversight process or selection process during the tax year, explain on Schedule O.
- 3a As a result of a federal award, was the organization required to undergo an audit or audits as set forth in the Uniform Guidance, 2 C.F.R. Part 200, Subpart F?
- b If "Yes," did the organization undergo the required audit or audits? If the organization did not undergo the required audit or audits, explain why on Schedule O and describe any steps taken to undergo such audits

	Yes	No
2a		X
2b	X	
2c	X	
3a		X
3b		

Form 990 (2022)

SCHEDULE A
(Form 990)

Department of the Treasury
Internal Revenue Service

Public Charity Status and Public Support

Complete if the organization is a section 501(c)(3) organization or a section 4947(a)(1) nonexempt charitable trust.
Attach to Form 990 or Form 990-EZ.

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2022

Open to Public Inspection

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
--	--

Part I Reason for Public Charity Status. (All organizations must complete this part.) See instructions.

The organization is not a private foundation because it is: (For lines 1 through 12, check only one box.)

- 1 A church, convention of churches, or association of churches described in **section 170(b)(1)(A)(i).**
- 2 A school described in **section 170(b)(1)(A)(ii).** (Attach Schedule E (Form 990).)
- 3 A hospital or a cooperative hospital service organization described in **section 170(b)(1)(A)(iii).**
- 4 A medical research organization operated in conjunction with a hospital described in **section 170(b)(1)(A)(iii).** Enter the hospital's name, city, and state: _____
- 5 An organization operated for the benefit of a college or university owned or operated by a governmental unit described in **section 170(b)(1)(A)(iv).** (Complete Part II.)
- 6 A federal, state, or local government or governmental unit described in **section 170(b)(1)(A)(v).**
- 7 An organization that normally receives a substantial part of its support from a governmental unit or from the general public described in **section 170(b)(1)(A)(vi).** (Complete Part II.)
- 8 A community trust described in **section 170(b)(1)(A)(vi).** (Complete Part II.)
- 9 An agricultural research organization described in **section 170(b)(1)(A)(ix)** operated in conjunction with a land-grant college or university or a non-land-grant college of agriculture (see instructions). Enter the name, city, and state of the college or university: _____
- 10 An organization that normally receives (1) more than 33 1/3% of its support from contributions, membership fees, and gross receipts from activities related to its exempt functions, subject to certain exceptions; and (2) no more than 33 1/3% of its support from gross investment income and unrelated business taxable income (less section 511 tax) from businesses acquired by the organization after June 30, 1975. See **section 509(a)(2).** (Complete Part III.)
- 11 An organization organized and operated exclusively to test for public safety. See **section 509(a)(4).**
- 12 An organization organized and operated exclusively for the benefit of, to perform the functions of, or to carry out the purposes of one or more publicly supported organizations described in **section 509(a)(1)** or **section 509(a)(2).** See **section 509(a)(3).** Check the box on lines 12a through 12d that describes the type of supporting organization and complete lines 12e, 12f, and 12g.
 - a **Type I.** A supporting organization operated, supervised, or controlled by its supported organization(s), typically by giving the supported organization(s) the power to regularly appoint or elect a majority of the directors or trustees of the supporting organization. **You must complete Part IV, Sections A and B.**
 - b **Type II.** A supporting organization supervised or controlled in connection with its supported organization(s), by having control or management of the supporting organization vested in the same persons that control or manage the supported organization(s). **You must complete Part IV, Sections A and C.**
 - c **Type III functionally integrated.** A supporting organization operated in connection with, and functionally integrated with, its supported organization(s) (see instructions). **You must complete Part IV, Sections A, D, and E.**
 - d **Type III non-functionally integrated.** A supporting organization operated in connection with its supported organization(s) that is not functionally integrated. The organization generally must satisfy a distribution requirement and an attentiveness requirement (see instructions). **You must complete Part IV, Sections A and D, and Part V.**
 - e Check this box if the organization received a written determination from the IRS that it is a Type I, Type II, Type III functionally integrated, or Type III non-functionally integrated supporting organization.
 - f Enter the number of supported organizations
- g Provide the following information about the supported organization(s).

(i) Name of supported organization	(ii) EIN	(iii) Type of organization (described on lines 1-10 above (see instructions))	(iv) Is the organization listed in your governing document?		(v) Amount of monetary support (see instructions)	(vi) Amount of other support (see instructions)
			Yes	No		
Total						

Part II Support Schedule for Organizations Described in Sections 170(b)(1)(A)(iv) and 170(b)(1)(A)(vi)

(Complete only if you checked the box on line 5, 7, or 8 of Part I or if the organization failed to qualify under Part III. If the organization fails to qualify under the tests listed below, please complete Part III.)

Section A. Public Support

Calendar year (or fiscal year beginning in)	(a) 2018	(b) 2019	(c) 2020	(d) 2021	(e) 2022	(f) Total
1 Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.")	39635190.	35740875.	48502473.	46522410.	43451535.	213852483
2 Tax revenues levied for the organization's benefit and either paid to or expended on its behalf						
3 The value of services or facilities furnished by a governmental unit to the organization without charge						
4 Total. Add lines 1 through 3	39635190.	35740875.	48502473.	46522410.	43451535.	213852483
5 The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f)						483,485.
6 Public support. Subtract line 5 from line 4.						213368998

Section B. Total Support

Calendar year (or fiscal year beginning in)	(a) 2018	(b) 2019	(c) 2020	(d) 2021	(e) 2022	(f) Total
7 Amounts from line 4	39635190.	35740875.	48502473.	46522410.	43451535.	213852483
8 Gross income from interest, dividends, payments received on securities loans, rents, royalties, and income from similar sources	1925519.	2176998.	1887633.	2074361.	1972869.	10037380.
9 Net income from unrelated business activities, whether or not the business is regularly carried on						
10 Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.)				7,500.		7,500.
11 Total support. Add lines 7 through 10						223897363
12 Gross receipts from related activities, etc. (see instructions)					12	
13 First 5 years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization, check this box and stop here						<input type="checkbox"/>

Section C. Computation of Public Support Percentage

14 Public support percentage for 2022 (line 6, column (f), divided by line 11, column (f))	14	95.30	%
15 Public support percentage from 2021 Schedule A, Part II, line 14	15	95.09	%
16a 33 1/3% support test - 2022. If the organization did not check the box on line 13, and line 14 is 33 1/3% or more, check this box and stop here. The organization qualifies as a publicly supported organization			<input checked="" type="checkbox"/>
b 33 1/3% support test - 2021. If the organization did not check a box on line 13 or 16a, and line 15 is 33 1/3% or more, check this box and stop here. The organization qualifies as a publicly supported organization			<input type="checkbox"/>
17a 10% -facts-and-circumstances test - 2022. If the organization did not check a box on line 13, 16a, or 16b, and line 14 is 10% or more, and if the organization meets the facts-and-circumstances test, check this box and stop here. Explain in Part VI how the organization meets the facts-and-circumstances test. The organization qualifies as a publicly supported organization			<input type="checkbox"/>
b 10% -facts-and-circumstances test - 2021. If the organization did not check a box on line 13, 16a, 16b, or 17a, and line 15 is 10% or more, and if the organization meets the facts-and-circumstances test, check this box and stop here. Explain in Part VI how the organization meets the facts-and-circumstances test. The organization qualifies as a publicly supported organization			<input type="checkbox"/>
18 Private foundation. If the organization did not check a box on line 13, 16a, 16b, 17a, or 17b, check this box and see instructions			<input type="checkbox"/>

Part III Support Schedule for Organizations Described in Section 509(a)(2)

(Complete only if you checked the box on line 10 of Part I or if the organization failed to qualify under Part II. If the organization fails to qualify under the tests listed below, please complete Part II.)

Section A. Public Support

Table with 7 columns: (a) 2018, (b) 2019, (c) 2020, (d) 2021, (e) 2022, (f) Total. Rows include: 1 Gifts, grants, contributions, and membership fees received; 2 Gross receipts from admissions, merchandise sold or services performed; 3 Gross receipts from activities that are not an unrelated trade or business; 4 Tax revenues levied for the organization's benefit; 5 The value of services or facilities furnished by a governmental unit; 6 Total. Add lines 1 through 5; 7a Amounts included on lines 1, 2, and 3 received from disqualified persons; 7b Amounts included on lines 2 and 3 received from other than disqualified persons; 8 Public support. (Subtract line 7c from line 6.)

Section B. Total Support

Table with 7 columns: (a) 2018, (b) 2019, (c) 2020, (d) 2021, (e) 2022, (f) Total. Rows include: 9 Amounts from line 6; 10a Gross income from interest, dividends, payments received on securities loans, rents, royalties, and income from similar sources; 10b Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975; 10c Add lines 10a and 10b; 11 Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on; 12 Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.); 13 Total support. (Add lines 9, 10c, 11, and 12.)

14 First 5 years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization, check this box and stop here

Section C. Computation of Public Support Percentage

Table with 2 columns: Line number, Percentage. Row 15: Public support percentage for 2022 (line 8, column (f), divided by line 13, column (f)) 15 %; Row 16: Public support percentage from 2021 Schedule A, Part III, line 15 16 %

Section D. Computation of Investment Income Percentage

Table with 2 columns: Line number, Percentage. Row 17: Investment income percentage for 2022 (line 10c, column (f), divided by line 13, column (f)) 17 %; Row 18: Investment income percentage from 2021 Schedule A, Part III, line 17 18 %

19a 33 1/3% support tests - 2022. If the organization did not check the box on line 14, and line 15 is more than 33 1/3%, and line 17 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization

b 33 1/3% support tests - 2021. If the organization did not check a box on line 14 or line 19a, and line 16 is more than 33 1/3%, and line 18 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization

20 Private foundation. If the organization did not check a box on line 14, 19a, or 19b, check this box and see instructions

Part IV Supporting Organizations

(Complete only if you checked a box on line 12 of Part I. If you checked box 12a, Part I, complete Sections A and B. If you checked box 12b, Part I, complete Sections A and C. If you checked box 12c, Part I, complete Sections A, D, and E. If you checked box 12d, Part I, complete Sections A and D, and complete Part V.)

Section A. All Supporting Organizations

	Yes	No
1 Are all of the organization's supported organizations listed by name in the organization's governing documents? <i>If "No," describe in Part VI how the supported organizations are designated. If designated by class or purpose, describe the designation. If historic and continuing relationship, explain.</i>		
2 Did the organization have any supported organization that does not have an IRS determination of status under section 509(a)(1) or (2)? <i>If "Yes," explain in Part VI how the organization determined that the supported organization was described in section 509(a)(1) or (2).</i>		
3a Did the organization have a supported organization described in section 501(c)(4), (5), or (6)? <i>If "Yes," answer lines 3b and 3c below.</i>		
b Did the organization confirm that each supported organization qualified under section 501(c)(4), (5), or (6) and satisfied the public support tests under section 509(a)(2)? <i>If "Yes," describe in Part VI when and how the organization made the determination.</i>		
c Did the organization ensure that all support to such organizations was used exclusively for section 170(c)(2)(B) purposes? <i>If "Yes," explain in Part VI what controls the organization put in place to ensure such use.</i>		
4a Was any supported organization not organized in the United States ("foreign supported organization")? <i>If "Yes," and if you checked box 12a or 12b in Part I, answer lines 4b and 4c below.</i>		
b Did the organization have ultimate control and discretion in deciding whether to make grants to the foreign supported organization? <i>If "Yes," describe in Part VI how the organization had such control and discretion despite being controlled or supervised by or in connection with its supported organizations.</i>		
c Did the organization support any foreign supported organization that does not have an IRS determination under sections 501(c)(3) and 509(a)(1) or (2)? <i>If "Yes," explain in Part VI what controls the organization used to ensure that all support to the foreign supported organization was used exclusively for section 170(c)(2)(B) purposes.</i>		
5a Did the organization add, substitute, or remove any supported organizations during the tax year? <i>If "Yes," answer lines 5b and 5c below (if applicable). Also, provide detail in Part VI, including (i) the names and EIN numbers of the supported organizations added, substituted, or removed; (ii) the reasons for each such action; (iii) the authority under the organization's organizing document authorizing such action; and (iv) how the action was accomplished (such as by amendment to the organizing document).</i>		
b Type I or Type II only. Was any added or substituted supported organization part of a class already designated in the organization's organizing document?		
c Substitutions only. Was the substitution the result of an event beyond the organization's control?		
6 Did the organization provide support (whether in the form of grants or the provision of services or facilities) to anyone other than (i) its supported organizations, (ii) individuals that are part of the charitable class benefited by one or more of its supported organizations, or (iii) other supporting organizations that also support or benefit one or more of the filing organization's supported organizations? <i>If "Yes," provide detail in Part VI.</i>		
7 Did the organization provide a grant, loan, compensation, or other similar payment to a substantial contributor (as defined in section 4958(c)(3)(C)), a family member of a substantial contributor, or a 35% controlled entity with regard to a substantial contributor? <i>If "Yes," complete Part I of Schedule L (Form 990).</i>		
8 Did the organization make a loan to a disqualified person (as defined in section 4958) not described on line 7? <i>If "Yes," complete Part I of Schedule L (Form 990).</i>		
9a Was the organization controlled directly or indirectly at any time during the tax year by one or more disqualified persons, as defined in section 4946 (other than foundation managers and organizations described in section 509(a)(1) or (2))? <i>If "Yes," provide detail in Part VI.</i>		
b Did one or more disqualified persons (as defined on line 9a) hold a controlling interest in any entity in which the supporting organization had an interest? <i>If "Yes," provide detail in Part VI.</i>		
c Did a disqualified person (as defined on line 9a) have an ownership interest in, or derive any personal benefit from, assets in which the supporting organization also had an interest? <i>If "Yes," provide detail in Part VI.</i>		
10a Was the organization subject to the excess business holdings rules of section 4943 because of section 4943(f) (regarding certain Type II supporting organizations, and all Type III non-functionally integrated supporting organizations)? <i>If "Yes," answer line 10b below.</i>		
b Did the organization have any excess business holdings in the tax year? <i>(Use Schedule C, Form 4720, to determine whether the organization had excess business holdings.)</i>		

Part IV Supporting Organizations (continued)

Table with 3 columns: Question, Yes, No. Row 11: Has the organization accepted a gift or contribution from any of the following persons? a A person who directly or indirectly controls... b A family member... c A 35% controlled entity...

Section B. Type I Supporting Organizations

Table with 3 columns: Question, Yes, No. Row 1: Did the governing body, members of the governing body, officers acting in their official capacity... Row 2: Did the organization operate for the benefit of any supported organization other than the supported organization(s)...

Section C. Type II Supporting Organizations

Table with 3 columns: Question, Yes, No. Row 1: Were a majority of the organization's directors or trustees during the tax year also a majority of the directors or trustees of each of the organization's supported organization(s)?

Section D. All Type III Supporting Organizations

Table with 3 columns: Question, Yes, No. Row 1: Did the organization provide to each of its supported organizations, by the last day of the fifth month of the organization's tax year... Row 2: Were any of the organization's officers, directors, or trustees either (i) appointed or elected... Row 3: By reason of the relationship described on line 2, above, did the organization's supported organizations have a significant voice...

Section E. Type III Functionally Integrated Supporting Organizations

Table with 3 columns: Question, Yes, No. Row 1: Check the box next to the method that the organization used to satisfy the Integral Part Test during the year (see instructions). a The organization satisfied the Activities Test... b The organization is the parent of each of its supported organizations... c The organization supported a governmental entity... Row 2: Activities Test. Answer lines 2a and 2b below. a Did substantially all of the organization's activities during the tax year directly further the exempt purposes... b Did the activities described on line 2a, above, constitute activities that, but for the organization's involvement... Row 3: Parent of Supported Organizations. Answer lines 3a and 3b below. a Did the organization have the power to regularly appoint or elect a majority of the officers, directors, or trustees... b Did the organization exercise a substantial degree of direction over the policies, programs, and activities of each of its supported organizations?

Part V Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations

1 Check here if the organization satisfied the Integral Part Test as a qualifying trust on Nov. 20, 1970 (*explain in Part VI*). See instructions.
All other Type III non-functionally integrated supporting organizations must complete Sections A through E.

Section A - Adjusted Net Income		(A) Prior Year	(B) Current Year (optional)
1	Net short-term capital gain	1	
2	Recoveries of prior-year distributions	2	
3	Other gross income (see instructions)	3	
4	Add lines 1 through 3.	4	
5	Depreciation and depletion	5	
6	Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions)	6	
7	Other expenses (see instructions)	7	
8	Adjusted Net Income (subtract lines 5, 6, and 7 from line 4)	8	

Section B - Minimum Asset Amount		(A) Prior Year	(B) Current Year (optional)
1	Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year):		
a	Average monthly value of securities	1a	
b	Average monthly cash balances	1b	
c	Fair market value of other non-exempt-use assets	1c	
d	Total (add lines 1a, 1b, and 1c)	1d	
e	Discount claimed for blockage or other factors (<i>explain in detail in Part VI</i>):		
2	Acquisition indebtedness applicable to non-exempt-use assets	2	
3	Subtract line 2 from line 1d.	3	
4	Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions).	4	
5	Net value of non-exempt-use assets (subtract line 4 from line 3)	5	
6	Multiply line 5 by 0.035.	6	
7	Recoveries of prior-year distributions	7	
8	Minimum Asset Amount (add line 7 to line 6)	8	

Section C - Distributable Amount			Current Year
1	Adjusted net income for prior year (from Section A, line 8, column A)	1	
2	Enter 0.85 of line 1.	2	
3	Minimum asset amount for prior year (from Section B, line 8, column A)	3	
4	Enter greater of line 2 or line 3.	4	
5	Income tax imposed in prior year	5	
6	Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions).	6	
7	<input type="checkbox"/> Check here if the current year is the organization's first as a non-functionally integrated Type III supporting organization (see instructions).		

Part V Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations (continued)

Section D - Distributions		Current Year
1	Amounts paid to supported organizations to accomplish exempt purposes	1
2	Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity	2
3	Administrative expenses paid to accomplish exempt purposes of supported organizations	3
4	Amounts paid to acquire exempt-use assets	4
5	Qualified set-aside amounts (prior IRS approval required - provide details in Part VI)	5
6	Other distributions (describe in Part VI). See instructions.	6
7	Total annual distributions. Add lines 1 through 6.	7
8	Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions.	8
9	Distributable amount for 2022 from Section C, line 6	9
10	Line 8 amount divided by line 9 amount	10

Section E - Distribution Allocations (see instructions)	(i) Excess Distributions	(ii) Underdistributions Pre-2022	(iii) Distributable Amount for 2022
1	Distributable amount for 2022 from Section C, line 6		
2	Underdistributions, if any, for years prior to 2022 (reasonable cause required - explain in Part VI). See instructions.		
3	Excess distributions carryover, if any, to 2022		
a	From 2017		
b	From 2018		
c	From 2019		
d	From 2020		
e	From 2021		
f	Total of lines 3a through 3e		
g	Applied to underdistributions of prior years		
h	Applied to 2022 distributable amount		
i	Carryover from 2017 not applied (see instructions)		
j	Remainder. Subtract lines 3g, 3h, and 3i from line 3f.		
4	Distributions for 2022 from Section D, line 7: \$		
a	Applied to underdistributions of prior years		
b	Applied to 2022 distributable amount		
c	Remainder. Subtract lines 4a and 4b from line 4.		
5	Remaining underdistributions for years prior to 2022, if any. Subtract lines 3g and 4a from line 2. For result greater than zero, explain in Part VI. See instructions.		
6	Remaining underdistributions for 2022. Subtract lines 3h and 4b from line 1. For result greater than zero, explain in Part VI. See instructions.		
7	Excess distributions carryover to 2023. Add lines 3j and 4c.		
8	Breakdown of line 7:		
a	Excess from 2018		
b	Excess from 2019		
c	Excess from 2020		
d	Excess from 2021		
e	Excess from 2022		

Schedule A (Form 990) 2022

Part VI **Supplemental Information.** Provide the explanations required by Part II, line 10; Part II, line 17a or 17b; Part III, line 12; Part IV, Section A, lines 1, 2, 3b, 3c, 4b, 4c, 5a, 6, 9a, 9b, 9c, 11a, 11b, and 11c; Part IV, Section B, lines 1 and 2; Part IV, Section C, line 1; Part IV, Section D, lines 2 and 3; Part IV, Section E, lines 1c, 2a, 2b, 3a, and 3b; Part V, line 1; Part V, Section B, line 1e; Part V, Section D, lines 5, 6, and 8; and Part V, Section E, lines 2, 5, and 6. Also complete this part for any additional information.
 (See instructions.)

SCHEDULE A, PART II, LINE 10, EXPLANATION FOR OTHER INCOME:

SAVINGS BOND PAYOUT

2021 AMOUNT: \$ 7,500.

SCHEDULE C
(Form 990)

Political Campaign and Lobbying Activities

OMB No. 1545-0047

2022

Department of the Treasury
Internal Revenue Service

For Organizations Exempt From Income Tax Under section 501(c) and section 527
Complete if the organization is described below. Attach to Form 990 or Form 990-EZ.
Go to www.irs.gov/Form990 for instructions and the latest information.

Open to Public
Inspection

If the organization answered "Yes," on Form 990, Part IV, line 3, or Form 990-EZ, Part V, line 46 (Political Campaign Activities), then

- Section 501(c)(3) organizations: Complete Parts I-A and B. Do not complete Part I-C.
- Section 501(c) (other than section 501(c)(3)) organizations: Complete Parts I-A and C below. Do not complete Part I-B.
- Section 527 organizations: Complete Part I-A only.

If the organization answered "Yes," on Form 990, Part IV, line 4, or Form 990-EZ, Part VI, line 47 (Lobbying Activities), then

- Section 501(c)(3) organizations that have filed Form 5768 (election under section 501(h)): Complete Part II-A. Do not complete Part II-B.
- Section 501(c)(3) organizations that have NOT filed Form 5768 (election under section 501(h)): Complete Part II-B. Do not complete Part II-A.

If the organization answered "Yes," on Form 990, Part IV, line 5 (Proxy Tax) (See separate instructions) or Form 990-EZ, Part V, line 35c (Proxy Tax) (See separate instructions), then

- Section 501(c)(4), (5), or (6) organizations: Complete Part III.

Name of organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
---	---

Part I-A Complete if the organization is exempt under section 501(c) or is a section 527 organization.

- 1 Provide a description of the organization's direct and indirect political campaign activities in Part IV.
- 2 Political campaign activity expenditures \$ _____
- 3 Volunteer hours for political campaign activities _____

Part I-B Complete if the organization is exempt under section 501(c)(3).

- 1 Enter the amount of any excise tax incurred by the organization under section 4955 \$ _____
- 2 Enter the amount of any excise tax incurred by organization managers under section 4955 \$ _____
- 3 If the organization incurred a section 4955 tax, did it file Form 4720 for this year? **Yes** **No**
- 4a Was a correction made? **Yes** **No**
- b If "Yes," describe in Part IV.

Part I-C Complete if the organization is exempt under section 501(c), except section 501(c)(3).

- 1 Enter the amount directly expended by the filing organization for section 527 exempt function activities \$ _____
- 2 Enter the amount of the filing organization's funds contributed to other organizations for section 527 exempt function activities \$ _____
- 3 Total exempt function expenditures. Add lines 1 and 2. Enter here and on Form 1120-POL, line 17b \$ _____
- 4 Did the filing organization file Form 1120-POL for this year? **Yes** **No**
- 5 Enter the names, addresses and employer identification number (EIN) of all section 527 political organizations to which the filing organization made payments. For each organization listed, enter the amount paid from the filing organization's funds. Also enter the amount of political contributions received that were promptly and directly delivered to a separate political organization, such as a separate segregated fund or a political action committee (PAC). If additional space is needed, provide information in Part IV.

(a) Name	(b) Address	(c) EIN	(d) Amount paid from filing organization's funds. If none, enter -0-.	(e) Amount of political contributions received and promptly and directly delivered to a separate political organization. If none, enter -0-.

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ. Schedule C (Form 990) 2022

Part II-A Complete if the organization is exempt under section 501(c)(3) and filed Form 5768 (election under section 501(h)).

- A** Check if the filing organization belongs to an affiliated group (and list in Part IV each affiliated group member's name, address, EIN, expenses, and share of excess lobbying expenditures).
- B** Check if the filing organization checked box A and "limited control" provisions apply.

Limits on Lobbying Expenditures (The term "expenditures" means amounts paid or incurred.)		(a) Filing organization's totals	(b) Affiliated group totals												
1a	Total lobbying expenditures to influence public opinion (grassroots lobbying)	0.													
b	Total lobbying expenditures to influence a legislative body (direct lobbying)	0.													
c	Total lobbying expenditures (add lines 1a and 1b)	0.													
d	Other exempt purpose expenditures	47,565,242.													
e	Total exempt purpose expenditures (add lines 1c and 1d)	47,565,242.													
f	Lobbying nontaxable amount. Enter the amount from the following table in both columns.	1,000,000.													
<table border="1"> <thead> <tr> <th>If the amount on line 1e, column (a) or (b) is:</th> <th>The lobbying nontaxable amount is:</th> </tr> </thead> <tbody> <tr> <td>Not over \$500,000</td> <td>20% of the amount on line 1e.</td> </tr> <tr> <td>Over \$500,000 but not over \$1,000,000</td> <td>\$100,000 plus 15% of the excess over \$500,000.</td> </tr> <tr> <td>Over \$1,000,000 but not over \$1,500,000</td> <td>\$175,000 plus 10% of the excess over \$1,000,000.</td> </tr> <tr> <td>Over \$1,500,000 but not over \$17,000,000</td> <td>\$225,000 plus 5% of the excess over \$1,500,000.</td> </tr> <tr> <td>Over \$17,000,000</td> <td>\$1,000,000.</td> </tr> </tbody> </table>		If the amount on line 1e, column (a) or (b) is:	The lobbying nontaxable amount is:	Not over \$500,000	20% of the amount on line 1e.	Over \$500,000 but not over \$1,000,000	\$100,000 plus 15% of the excess over \$500,000.	Over \$1,000,000 but not over \$1,500,000	\$175,000 plus 10% of the excess over \$1,000,000.	Over \$1,500,000 but not over \$17,000,000	\$225,000 plus 5% of the excess over \$1,500,000.	Over \$17,000,000	\$1,000,000.		
If the amount on line 1e, column (a) or (b) is:	The lobbying nontaxable amount is:														
Not over \$500,000	20% of the amount on line 1e.														
Over \$500,000 but not over \$1,000,000	\$100,000 plus 15% of the excess over \$500,000.														
Over \$1,000,000 but not over \$1,500,000	\$175,000 plus 10% of the excess over \$1,000,000.														
Over \$1,500,000 but not over \$17,000,000	\$225,000 plus 5% of the excess over \$1,500,000.														
Over \$17,000,000	\$1,000,000.														
g	Grassroots nontaxable amount (enter 25% of line 1f)	250,000.													
h	Subtract line 1g from line 1a. If zero or less, enter -0-	0.													
i	Subtract line 1f from line 1c. If zero or less, enter -0-	0.													
j	If there is an amount other than zero on either line 1h or line 1i, did the organization file Form 4720 reporting section 4911 tax for this year?		<input type="checkbox"/> Yes <input type="checkbox"/> No												

4-Year Averaging Period Under Section 501(h)
 (Some organizations that made a section 501(h) election do not have to complete all of the five columns below.
 See the separate instructions for lines 2a through 2f.)

Lobbying Expenditures During 4-Year Averaging Period					
Calendar year (or fiscal year beginning in)	(a) 2019	(b) 2020	(c) 2021	(d) 2022	(e) Total
2a Lobbying nontaxable amount	1,000,000.	1,000,000.	1,000,000.	1,000,000.	4,000,000.
b Lobbying ceiling amount (150% of line 2a, column(e))					6,000,000.
c Total lobbying expenditures					
d Grassroots nontaxable amount	250,000.	250,000.	250,000.	250,000.	1,000,000.
e Grassroots ceiling amount (150% of line 2d, column (e))					1,500,000.
f Grassroots lobbying expenditures					

Part II-B Complete if the organization is exempt under section 501(c)(3) and has NOT filed Form 5768 (election under section 501(h)).

Table with 3 columns: (a) Yes, (a) No, (b) Amount. Rows include: 1 During the year, did the filing organization attempt to influence foreign, national, state, or local legislation... a Volunteers? b Paid staff or management... c Media advertisements? d Mailings to members... e Publications... f Grants to other organizations... g Direct contact with legislators... h Rallies, demonstrations... i Other activities? j Total. Add lines 1c through 1i... 2a Did the activities in line 1 cause the organization to be not described in section 501(c)(3)? b If "Yes," enter the amount of any tax incurred under section 4912... c If "Yes," enter the amount of any tax incurred by organization managers under section 4912... d If the filing organization incurred a section 4912 tax, did it file Form 4720 for this year?

Part III-A Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6).

Table with 3 columns: Question, Yes, No. Rows include: 1 Were substantially all (90% or more) dues received nondeductible by members? 2 Did the organization make only in-house lobbying expenditures of \$2,000 or less? 3 Did the organization agree to carry over lobbying and political campaign activity expenditures from the prior year?

Part III-B Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6) and if either (a) BOTH Part III-A, lines 1 and 2, are answered "No" OR (b) Part III-A, line 3, is answered "Yes."

Table with 2 columns: Question, Amount. Rows include: 1 Dues, assessments and similar amounts from members 2 Section 162(e) nondeductible lobbying and political expenditures (do not include amounts of political expenses for which the section 527(f) tax was paid). a Current year b Carryover from last year c Total 3 Aggregate amount reported in section 6033(e)(1)(A) notices of nondeductible section 162(e) dues 4 If notices were sent and the amount on line 2c exceeds the amount on line 3, what portion of the excess does the organization agree to carryover to the reasonable estimate of nondeductible lobbying and political expenditures next year? 5 Taxable amount of lobbying and political expenditures. See instructions

Part IV Supplemental Information

Provide the descriptions required for Part I-A, line 1; Part I-B, line 4; Part I-C, line 5; Part II-A (affiliated group list); Part II-A, lines 1 and 2 (See instructions); and Part II-B, line 1. Also, complete this part for any additional information.

Blank lines for supplemental information.

SCHEDULE D (Form 990)

Department of the Treasury Internal Revenue Service

Supplemental Financial Statements

Complete if the organization answered "Yes" on Form 990, Part IV, line 6, 7, 8, 9, 10, 11a, 11b, 11c, 11d, 11e, 11f, 12a, or 12b. Attach to Form 990.

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2022

Open to Public Inspection

Name of the organization BRIGHTFOCUS FOUNDATION Employer identification number 23-7337229

Part I Organizations Maintaining Donor Advised Funds or Other Similar Funds or Accounts. Complete if the organization answered "Yes" on Form 990, Part IV, line 6.

Table with 3 columns: Question, (a) Donor advised funds, (b) Funds and other accounts. Rows include total number at end of year, aggregate value of contributions, grants, and end of year, and two Yes/No questions regarding donor property and grant fund usage.

Part II Conservation Easements. Complete if the organization answered "Yes" on Form 990, Part IV, line 7.

Table with 3 columns: Question, (a) Donor advised funds, (b) Funds and other accounts. Rows include purpose of easements, total number and acreage, modified easements, states where located, monitoring policy, staff hours, expenses, and requirements of section 170(h)(4)(B)(i).

Part III Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets. Complete if the organization answered "Yes" on Form 990, Part IV, line 8.

Table with 3 columns: Question, (a) Donor advised funds, (b) Funds and other accounts. Rows include elected not to report art collections and elected to report art collections with revenue and asset amounts.

LHA For Paperwork Reduction Act Notice, see the Instructions for Form 990. Schedule D (Form 990) 2022

Part III Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets (continued)

- 3 Using the organization's acquisition, accession, and other records, check any of the following that make significant use of its collection items (check all that apply):
- a Public exhibition
 - b Scholarly research
 - c Preservation for future generations
 - d Loan or exchange program
 - e Other _____
- 4 Provide a description of the organization's collections and explain how they further the organization's exempt purpose in Part XIII.
- 5 During the year, did the organization solicit or receive donations of art, historical treasures, or other similar assets to be sold to raise funds rather than to be maintained as part of the organization's collection? Yes No

Part IV Escrow and Custodial Arrangements. Complete if the organization answered "Yes" on Form 990, Part IV, line 9, or reported an amount on Form 990, Part X, line 21.

- 1a Is the organization an agent, trustee, custodian or other intermediary for contributions or other assets not included on Form 990, Part X? Yes No
- b If "Yes," explain the arrangement in Part XIII and complete the following table:
- | | Amount |
|---------------------------------|--------|
| c Beginning balance | 1c |
| d Additions during the year | 1d |
| e Distributions during the year | 1e |
| f Ending balance | 1f |
- 2a Did the organization include an amount on Form 990, Part X, line 21, for escrow or custodial account liability? Yes No
- b If "Yes," explain the arrangement in Part XIII. Check here if the explanation has been provided on Part XIII

Part V Endowment Funds. Complete if the organization answered "Yes" on Form 990, Part IV, line 10.

	(a) Current year	(b) Prior year	(c) Two years back	(d) Three years back	(e) Four years back
1a Beginning of year balance	325,000.	302,000.	302,000.	302,000.	320,000.
b Contributions	14,978.	13,634.	14,744.	14,778.	14,385.
c Net investment earnings, gains, and losses	-14,978.	23,000.			-18,000.
d Grants or scholarships					
e Other expenditures for facilities and programs	14,978.	13,634.	14,744.	14,778.	14,385.
f Administrative expenses					
g End of year balance	310,022.	325,000.	302,000.	302,000.	302,000.

- 2 Provide the estimated percentage of the current year end balance (line 1g, column (a)) held as:
- a Board designated or quasi-endowment .0000 %
 - b Permanent endowment 100 %
 - c Term endowment .0000 %
- The percentages on lines 2a, 2b, and 2c should equal 100%.
- 3a Are there endowment funds not in the possession of the organization that are held and administered for the organization by:
- | | Yes | No |
|---|-----|----|
| (i) Unrelated organizations | X | |
| (ii) Related organizations | | X |
| b If "Yes" on line 3a(ii), are the related organizations listed as required on Schedule R? <input type="checkbox"/> | 3b | |
- 4 Describe in Part XIII the intended uses of the organization's endowment funds.

Part VI Land, Buildings, and Equipment.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11a. See Form 990, Part X, line 10.

Description of property	(a) Cost or other basis (investment)	(b) Cost or other basis (other)	(c) Accumulated depreciation	(d) Book value
1a Land	2,800,000.	1,147,363.		3,947,363.
b Buildings	1,629,400.	5,328,141.	4,057,635.	2,899,906.
c Leasehold improvements				
d Equipment		1,946,235.	694,631.	1,251,604.
e Other		216,753.	187,347.	29,406.
Total. Add lines 1a through 1e. (Column (d) must equal Form 990, Part X, column (B), line 10c.)				8,128,279.

Part VII Investments - Other Securities.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11b. See Form 990, Part X, line 12.

(a) Description of security or category (including name of security)	(b) Book value	(c) Method of valuation: Cost or end-of-year market value
(1) Financial derivatives		
(2) Closely held equity interests		
(3) Other		
(A)		
(B)		
(C)		
(D)		
(E)		
(F)		
(G)		
(H)		
Total. (Col. (b) must equal Form 990, Part X, col. (B) line 12.)		

Part VIII Investments - Program Related.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11c. See Form 990, Part X, line 13.

(a) Description of investment	(b) Book value	(c) Method of valuation: Cost or end-of-year market value
(1)		
(2)		
(3)		
(4)		
(5)		
(6)		
(7)		
(8)		
(9)		
Total. (Col. (b) must equal Form 990, Part X, col. (B) line 13.)		

Part IX Other Assets.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11d. See Form 990, Part X, line 15.

(a) Description	(b) Book value
(1)	
(2)	
(3)	
(4)	
(5)	
(6)	
(7)	
(8)	
(9)	
Total. (Column (b) must equal Form 990, Part X, col. (B) line 15.)	

Part X Other Liabilities.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11e or 11f. See Form 990, Part X, line 25.

1. (a) Description of liability	(b) Book value
(1) Federal income taxes	
(2) CHARITABLE GIFT ANNUITIES	584,542.
(3) CAPITAL LEASE OBLIGATIONS	106,015.
(4) RENTAL DEPOSITS	25,000.
(5)	
(6)	
(7)	
(8)	
(9)	
Total. (Column (b) must equal Form 990, Part X, col. (B) line 25.)	

2. Liability for uncertain tax positions. In Part XIII, provide the text of the footnote to the organization's financial statements that reports the organization's liability for uncertain tax positions under FASB ASC 740. Check here if the text of the footnote has been provided in Part XIII ...

Part XI Reconciliation of Revenue per Audited Financial Statements With Revenue per Return.

Complete if the organization answered "Yes" on Form 990, Part IV, line 12a.

1	Total revenue, gains, and other support per audited financial statements		1	67,833,289.
2	Amounts included on line 1 but not on Form 990, Part VIII, line 12:			
	a Net unrealized gains (losses) on investments	2a	-2,139,406.	
	b Donated services and use of facilities	2b	25,308,680.	
	c Recoveries of prior year grants	2c	1,028,552.	
	d Other (Describe in Part XIII.)	2d		
	e Add lines 2a through 2d	2e	24,197,826.	
3	Subtract line 2e from line 1		3	43,635,463.
4	Amounts included on Form 990, Part VIII, line 12, but not on line 1:			
	a Investment expenses not included on Form 990, Part VIII, line 7b	4a	327,036.	
	b Other (Describe in Part XIII.)	4b	-68,702.	
	c Add lines 4a and 4b	4c	258,334.	
5	Total revenue. Add lines 3 and 4c. (This must equal Form 990, Part I, line 12.)		5	43,893,797.

Part XII Reconciliation of Expenses per Audited Financial Statements With Expenses per Return.

Complete if the organization answered "Yes" on Form 990, Part IV, line 12a.

1	Total expenses and losses per audited financial statements		1	73,291,396.
2	Amounts included on line 1 but not on Form 990, Part IX, line 25:			
	a Donated services and use of facilities	2a	25,308,680.	
	b Prior year adjustments	2b		
	c Other losses	2c		
	d Other (Describe in Part XIII.)	2d	26,923.	
	e Add lines 2a through 2d	2e	25,335,603.	
3	Subtract line 2e from line 1		3	47,955,793.
4	Amounts included on Form 990, Part IX, line 25, but not on line 1:			
	a Investment expenses not included on Form 990, Part VIII, line 7b	4a	327,036.	
	b Other (Describe in Part XIII.)	4b	225,385.	
	c Add lines 4a and 4b	4c	552,421.	
5	Total expenses. Add lines 3 and 4c. (This must equal Form 990, Part I, line 18.)		5	48,508,214.

Part XIII Supplemental Information.

Provide the descriptions required for Part II, lines 3, 5, and 9; Part III, lines 1a and 4; Part IV, lines 1b and 2b; Part V, line 4; Part X, line 2; Part XI, lines 2d and 4b; and Part XII, lines 2d and 4b. Also complete this part to provide any additional information.

PART V, LINE 4:

THE EARNINGS ON THIS ENDOWMENT ARE AVAILABLE FOR THE ALZHEIMER'S DISEASE RESEARCH PROGRAM, ARE RECORDED AS TEMPORARILY RESTRICTED INVESTMENT INCOME, AND ARE RELEASED AS SPENT.

PART X, LINE 2:

BRIGHTFOCUS PERFORMED AN EVALUATION OF UNCERTAINTY IN INCOME TAXES FOR THE YEAR ENDED MARCH 31, 2023, AND DETERMINED THAT THERE WERE NO MATTERS THAT WOULD REQUIRE RECOGNITION IN THE CONSOLIDATED FINANCIAL STATEMENTS OR THAT MAY HAVE ANY EFFECT ON ITS TAX-EXEMPT STATUS.

PART XI, LINE 4B - OTHER ADJUSTMENTS:

Part XIII Supplemental Information (continued)

DEPRECIATION OF RENTAL PROPERTY -41,779.

FUNDRAISING EVENT EXPENSES -26,923.

TOTAL TO SCHEDULE D, PART XI, LINE 4B -68,702.

PART XII, LINE 2D - OTHER ADJUSTMENTS:

FUNDRAISING EVENT EXPENSES 26,923.

PART XII, LINE 4B - OTHER ADJUSTMENTS:

DEPRECIATION ON RENTAL PROPERTY -41,779.

CHANGE IN PRESENT VALUE OF GRANTS 267,164.

TOTAL TO SCHEDULE D, PART XII, LINE 4B 225,385.

**SCHEDULE F
(Form 990)**

Statement of Activities Outside the United States

Complete if the organization answered "Yes" on Form 990, Part IV, line 14b, 15, or 16.

Attach to Form 990.

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2022

Open to Public Inspection

Department of the Treasury
Internal Revenue Service

Name of the organization: **BRIGHTFOCUS FOUNDATION**
Employer identification number: **23-7337229**

Part I General Information on Activities Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 14b.

1 For grantmakers. Does the organization maintain records to substantiate the amount of its grants and other assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used to award the grants or assistance? Yes No

2 For grantmakers. Describe in Part V the organization's procedures for monitoring the use of its grants and other assistance outside the United States.

3 Activities per Region. (The following Part I, line 3 table can be duplicated if additional space is needed.)

(a) Region	(b) Number of offices in the region	(c) Number of employees, agents, and independent contractors in the region	(d) Activities conducted in the region (by type) (such as, fundraising, program services, investments, grants to recipients located in the region)	(e) If activity listed in (d) is a program service, describe specific type of service(s) in the region	(f) Total expenditures for and investments in the region
EAST ASIA AND THE PACIFIC	0	0	GRANTMAKING		334,938.
EUROPE	0	0	GRANTMAKING		1,765,924.
MIDDLE EAST AND NORTH AFRICA	0	0	GRANTMAKING		300,000.
NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES	0	0	GRANTMAKING		200,000.
3 a Subtotal	0	0			2,600,862.
b Total from continuation sheets to Part I	0	0			0.
c Totals (add lines 3a and 3b)	0	0			2,600,862.

Part II **Grants and Other Assistance to Organizations or Entities Outside the United States.** Complete if the organization answered "Yes" on Form 990, Part IV, line 15, for any recipient who received more than \$5,000. Part II can be duplicated if additional space is needed.

1 (a) Name of organization	(b) IRS code section and EIN (if applicable)	(c) Region	(d) Purpose of grant	(e) Amount of cash grant	(f) Manner of cash disbursement	(g) Amount of noncash assistance	(h) Description of noncash assistance	(i) Method of valuation (book, FMV, appraisal, other)
		EUROPE	ALZHEIMER'S DISEASE RESEARCH BY L. CHAVEZ GUTIERREZ, PHD, ENTITLED: (A2023005S)	300,000.	WIRE TRANSFER	0.		
		EUROPE	ALZHEIMER'S DISEASE RESEARCH BY MARTA CASQUERO-VEIGA, PHD, ENTITLED: (A2023012F)	200,000.	WIRE TRANSFER	0.		
		EUROPE	ALZHEIMER'S DISEASE RESEARCH BY QI WANG, PHD, ENTITLED: (A2023018F)	200,000.	WIRE TRANSFER	0.		
		MIDDLE EAST	ALZHEIMER'S DISEASE RESEARCH BY ARIEL GILAD, PHD, ENTITLED: (A2023024S)	300,000.	WIRE TRANSFER	0.		
		EUROPE	ALZHEIMER'S DISEASE RESEARCH BY LOUISE VAN DER WEERD, PHD, ENTITLED: (A2023026S)	299,354.	WIRE TRANSFER	0.		
		EUROPE	ALZHEIMER'S DISEASE RESEARCH CONFERENCE SUPPORT	99,353.	WIRE TRANSFER	0.		
		EUROPE	TRAVEL GRANTS FOR CONFERENCE ATTENDANCE	10,000.	WIRE TRANSFER	0.		
		EUROPE	ALZHEIMER'S DISEASE RESEARCH BY DR. GAELLE CHETELAT, ENTITLED: (CA2021013)	25,000.	WIRE TRANSFER	0.		

2 Enter total number of recipient organizations listed above that are recognized as charities by the foreign country, recognized as a tax exempt 501(c)(3) organization by the IRS, or for which the grantee or counsel has provided a section 501(c)(3) equivalency letter 13

3 Enter total number of other organizations or entities 0

Part II Continuation of Grants and Other Assistance to Organizations or Entities Outside the United States. (Schedule F (Form 990), Part II, line 1)									
1	(a) Name of organization	(b) IRS code section and EIN (if applicable)	(c) Region	(d) Purpose of grant	(e) Amount of cash grant	(f) Manner of cash disbursement	(g) Amount of non-cash assistance	(h) Description of non-cash assistance	(i) Method of valuation (book, FMV, appraisal, other)
			EUROPE	NATIONAL GLAUCOMA RESEARCH BY KAREN PEYNSHAERT, PHD, ENTITLED: (G2023002F)	150,000.	WIRE TRANSFER	0.		
			NORTH AMERICA	NATIONAL GLAUCOMA RESEARCH BY ADRIANA DI POLO, PHD, ENTITLED: (G2023005S)	200,000.	WIRE TRANSFER	0.		
			EUROPE	NATIONAL GLAUCOMA RESEARCH BY SILVIA MARINELLI, PHD, ENTITLED: (G2023006S)	200,000.	WIRE TRANSFER	0.		
			EUROPE	NATIONAL GLAUCOMA RESEARCH BY DARRYL OVERBY, PHD, ENTITLED: (G2023011S)	184,242.	WIRE TRANSFER	0.		
			EUROPE	NATIONAL GLAUCOMA RESEARCH BY DARRYL OVERBY, PHD, ENTITLED: (CG2020003)	97,975.	WIRE TRANSFER	0.		
			EAST ASIA & PACIFIC	MACULAR DEGENERATION RESEARCH BY MATTHEW RUTAR, PHD, ENTITLED: (M2023009N)	334,938.	WIRE TRANSFER	0.		

BRIGHTFOCUS FOUNDATION

23-7337229

Part III Grants and Other Assistance to Individuals Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 16.

Part III can be duplicated if additional space is needed.

(a) Type of grant or assistance	(b) Region	(c) Number of recipients	(d) Amount of cash grant	(e) Manner of cash disbursement	(f) Amount of noncash assistance	(g) Description of noncash assistance	(h) Method of valuation (book, FMV, appraisal, other)

Part IV Foreign Forms

- 1 Was the organization a U.S. transferor of property to a foreign corporation during the tax year? *If "Yes," the organization may be required to file Form 926, Return by a U.S. Transferor of Property to a Foreign Corporation (see Instructions for Form 926)* Yes No
- 2 Did the organization have an interest in a foreign trust during the tax year? *If "Yes," the organization may be required to separately file Form 3520, Annual Return To Report Transactions With Foreign Trusts and Receipt of Certain Foreign Gifts, and/or Form 3520-A, Annual Information Return of Foreign Trust With a U.S. Owner (see Instructions for Forms 3520 and 3520-A; don't file with Form 990)* Yes No
- 3 Did the organization have an ownership interest in a foreign corporation during the tax year? *If "Yes," the organization may be required to file Form 5471, Information Return of U.S. Persons With Respect to Certain Foreign Corporations (see Instructions for Form 5471)* Yes No
- 4 Was the organization a direct or indirect shareholder of a passive foreign investment company or a qualified electing fund during the tax year? *If "Yes," the organization may be required to file Form 8621, Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund (see Instructions for Form 8621)* Yes No
- 5 Did the organization have an ownership interest in a foreign partnership during the tax year? *If "Yes," the organization may be required to file Form 8865, Return of U.S. Persons With Respect to Certain Foreign Partnerships (see Instructions for Form 8865)* Yes No
- 6 Did the organization have any operations in or related to any boycotting countries during the tax year? *If "Yes," the organization may be required to separately file Form 5713, International Boycott Report (see Instructions for Form 5713; don't file with Form 990)* Yes No

Schedule F (Form 990) 2022

Part V Supplemental Information

Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.

PART I, LINE 2:

BRIGHTFOCUS INTERACTS WITH ALL GRANTEES AT LEAST QUARTERLY BY E-MAIL OR AT SCIENTIFIC MEETINGS. IN ADDITION TO THESE INTERACTIONS, EACH GRANT RECIPIENT IS REQUIRED TO SUBMIT SEPARATE DETAILED ANNUAL SCIENTIFIC PROGRESS AND FINANCIAL REPORTS TO BRIGHTFOCUS. THESE ARE RECEIVED BY THE BRIGHTFOCUS SCIENTIFIC AFFAIRS DEPARTMENT, AND REVIEWED BY SCIENTIFIC STAFF WITH BROAD EXPERTISE, INCLUDING IMAGING, MOLECULAR BIOLOGY AND SIGNALING PATHWAYS, CELL BIOLOGY, ANGIOGENESIS, BIOCHEMISTRY, NEUROSCIENCE, AND GENETICS. SENIOR STAFF REVIEWS EACH PROGRESS REPORT AND EVALUATES THE PROJECT FOR SUFFICIENT PROGRESS TOWARDS THE SPECIFIC AIMS PROPOSED IN THE ORIGINAL APPLICATION OR ANY BUDGETARY CONCERNS. THIS EFFORT IS SUPPORTED BY ADDITIONAL SCIENTIFIC COUNSEL FROM MEMBERS OF THE BRIGHTFOCUS SCIENTIFIC REVIEW COMMITTEES, WHEN REQUIRED. IN ADDITION TO STATEMENTS OF EXPERIMENTAL PROGRESS, ALL GRANTEES ARE ASKED TO REPORT ANY TECHNICAL PUBLICATIONS, MEDIA REPORTS, OR PATENT APPLICATIONS IN WHICH BRIGHTFOCUS-SPONSORED RESEARCH IS DESCRIBED. IF SIGNIFICANT CONCERNS RELATED TO PROGRESS ON THE AWARDS ARE DISCOVERED, AND NOT RESOLVED AFTER INTERACTION WITH THE AWARD GRANTEE, THE BRIGHTFOCUS STAFF RECOMMENDS APPROPRIATE ACTIONS TO THE CHAIR OF THE SCIENTIFIC AFFAIRS COMMITTEE OF THE BOARD OF DIRECTORS. IN ACCORDANCE WITH THE GRANT AGREEMENT TERMS AND CONDITIONS, BRIGHTFOCUS MAY WITHHOLD FUNDING, OR DISCONTINUE AN AWARD, FOR ANY GRANTEE THAT FAILS TO ACHIEVE SUFFICIENT PROGRESS OR SUBMIT REQUIRED REPORTS.

AT THE CONCLUSION OF THE GRANT AWARD PERIOD, EACH GRANTEE MUST COMPLETE AND SUBMIT A FINAL REPORT THAT IS ALSO REVIEWED BY THE BRIGHTFOCUS SENIOR SCIENTIFIC STAFF. EVALUATION OF THE WORK OF EACH GRANTEE IS QUALITATIVELY

Part V Supplemental Information

Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.

AND QUANTITATIVELY ASSESSED THROUGH VARIOUS METRICS RELATED TO THE IMPACT OF THE GRANT ON ITS TARGETED DISEASE FIELD. SUCH IMPACT METRICS HAVE REVEALED THAT 95% OF BRIGHTFOCUS-SUPPORTED RESEARCH RESULTS IN RESEARCH PUBLICATIONS THAT ADVANCE THE FIELDS SERVED BY BRIGHTFOCUS. THIS IMPACT IS FURTHER SUPPORTED BY ANNUAL CATEGORY NORMALIZED CITATION IMPACT ANALYSIS THAT COMPARES BRIGHTFOCUS-SUPPORTED WORKS TO AN UNBIASED COMPARISON OF IMPACT PERFORMANCE VERSUS THE WORLD AVERAGE. BRIGHTFOCUS-SUPPORTED PUBLICATIONS WERE RECENTLY CITED AT 2 TIMES THE FREQUENCY OF THE WORLD AVERAGE. A FINAL EXAMPLE OF IMPACT ASSESSMENT REVEALED THAT THE SUCCESSES OF BRIGHTFOCUS GRANTEES CONTINUE LONG AFTER THE GRANT EXPIRES. ON AVERAGE, EACH GRANTEE RECEIVES ADDITIONAL GRANTS FOR FOLLOW-ON PROJECTS SPAWNED BY THE BRIGHTFOCUS GRANT, WITH VALUES UP TO 10 TIMES THE LEVEL OF THE INITIAL BRIGHTFOCUS INVESTMENT.

BRIGHTFOCUS SOLICITS FEEDBACK FROM ITS GRANTEES, AND PROVIDES AN ANONYMOUS FORUM FOR COLLECTING SUCH INFORMATION. THROUGH THE BRIGHTFOCUS FOUNDATION WEBSITE AND WITHIN THE SCIENTIFIC PROGRESS REPORTS, THERE ARE DESIGNATED SECTIONS WHERE AWARDEES ARE ASKED TO PROVIDE FEEDBACK TO THE FOUNDATION. THROUGH THIS MECHANISM, THEY ARE GIVEN THE ABILITY TO ANONYMOUSLY PROVIDE FEEDBACK OR COMMUNICATE THEIR CONCERNS TO PROGRAM STAFF OR THE BRIGHTFOCUS' COMPLIANCE OFFICE. ANY SUGGESTIONS, CONCERNS, COMPLAINTS, OR POSITIVE EXPERIENCES CAN BE OUTLINED AND BROUGHT TO THE ATTENTION OF BRIGHTFOCUS IN THIS MANNER, SO THAT BRIGHTFOCUS CAN ADDRESS ANY AREAS NEEDING IMPROVEMENT, REAFFIRM PRAISE-WORTHY POLICIES, OR OTHERWISE ASSESS NEEDS FOR PROGRAMMATIC CHANGE. THE SENIOR LEADERSHIP PRESENTS AND SUMMARIZES THE STATUS AND PROGRESS ON GRANTS TO THE BRIGHTFOCUS BOARD OF DIRECTORS AT EACH OF THEIR QUARTERLY BOARD MEETINGS.

Part V Supplemental Information

Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.

PART I, LINE 3:

BRIGHTFOCUS REPORTED THE EXPENDITURES BASED ON THE ACCOUNTING METHOD USED IN ITS AUDITED FINANCIAL STATEMENTS WHICH IS ON AN ACCRUAL BASIS.

PART II, LINE 1:

BRIGHTFOCUS REPORTED THE EXPENDITURES BASED ON THE ACCOUNTING METHOD USED IN ITS AUDITED FINANCIAL STATEMENTS WHICH IS ON AN ACCRUAL BASIS.

**SCHEDULE G
(Form 990)**

Supplemental Information Regarding Fundraising or Gaming Activities

OMB No. 1545-0047

Complete if the organization answered "Yes" on Form 990, Part IV, line 17, 18, or 19, or if the organization entered more than \$15,000 on Form 990-EZ, line 6a.

2022

Department of the Treasury
Internal Revenue Service

Attach to Form 990 or Form 990-EZ.

Open to Public Inspection

Go to www.irs.gov/Form990 for instructions and the latest information.

Name of the organization **BRIGHTFOCUS FOUNDATION** Employer identification number **23-7337229**

Part I Fundraising Activities. Complete if the organization answered "Yes" on Form 990, Part IV, line 17. Form 990-EZ filers are not required to complete this part.

- 1 Indicate whether the organization raised funds through any of the following activities. Check all that apply.
- a Mail solicitations
 - b Internet and email solicitations
 - c Phone solicitations
 - d In-person solicitations
 - e Solicitation of non-government grants
 - f Solicitation of government grants
 - g Special fundraising events
- 2 a Did the organization have a written or oral agreement with any individual (including officers, directors, trustees, or key employees listed in Form 990, Part VII) or entity in connection with professional fundraising services? Yes No
- b If "Yes," list the 10 highest paid individuals or entities (fundraisers) pursuant to agreements under which the fundraiser is to be compensated at least \$5,000 by the organization.

(i) Name and address of individual or entity (fundraiser)	(ii) Activity	(iii) Did fundraiser have custody or control of contributions?		(iv) Gross receipts from activity	(v) Amount paid to (or retained by) fundraiser listed in col. (i)	(vi) Amount paid to (or retained by) organization
		Yes	No			
RKD GROUP - 35 PARKWOOD DRIVE, STE. 160, HOPKINTON, ALLEGIANCE GROUP - 2300 CLARENDON BLVD., STE. 925,	FUNDRAISING AND COMMUNICATIONS CONSULTANT		X	30,452,088.	499,942.	29,952,146.
	FUNDRAISING AND COMMUNICATIONS CONSULTANT		X	2,368,623.	452,839.	1,915,784.
Total				32,820,711.	952,781.	31,867,930.

- 3 List all states in which the organization is registered or licensed to solicit contributions or has been notified it is exempt from registration or licensing.
- AK, AL, AR, AZ, CA, CO, CT, DC, FL, GA, HI, IL, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, NC, ND, NH, NJ, NM, NV, NY, OH, OK, OR, PA, RI, SC, TN, UT, VA, WA, WI, WV

Part II Fundraising Events. Complete if the organization answered "Yes" on Form 990, Part IV, line 18, or reported more than \$15,000 of fundraising event contributions and gross income on Form 990-EZ, lines 1 and 6b. List events with gross receipts greater than \$5,000.

		(a) Event #1	(b) Event #2	(c) Other events	(d) Total events (add col. (a) through col. (c))
		AN EVENING OF BRIGHTFOC (event type)	(event type)	NONE (total number)	
Revenue	1	Gross receipts	306,298.		306,298.
	2	Less: Contributions	242,498.		242,498.
	3	Gross income (line 1 minus line 2)	63,800.		63,800.
Direct Expenses	4	Cash prizes			
	5	Noncash prizes			
	6	Rent/facility costs	44,401.		44,401.
	7	Food and beverages	129,808.		129,808.
	8	Entertainment	71,034.		71,034.
	9	Other direct expenses	127,811.		127,811.
	10	Direct expense summary. Add lines 4 through 9 in column (d)			
11	Net income summary. Subtract line 10 from line 3, column (d)				-309,254.

Part III Gaming. Complete if the organization answered "Yes" on Form 990, Part IV, line 19, or reported more than \$15,000 on Form 990-EZ, line 6a.

		(a) Bingo	(b) Pull tabs/instant bingo/progressive bingo	(c) Other gaming	(d) Total gaming (add col. (a) through col. (c))	
Revenue	1	Gross revenue				
Direct Expenses	2	Cash prizes				
	3	Noncash prizes				
	4	Rent/facility costs				
	5	Other direct expenses				
	6	Volunteer labor	<input type="checkbox"/> Yes _____ % <input type="checkbox"/> No	<input type="checkbox"/> Yes _____ % <input type="checkbox"/> No	<input type="checkbox"/> Yes _____ % <input type="checkbox"/> No	
	7	Direct expense summary. Add lines 2 through 5 in column (d)				
	8	Net gaming income summary. Subtract line 7 from line 1, column (d)				

9 Enter the state(s) in which the organization conducts gaming activities: _____

a Is the organization licensed to conduct gaming activities in each of these states? Yes No

b If "No," explain: _____

10a Were any of the organization's gaming licenses revoked, suspended, or terminated during the tax year? Yes No

b If "Yes," explain: _____

- 11 Does the organization conduct gaming activities with nonmembers? Yes No
- 12 Is the organization a grantor, beneficiary or trustee of a trust, or a member of a partnership or other entity formed to administer charitable gaming? Yes No
- 13 Indicate the percentage of gaming activity conducted in:

a The organization's facility	13a	%
b An outside facility	13b	%
- 14 Enter the name and address of the person who prepares the organization's gaming/special events books and records:

Name _____

Address _____

- 15a Does the organization have a contract with a third party from whom the organization receives gaming revenue? Yes No
- b If "Yes," enter the amount of gaming revenue received by the organization \$ _____ and the amount of gaming revenue retained by the third party \$ _____
- c If "Yes," enter name and address of the third party:

Name _____

Address _____

16 Gaming manager information:

Name _____

Gaming manager compensation \$ _____

Description of services provided _____

- Director/officer
- Employee
- Independent contractor

17 Mandatory distributions:

- a Is the organization required under state law to make charitable distributions from the gaming proceeds to retain the state gaming license? Yes No
- b Enter the amount of distributions required under state law to be distributed to other exempt organizations or spent in the organization's own exempt activities during the tax year \$ _____

Part IV Supplemental Information. Provide the explanations required by Part I, line 2b, columns (iii) and (v); and Part III, lines 9, 9b, 10b, 15b, 15c, 16, and 17b, as applicable. Also provide any additional information. See instructions.

SCHEDULE G, PART I, LINE 2B, LIST OF TEN HIGHEST PAID FUNDRAISERS:

(I) NAME OF FUNDRAISER: RKD GROUP

(I) ADDRESS OF FUNDRAISER:

35 PARKWOOD DRIVE, STE. 160, HOPKINTON, MA 01748

(I) NAME OF FUNDRAISER: ALLEGIANCE GROUP

(I) ADDRESS OF FUNDRAISER:

2300 CLARENDON BLVD., STE. 925, ARLINGTON, VA 22201

Part IV Supplemental Information (continued)

PART I, LINE 2B, COLUMN (V):

IN THE CONTRACT WITH RKD GROUP, THE MANAGEMENT FEES ARE FIXED AMOUNTS PER MONTH FOR IN-SCOPE SERVICES THAT TOTALS \$1,128,624 PER YEAR OF WHICH \$628,682 HAS BEEN ALLOCATED UNDER PART XI, LINE 11(G) TO PROGRAM AND MANAGEMENT AND ARE NOT CONSIDERED TO BE THE PROFESSIONAL FUNDRAISING CONSULTANT FEE.

**SCHEDULE I
(Form 990)**

Department of the Treasury
Internal Revenue Service

**Grants and Other Assistance to Organizations,
Governments, and Individuals in the United States**

Complete if the organization answered "Yes" on Form 990, Part IV, line 21 or 22.
Attach to Form 990.

Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2022

Open to Public
Inspection

Name of the organization

BRIGHTFOCUS FOUNDATION

Part I General Information on Grants and Assistance

Employer identification number
23-7337229

- 1** Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used to award the grants or assistance? Yes No
- 2** Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.

Part II Grants and Other Assistance to Domestic Organizations and Domestic Governments. Complete if the organization answered "Yes" on Form 990, Part IV, line 21, for any recipient that received more than \$5,000. Part II can be duplicated if additional space is needed.

1 (a) Name and address of organization or government	(b) EIN	(c) IRC section (if applicable)	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of noncash assistance	(h) Purpose of grant or assistance
MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02145	04-2697983	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY ZAHRA SHIRZADI, PHD, ENTITLED: (A2023001F)
BAYLOR COLLEGE OF MEDICINE ONE BAYLOR PLAZA, MS: BCM 310 HOUSTON, TX 77030	74-1613878	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY DAHEUN CHUNG, PHD, ENTITLED: (A2023002F)
NORTHWESTERN UNIVERSITY FEINBERG SCHOOL OF MEDICINE - 750 N. LAKE SHORE DRIVE, RUBLOFF, 7TH FLOOR - CHICAGO, IL 60611	36-2167817	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY DAVID GATE, PHD, ENTITLED: (A2023003S)
JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE - 733 NORTH BROADWAY, SUITE 117, BROADWAY RESEARCH BUILDING - BALTIMORE, MD 21205	52-0595110	501(C)(3)	296,426.	0.			ALZHEIMER'S DISEASE RESEARCH BY MEAGHAN MORRIS, MD, PHD, ENTITLED: (A2023004S)
CORNELL UNIVERSITY 373 PINE TREE ROAD ITHACA, NY 14850	15-0532082	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY MATTHEW ISAACSON, PHD, ENTITLED: (A2023006F)
MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02145	04-2697983	501(C)(3)	199,600.	0.			ALZHEIMER'S DISEASE RESEARCH BY JOOST RIPHAGEN, MD, PHD, ENTITLED: (A2023007F)

- 2** Enter total number of section 501(c)(3) and government organizations listed in the line 1 table **58.**
- 3** Enter total number of other organizations listed in the line 1 table **0.**

LHA For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Schedule I (Form 990) 2022

Part II Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments (Schedule I (Form 990), Part II).

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY - 1300 YORK AVE - NEW YORK, NY 10065	13-1623978	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY TILL ZIMMER, PHD, ENTITLED: (A2023008F)
UNIVERSITY OF SOUTH FLORIDA 3702 SPECTRUM BLVD, SUITE 165 TAMPA, FL 33612	59-3102112	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY ARI SUDWARTS, PHD, ENTITLED: (A2023009F)
UNIVERSITY OF CALIFORNIA, LOS ANGELES - 10889 WILSHIRE BOULEVARD, SUITE - LOS ANGELES, CA 90095	95-6006143	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY DAVID BOYER, PHD, ENTITLED: (A2023010F)
MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02145	04-2697983	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY JINGYUAN CHEN, PHD, ENTITLED: (A2023011S)
NORTHWESTERN UNIVERSITY FEINBERG SCHOOL OF MEDICINE - 750 N. LAKE SHORE DRIVE, RUBLOFF, 7TH FLOOR - CHICAGO, IL 60611	36-2167817	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY ARUN UPADHYAY, PHD, ENTITLED: (A2023013F)
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY - 1300 YORK AVE - NEW YORK, NY 10065	13-1623978	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY SUNG JI AHN, PHD, ENTITLED: (A2023014F)
JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE - 733 NORTH BROADWAY, SUITE 117, BROADWAY RESEARCH BUILDING - BALTIMORE, MD 21205	52-0595110	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY ALYSSA COYNE, PHD, ENTITLED: (A2023015S)
UNIVERSITY OF SOUTHERN CALIFORNIA 3720 S. FLOWER STREET, 3RD FLOOR LOS ANGELES, CA 90089	95-1642394	501(C)(3)	299,141.	0.			ALZHEIMER'S DISEASE RESEARCH BY PAUL SEIDLER, PHD, ENTITLED: (A2023016S)
SHRINERS HOSPITALS FOR CHILDREN - NORTHERN CALIFORNIA - 2425 STOCKTON BLVD - SACRAMENTO, CA 95817	36-2193608	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY OLGA CHECHNEVA, PHD, ENTITLED: (A2023017S)

Schedule I (Form 990)

Part II Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO - OFFICE OF SPONSORED RESEARCH, 490 ILLINOIS STREET, 4TH FLOOR - SAN FRANCISCO, CA 94143	94-6036493	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY HENRY PAN, PHD, ENTITLED: (A2023019F)
UNIVERSITY OF KENTUCKY 500 SOUTH LIMESTONE LEXINGTON, KY 40526	61-6033693	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY KATE FOLEY, PHD, ENTITLED: (A2023020F)
MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02145	04-2697983	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY MARIA VIRTUDES SANCHEZ MICO, PHD, ENTITLED:
YALE UNIVERSITY 150 MUNSON STREET, PO BOX 208327 NEW HAVEN, CT 06520	06-0646973	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY CARLA ROTHLIN, PHD, ENTITLED: (A2023022S)
UNIVERSITY OF CALIFORNIA, SAN DIEGO - 9500 GILMAN DRIVE, DEPT 0934 - LA JOLLA, CA 92093	95-6006144	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY SUBHOJIT ROY, MD, PHD, ENTITLED: (A2023023S)
UNIVERSITY OF KENTUCKY 500 SOUTH LIMESTONE LEXINGTON, KY 40526	61-6033693	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY DANIEL C. LEE, PHD, ENTITLED: (A2023025S)
MAYO CLINIC, JACKSONVILLE 4500 SAN PABLO ROAD, ROOM 110 JACKSONVILLE, FL 32224	59-3337028	501(C)(3)	235,163.	0.			ALZHEIMER'S DISEASE RESEARCH ENTITLED: (CA2021010)
LUMIND IDSC 20 MALL ROAD, SUITE 200 BURLINGTON, VT 01803	37-1483975	501(C)(3)	65,000.	0.			ALZHEIMER'S DISEASE RESEARCH RELATED TO DOWN SYNDROME
INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION - 1001 MAYPORT RD - ATLANTIC BEACH, FL 32233	86-2907045	501(C)(3)	9,000.	0.			ALZHEIMER'S DISEASE RESEARCH TRAVEL GRANTS FOR CONFERENCE ATTENDANCE

Part II Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION - 1001 MAYPORT RD - ATLANTIC BEACH, FL 32233	86-2907045	501(C)(3)	115,000.	0.			ALZHEIMER'S DISEASE RESEARCH ENTITLED: (CA2021011)
UNIVERSITY OF CALIFORNIA, IRVINE 320 QURESHY RESEARCH LAB IRVINE, CA 92697	95-2226406	501(C)(3)	10,000.	0.			ALZHEIMER'S DISEASE RESEARCH TRAVEL GRANTS FOR CONFERENCE ATTENDANCE
FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH - 11400 ROCKVILLE PIKE, SUITE 600 - NORTH BETHESDA, MD 20852	52-1986675	501(C)(3)	100,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY SJOERD FINNEMA, PHD, ENTITLED: (CA2021012)
UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL BUILDING, 13001 E 17TH PLACE - AURORA, CO 80045	84-6000555	501(C)(3)	87,500.	0.			ALZHEIMER'S DISEASE RESEARCH BY LOTTA GRANHOLM, PHD, ENTITLED: (CA2018010)
UNIVERSITY OF SOUTHERN CALIFORNIA 3720 S. FLOWER STREET, 3RD FLOOR LOS ANGELES, CA 90089	95-1642394	501(C)(3)	600,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY JINKOOK LEE, PHD, ENTITLED: (CA2023001)
UNIVERSITY OF CALIFORNIA, BERKELEY 1608 FOURTH STREET, SUITE 220 BERKELEY, CA 94710	94-6002123	501(C)(3)	150,000.	0.			NATIONAL GLAUCOMA RESEARCH BY SHUBHAM MAURYA, PHD, ENTITLED: (G2023001F)
UNIVERSITY OF WISCONSIN-MADISON 21 NORTH PARK STREET, SUITE 6301 MADISON, WI 53715	39-6006492	501(C)(3)	150,000.	0.			NATIONAL GLAUCOMA RESEARCH BY KAZUYA OIKAWA, PHD, BVSC, ENTITLED: (G2023003F)
UNIVERSITY OF CALIFORNIA, BERKELEY 1608 FOURTH STREET, SUITE 220 BERKELEY, CA 94710	94-6002123	501(C)(3)	199,999.	0.			NATIONAL GLAUCOMA RESEARCH BY KARTHIK SHEKHAR, PHD, ENTITLED: (G2023004S)
GEORGIA TECH RESEARCH CORPORATION 926 DALNEY STREET, NW ATLANTA, GA 30332	58-0603146	501(C)(3)	200,000.	0.			NATIONAL GLAUCOMA RESEARCH BY MARK PRAUSNITZ, PHD, ENTITLED: (G2023007S)

Schedule I (Form 990)

Part II Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
DUKE UNIVERSITY SCHOOL OF MEDICINE 2200 WEST MAIN STREET, SUITE 820 DURHAM, NC 27705	56-0532129	501(C)(3)	200,000.	0.		NATIONAL GLAUCOMA RESEARCH BY RUPALATHA MADDALA, PHD, ENTITLED: (G2023008S)	NATIONAL GLAUCOMA RESEARCH BY RUPALATHA MADDALA, PHD, ENTITLED: (G2023008S)
INDIANA UNIVERSITY, INDIANAPOLIS 509 E 3RD STREET BLOOMINGTON, IN 47401	35-6001673	501(C)(3)	200,000.	0.		NATIONAL GLAUCOMA RESEARCH BY WEIMING MAO, PHD, ENTITLED: (G2023009S)	NATIONAL GLAUCOMA RESEARCH BY WEIMING MAO, PHD, ENTITLED: (G2023009S)
JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE - 733 NORTH BROADWAY, SUITE 117, BROADWAY RESEARCH BUILDING - BALTIMORE, MD 21205	52-0595110	501(C)(3)	200,000.	0.		NATIONAL GLAUCOMA RESEARCH BY JITHIN YOHANNAN, MD, ENTITLED: (G2023010S)	NATIONAL GLAUCOMA RESEARCH BY JITHIN YOHANNAN, MD, ENTITLED: (G2023010S)
INTERNATIONAL SOCIETY FOR EYE RESEARCH - 655 BEACH STREET - SAN FRANCISCO, CA 94109	51-0171667	501(C)(3)	8,000.	0.		TRAVEL GRANTS FOR CONFERENCE ATTENDANCE	TRAVEL GRANTS FOR CONFERENCE ATTENDANCE
GEORGIA INSTITUTE OF TECHNOLOGY FERST DRIVE, ROOM 230 ATLANTA, GA 30332	58-6002023	501(C)(3)	85,561.	0.		NATIONAL GLAUCOMA RESEARCH BY C. ROSS ETHIER, PHD, ENTITLED: (CG2020001)	NATIONAL GLAUCOMA RESEARCH BY C. ROSS ETHIER, PHD, ENTITLED: (CG2020001)
DUKE UNIVERSITY 2200 WEST MAIN STREET, SUITE 820 DURHAM, NC 27705	56-0532129	501(C)(3)	52,324.	0.		NATIONAL GLAUCOMA RESEARCH BY W. DANIEL STAMER, PHD, ENTITLED: (CG2020002)	NATIONAL GLAUCOMA RESEARCH BY W. DANIEL STAMER, PHD, ENTITLED: (CG2020002)
COLUMBIA UNIVERSITY 535 W 116TH STREET NEW YORK, NY 10027	13-5598093	501(C)(3)	166,666.	0.		NATIONAL GLAUCOMA RESEARCH BY SIMON JOHN, PHD, ENTITLED: (CG2020004)	NATIONAL GLAUCOMA RESEARCH BY SIMON JOHN, PHD, ENTITLED: (CG2020004)
STANFORD UNIVERSITY 2452 WATSON CT PALO ALTO, CA 94305	94-1156365	501(C)(3)	74,023.	0.		NATIONAL GLAUCOMA RESEARCH BY JEFFREY GOLDBERG, PHD, ENTITLED: (CG2022001)	NATIONAL GLAUCOMA RESEARCH BY JEFFREY GOLDBERG, PHD, ENTITLED: (CG2022001)
THE JACKSON LABORATORY 600 MAIN STREET BAR HARBOR, ME 04609	01-0211513	501(C)(3)	200,000.	0.		MACULAR DEGENERATION RESEARCH BY NAVDEEP GOGNA, PHD, ENTITLED: (M2023001F)	MACULAR DEGENERATION RESEARCH BY NAVDEEP GOGNA, PHD, ENTITLED: (M2023001F)

Schedule I (Form 990)

BRIGHTFOCUS FOUNDATION

Part II Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET, FRANKLIN BUILDING, 5TH FLOOR - PHILADELPHIA, PA 19104	23-1352685	501(C)(3)	200,000.	0.			MACULAR DEGENERATION RESEARCH BY CATHARINA GRUBAUGH, PHD, ENTITLED: (M2023002F)
UNIVERSITY OF CALIFORNIA, SAN DIEGO - 9500 GILMAN DRIVE, MAIL CODE 0041 - LA JOLLA, CA 92093	95-6006144	501(C)(3)	200,000.	0.			MACULAR DEGENERATION RESEARCH BY JACLYN SWAN, PHD, ENTITLED: (M2023003F)
UNIVERSITY OF WASHINGTON 4333 BROOKLYN AVE NE, BOX 359472 SEATTLE, WA 98195	91-6001537	501(C)(3)	200,000.	0.			MACULAR DEGENERATION RESEARCH BY RAYNE LIM, PHD, ENTITLED: (M2023004F)
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO - OFFICE OF SPONSORED RESEARCH, 490 ILLINOIS STREET, 4TH FLOOR - SAN FRANCISCO, CA 94143	94-6036493	501(C)(3)	200,000.	0.			MACULAR DEGENERATION RESEARCH BY SANGEETHA KANDOI, PHD, ENTITLED: (M2023005F)
WASHINGTON UNIVERSITY IN ST. LOUIS CAMPUS BOX 1054, ONE BROOKINGS DR. ST. LOUIS, MO 63130	43-0653611	501(C)(3)	200,000.	0.			MACULAR DEGENERATION RESEARCH BY JAMES WALSH, MD, PHD, ENTITLED: (M2023006F)
THE UNIVERSITY OF IOWA DIVISION OF SPONSORED PROGRAMS, 2 G IOWA CITY, IA 52242	42-6004813	501(C)(3)	200,000.	0.			MACULAR DEGENERATION RESEARCH BY NARENDRA PANDALA, PHD, ENTITLED: (M2023007F)
OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK RD., MAIL PORTLAND, OR 97239	93-1176109	501(C)(3)	598,868.	0.			MACULAR DEGENERATION RESEARCH BY YALI JIA, PHD, ENTITLED: (M2023008I)
UNIVERSITY OF WISCONSIN-MADISON 21 NORTH PARK STREET, SUITE 6301 MADISON, WI 53715	39-6006492	501(C)(3)	450,000.	0.			MACULAR DEGENERATION RESEARCH BY FREYA MOWAT, PHD, ENTITLED: (M2023010N)
THE UNIVERSITY OF IOWA DIVISION OF SPONSORED PROGRAMS, 2 G IOWA CITY, IA 52242	42-6004813	501(C)(3)	450,000.	0.			MACULAR DEGENERATION RESEARCH BY KELLY MULFAUL, PHD, ENTITLED: (M2023011N)

Part II Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
THE UNIVERSITY OF TEXAS AT AUSTIN 3925 WEST BRAKER LN, SUITE 3.340 AUSTIN, TX 78759	74-6000203	501(C)(3)	436,312.	0.		MACULAR DEGENERATION RESEARCH BY LYNDSEY LEACH, PHD, ENTITLED: (M2023012N)	
YALE UNIVERSITY 150 MUNSON STREET, PO BOX 208327 NEW HAVEN, CT 06520	06-0646973	501(C)(3)	168,917.	0.		MACULAR DEGENERATION RESEARCH BY ABDELILAH MAJDOUBI, PHD, ENTITLED: (M2023013F)	
UNIVERSITY OF CALIFORNIA, IRVINE 120 THEORY STREET #200 IRVINE, CA 92617	95-2226406	501(C)(3)	25,000.	0.		MACULAR DEGENERATION RESEARCH BY DOROTA SKOWRONSKA-KRAWCZYK, PHD, ENTITLED: (M2020271)	
HELEN KELLER FOUNDATION FOR RESEARCH & EDUCATION - 1201 11TH AVE. SOUTH, SUITE 300 - BIRMINGHAM, AL 35205	63-0983733	501(C)(3)	75,000.	0.		2022 HELEN KELLER PRIZE FOR VISION RESEARCH PARTNERSHIP	
HELEN KELLER FOUNDATION FOR RESEARCH & EDUCATION - 1201 11TH AVE. SOUTH, SUITE 300 - BIRMINGHAM, AL 35205	63-0983733	501(C)(3)	75,000.	0.		2022 CONFERENCE SUPPORT	
ARVO FOUNDATION FOR EYE RESEARCH 1801 ROCKVILLE PIKE, SUITE 400 ROCKVILLE, MD 20852	52-2322462	501(C)(3)	10,000.	0.		2022 EYEFIND RESEARCH GRANT SPONSORSHIP	
ARVO FOUNDATION FOR EYE RESEARCH 1801 ROCKVILLE PIKE, SUITE 400 ROCKVILLE, MD 20852	52-2322462	501(C)(3)	15,240.	0.		2022 TRAVEL GRANTS FOR CONFERENCE ATTENDEES	

BRIGHTFOCUS FOUNDATION

Part III

Grants and Other Assistance to Domestic Individuals. Complete if the organization answered "Yes" on Form 990, Part IV, line 22. Part III can be duplicated if additional space is needed.

(a) Type of grant or assistance	(b) Number of recipients	(c) Amount of cash grant	(d) Amount of non-cash assistance	(e) Method of valuation (book, FMV, appraisal, other)	(f) Description of noncash assistance
CONFERENCE TRAVEL	6	6,000.	0.		

Part IV Supplemental Information. Provide the information required in Part I, line 2; Part III, column (b); and any other additional information.

PART I, LINE 2:

BRIGHTFOCUS INTERACTS WITH ALL GRANTEES AT LEAST QUARTERLY BY E-MAIL OR AT SCIENTIFIC MEETINGS. IN ADDITION TO THESE INTERACTIONS, EACH GRANT RECIPIENT IS REQUIRED TO SUBMIT SEPARATE DETAILED ANNUAL SCIENTIFIC PROGRESS AND FINANCIAL REPORTS TO BRIGHTFOCUS. THESE ARE RECEIVED BY THE BRIGHTFOCUS SCIENTIFIC AFFAIRS DEPARTMENT, AND REVIEWED BY SCIENTIFIC STAFF WITH BROAD EXPERTISE, INCLUDING IMAGING, MOLECULAR BIOLOGY AND SIGNALING PATHWAYS, CELL BIOLOGY, ANGIOGENESIS, BIOCHEMISTRY, NEUROSCIENCE, AND GENETICS. SENIOR STAFF REVIEWS EACH PROGRESS REPORT AND EVALUATES THE

Part IV Supplemental Information

PROJECT FOR SUFFICIENT PROGRESS TOWARDS THE SPECIFIC AIMS PROPOSED IN THE ORIGINAL APPLICATION OR ANY BUDGETARY CONCERNS. THIS EFFORT IS SUPPORTED BY ADDITIONAL SCIENTIFIC COUNSEL FROM MEMBERS OF THE BRIGHTFOCUS SCIENTIFIC REVIEW COMMITTEES, WHEN REQUIRED. IN ADDITION TO STATEMENTS OF EXPERIMENTAL PROGRESS, ALL GRANTEEES ARE ASKED TO REPORT ANY TECHNICAL PUBLICATIONS, MEDIA REPORTS, OR PATENT APPLICATIONS IN WHICH BRIGHTFOCUS-SPONSORED RESEARCH IS DESCRIBED. IF SIGNIFICANT CONCERNS RELATED TO PROGRESS ON THE AWARDS ARE DISCOVERED, AND NOT RESOLVED AFTER INTERACTION WITH THE AWARD GRANTEE, THE BRIGHTFOCUS STAFF RECOMMENDS APPROPRIATE ACTIONS TO THE CHAIR OF THE SCIENTIFIC AFFAIRS COMMITTEE OF THE BOARD OF DIRECTORS. IN ACCORDANCE WITH THE GRANT AGREEMENT TERMS AND CONDITIONS, BRIGHTFOCUS MAY WITHHOLD FUNDING, OR DISCONTINUE AN AWARD, FOR ANY GRANTEE THAT FAILS TO ACHIEVE SUFFICIENT PROGRESS OR SUBMIT REQUIRED REPORTS.

AT THE CONCLUSION OF THE GRANT AWARD PERIOD, EACH GRANTEE MUST COMPLETE AND SUBMIT A FINAL REPORT THAT IS ALSO REVIEWED BY THE BRIGHTFOCUS SENIOR SCIENTIFIC STAFF. EVALUATION OF THE WORK OF EACH GRANTEE IS QUALITATIVELY AND QUANTITATIVELY ASSESSED THROUGH VARIOUS METRICS RELATED TO THE IMPACT OF THE GRANT ON ITS TARGETED DISEASE FIELD. SUCH IMPACT METRICS HAVE REVEALED THAT 95% OF BRIGHTFOCUS-SUPPORTED RESEARCH RESULTS IN RESEARCH PUBLICATIONS THAT ADVANCE THE FIELDS SERVED BY BRIGHTFOCUS. THIS IMPACT IS FURTHER SUPPORTED BY ANNUAL CATEGORY NORMALIZED CITATION IMPACT ANALYSIS THAT COMPARES BRIGHTFOCUS-SUPPORTED WORKS TO AN UNBIASED COMPARISON OF IMPACT PERFORMANCE VERSUS THE WORLD AVERAGE. BRIGHTFOCUS-SUPPORTED PUBLICATIONS WERE RECENTLY CITED AT 2 TIMES THE FREQUENCY OF THE WORLD AVERAGE. A FINAL EXAMPLE OF IMPACT ASSESSMENT REVEALED THAT THE SUCCESSES OF BRIGHTFOCUS GRANTEEES CONTINUE LONG AFTER THE GRANT EXPIRES. ON AVERAGE, EACH GRANTEE RECEIVES ADDITIONAL GRANTS FOR FOLLOW-ON PROJECTS SPAWNED BY

Part IV Supplemental Information

THE BRIGHTFOCUS GRANT, WITH VALUES UP TO 10 TIMES THE LEVEL OF THE INITIAL BRIGHTFOCUS INVESTMENT.

BRIGHTFOCUS SOLICITS FEEDBACK FROM ITS GRANTEES, AND PROVIDES AN ANONYMOUS FORUM FOR COLLECTING SUCH INFORMATION. THROUGH THE BRIGHTFOCUS FOUNDATION WEBSITE AND WITHIN THE SCIENTIFIC PROGRESS REPORTS, THERE ARE DESIGNATED SECTIONS WHERE AWARDEES ARE ASKED TO PROVIDE FEEDBACK TO THE FOUNDATION. THROUGH THIS MECHANISM, THEY ARE GIVEN THE ABILITY TO ANONYMOUSLY PROVIDE FEEDBACK OR COMMUNICATE THEIR CONCERNS TO PROGRAM STAFF OR THE BRIGHTFOCUS' COMPLIANCE OFFICE. ANY SUGGESTIONS, CONCERNS, COMPLAINTS, OR POSITIVE EXPERIENCES CAN BE OUTLINED AND BROUGHT TO THE ATTENTION OF BRIGHTFOCUS IN THIS MANNER, SO THAT BRIGHTFOCUS CAN ADDRESS ANY AREAS NEEDING IMPROVEMENT, REAFFIRM PRAISE-WORTHY POLICIES, OR OTHERWISE ASSESS NEEDS FOR PROGRAMMATIC CHANGE. THE SENIOR LEADERSHIP PRESENTS AND SUMMARIZES THE STATUS AND PROGRESS ON GRANTS TO THE BRIGHTFOCUS BOARD OF DIRECTORS AT EACH OF THEIR QUARTERLY BOARD MEETINGS.

**SCHEDULE J
(Form 990)**

Department of the Treasury
Internal Revenue Service

Compensation Information

For certain Officers, Directors, Trustees, Key Employees, and Highest
Compensated Employees
Complete if the organization answered "Yes" on Form 990, Part IV, line 23.
Attach to Form 990.
Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2022

Open to Public
Inspection

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Part I Questions Regarding Compensation

1a Check the appropriate box(es) if the organization provided any of the following to or for a person listed on Form 990, Part VII, Section A, line 1a. Complete Part III to provide any relevant information regarding these items.

- | | |
|--|--|
| <input type="checkbox"/> First-class or charter travel | <input type="checkbox"/> Housing allowance or residence for personal use |
| <input type="checkbox"/> Travel for companions | <input type="checkbox"/> Payments for business use of personal residence |
| <input type="checkbox"/> Tax indemnification and gross-up payments | <input type="checkbox"/> Health or social club dues or initiation fees |
| <input type="checkbox"/> Discretionary spending account | <input type="checkbox"/> Personal services (such as maid, chauffeur, chef) |

b If any of the boxes on line 1a are checked, did the organization follow a written policy regarding payment or reimbursement or provision of all of the expenses described above? If "No," complete Part III to explain

2 Did the organization require substantiation prior to reimbursing or allowing expenses incurred by all directors, trustees, and officers, including the CEO/Executive Director, regarding the items checked on line 1a?

3 Indicate which, if any, of the following the organization used to establish the compensation of the organization's CEO/Executive Director. Check all that apply. Do not check any boxes for methods used by a related organization to establish compensation of the CEO/Executive Director, but explain in Part III.

- | | |
|---|---|
| <input checked="" type="checkbox"/> Compensation committee | <input type="checkbox"/> Written employment contract |
| <input checked="" type="checkbox"/> Independent compensation consultant | <input checked="" type="checkbox"/> Compensation survey or study |
| <input checked="" type="checkbox"/> Form 990 of other organizations | <input checked="" type="checkbox"/> Approval by the board or compensation committee |

4 During the year, did any person listed on Form 990, Part VII, Section A, line 1a, with respect to the filing organization or a related organization:

- a** Receive a severance payment or change-of-control payment?
- b** Participate in or receive payment from a supplemental nonqualified retirement plan?
- c** Participate in or receive payment from an equity-based compensation arrangement?
- If "Yes" to any of lines 4a-c, list the persons and provide the applicable amounts for each item in Part III.

Only section 501(c)(3), 501(c)(4), and 501(c)(29) organizations must complete lines 5-9.

5 For persons listed on Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any compensation contingent on the revenues of:

- a** The organization?
- b** Any related organization?
- If "Yes" on line 5a or 5b, describe in Part III.

6 For persons listed on Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any compensation contingent on the net earnings of:

- a** The organization?
- b** Any related organization?
- If "Yes" on line 6a or 6b, describe in Part III.

7 For persons listed on Form 990, Part VII, Section A, line 1a, did the organization provide any nonfixed payments not described on lines 5 and 6? If "Yes," describe in Part III

8 Were any amounts reported on Form 990, Part VII, paid or accrued pursuant to a contract that was subject to the initial contract exception described in Regulations section 53.4958-4(a)(3)? If "Yes," describe in Part III

9 If "Yes" on line 8, did the organization also follow the rebuttable presumption procedure described in Regulations section 53.4958-6(c)?

	Yes	No
1a		
1b		
2		
3		
4a		X
4b		X
4c		X
5a		X
5b		X
6a		X
6b		X
7	X	
8		X
9		

LHA For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Schedule J (Form 990) 2022

Part III Supplemental Information

Provide the information, explanation, or descriptions required for Part I, lines 1a, 1b, 3, 4a, 4b, 4c, 5a, 5b, 6a, 6b, 7, and 8, and for Part II. Also complete this part for any additional information.

PART I, LINE 7:

AS THE PRESIDENT/CEO'S BONUS WAS NOT A FIXED PAYMENT SPECIFIED IN HER EMPLOYMENT CONTRACT, THIS ITEM HAS BEEN ANSWERED 'YES' IN ACCORDANCE WITH THE INTERNAL REVENUE SERVICE INSTRUCTIONS. HOWEVER, IT SHOULD BE NOTED THAT HER BONUS WAS A NON-FIXED PAYMENT BASED ON BRIGHTFOCUS' INTERNAL PROCEDURES.

THE BOARD OF DIRECTORS CONSIDERS THE AWARD OF A DISCRETIONARY BONUS EACH YEAR. THE DETERMINATION OF THE BONUS COMPENSATION IS CAPPED AS SPECIFIED IN HER EMPLOYMENT CONTRACT, AND IF NOT WARRANTED WILL NOT BE AWARDED AT ALL. THE DETERMINATION IS MADE BY THE FULL BOARD UPON RECOMMENDATION OF ITS EXECUTIVE COMMITTEE THAT IS RESPONSIBLE FOR THE REVIEW OF PRESIDENT/CEO COMPENSATION. THE COMMITTEE CONSIDERS A SET OF GOALS FOR THE PRESIDENT/CEO'S PERFORMANCE DEVELOPED AT THE BEGINNING OF THE YEAR IN CONSULTATION WITH THE PRESIDENT/CEO. EACH GOAL IS EVALUATED AT THE END OF THE FISCAL YEAR TO DETERMINE WHETHER THE GOAL HAS BEEN MET OR EXCEEDED. THE BONUS IS AWARDED BASED ON A DETAILED REVIEW BY THE BOARD OF DIRECTORS OF WHETHER EACH GOAL HAS BEEN MET OR EXCEEDED.

**SCHEDULE M
(Form 990)**

Noncash Contributions

OMB No. 1545-0047

2022

Open to Public Inspection

Complete if the organizations answered "Yes" on Form 990, Part IV, lines 29 or 30.
Attach to Form 990.

Go to www.irs.gov/Form990 for instructions and the latest information.

Department of the Treasury
Internal Revenue Service

Name of the organization **BRIGHTFOCUS FOUNDATION** Employer identification number **23-7337229**

Part I Types of Property

	(a) Check if applicable	(b) Number of contributions or items contributed	(c) Noncash contribution amounts reported on Form 990, Part VIII, line 1g	(d) Method of determining noncash contribution amounts
1 Art - Works of art				
2 Art - Historical treasures				
3 Art - Fractional interests				
4 Books and publications				
5 Clothing and household goods				
6 Cars and other vehicles				
7 Boats and planes				
8 Intellectual property				
9 Securities - Publicly traded	X	21	468,968.	FMV
10 Securities - Closely held stock				
11 Securities - Partnership, LLC, or trust interests				
12 Securities - Miscellaneous				
13 Qualified conservation contribution - Historic structures				
14 Qualified conservation contribution - Other				
15 Real estate - Residential				
16 Real estate - Commercial				
17 Real estate - Other				
18 Collectibles				
19 Food inventory				
20 Drugs and medical supplies				
21 Taxidermy				
22 Historical artifacts				
23 Scientific specimens				
24 Archeological artifacts				
25 Other ()				
26 Other ()				
27 Other ()				
28 Other ()				

29 Number of Forms 8283 received by the organization during the tax year for contributions for which the organization completed Form 8283, Part V, Donee Acknowledgement **29**

30a During the year, did the organization receive by contribution any property reported in Part I, lines 1 through 28, that it must hold for at least 3 years from the date of the initial contribution, and which isn't required to be used for exempt purposes for the entire holding period? **X**

b If "Yes," describe the arrangement in Part II.

31 Does the organization have a gift acceptance policy that requires the review of any nonstandard contributions? **X**

32a Does the organization hire or use third parties or related organizations to solicit, process, or sell noncash contributions? **X**

b If "Yes," describe in Part II.

33 If the organization didn't report an amount in column (c) for a type of property for which column (a) is checked, describe in Part II.

	Yes	No
30a		X
31	X	
32a		X

Part II **Supplemental Information.** Provide the information required by Part I, lines 30b, 32b, and 33, and whether the organization is reporting in Part I, column (b), the number of contributions, the number of items received, or a combination of both. Also complete this part for any additional information.

SCHEDULE M, PART I, COLUMN (B):

BRIGHTFOCUS REPORTS THE NUMBER OF CONTRIBUTIONS IN PART I, COLUMN (B).

Multiple horizontal lines for supplemental information.

**SCHEDULE O
(Form 990)**

Department of the Treasury
Internal Revenue Service

Supplemental Information to Form 990 or 990-EZ

Complete to provide information for responses to specific questions on
Form 990 or 990-EZ or to provide any additional information.
Attach to Form 990 or Form 990-EZ.
Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2022

Open to Public
Inspection

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

FORM 990, PART III, LINE 1, DESCRIPTION OF ORGANIZATION MISSION:

BRIGHTFOCUS FUNDS EXCEPTIONAL SCIENTIFIC RESEARCH WORLDWIDE TO DEFEAT ALZHEIMER'S DISEASE, MACULAR DEGENERATION, AND GLAUCOMA AND PROVIDES EXPERT INFORMATION ON THESE HEARTBREAKING DISEASES. OUR VISION IS: A WORLD FREE FROM DISEASES OF MIND AND SIGHT. COLLECTIVELY, 300 MILLION PEOPLE WORLDWIDE SUFFER FROM THESE DISEASES.

BRIGHTFOCUS HAS A PROVEN TRACK RECORD OF SUPPORTING THE MOST INNOVATIVE, EARLY-STAGE RESEARCH SEEKING TO FOSTER A BETTER UNDERSTANDING OF, TREATMENTS FOR, AND ULTIMATELY, A CURE FOR, THESE AGE-RELATED DISEASES WITH NO CURE. SINCE 1973, BRIGHTFOCUS HAS AWARDED MORE THAN \$287 MILLION IN RESEARCH GRANTS TO THOUSANDS OF SCIENTISTS AROUND THE WORLD. OUR RESEARCH FUNDING HAS LED TO MAJOR CONTRIBUTIONS TO UNDERSTANDING THESE DISEASES AND SUPPORT FOR SCIENTISTS WHO HAVE RECEIVED PRESTIGIOUS AWARDS, INCLUDING TWO NOBEL PRIZES. AN INDICATOR OF OUR ABILITY TO PUSH NEW BOUNDARIES OF KNOWLEDGE IS THAT BRIGHTFOCUS-SUPPORTED RESEARCH WAS RECENTLY FOUND TO HAVE HAD 10 TIMES THE IMPACT ON DRIVING FUTURE SCIENCE THAN WORK SUPPORTED BY MANY OTHER ORGANIZATIONS.

THE WORLD-CLASS RESEARCH IDENTIFIED AND SUPPORTED BY BRIGHTFOCUS IS ON THE CUTTING EDGE OF THE FIGHT TO SAVE MIND AND SIGHT. OUR FUNDING ACTS AS A CATALYST IN EARLY-STAGE RESEARCH, AND BRIGHTFOCUS RESEARCH PROGRAMS ARE DESIGNED TO PROVIDE INITIAL FUNDING FOR HIGHLY INNOVATIVE EXPERIMENTAL IDEAS. DUE TO THE STRUCTURED GRANT REVIEW AND APPROVAL PROCESS, THE RESEARCH IMPACT OF BRIGHTFOCUS IS VERY HIGH. MOST

LHA For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ.

Schedule O (Form 990) 2022

232211 10-28-22

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
---	---

RECIPIENTS OF BRIGHTFOCUS FUNDING GO ON TO RECEIVE FUTURE GRANTS FROM OTHER SOURCES THAT ARE UP TO 10 TIMES LARGER THAN THE ORIGINAL BRIGHTFOCUS AWARD. THIS HIGH RETURN ON BRIGHTFOCUS INVESTMENT SPEAKS TO OUR ABILITY TO IDENTIFY PROMISING RESEARCH IN ITS EARLIEST STAGES AND SPAWN FUTURE SCIENTIFIC DISCOVERIES. IT IS OUR FIRM BELIEF THAT HAVING THE COURAGE TO INVEST IN INNOVATIVE IDEAS WILL LEAD TO REVOLUTIONARY APPROACHES AND LIFE-SAVING BREAKTHROUGHS.

ALONG WITH FUNDING CUTTING-EDGE RESEARCH TO FIND CURES FOR SOME OF THE WORLD'S COSTLIEST DISEASES, BRIGHTFOCUS ALSO PROVIDES FREE EDUCATIONAL MATERIALS AND SUPPORT TO HUNDREDS OF THOUSANDS OF THOSE IMPACTED BY THESE DISEASES NATIONWIDE. WE ROOT THESE EDUCATIONAL MATERIALS IN THE LATEST RESEARCH FINDINGS (VIEW OUR RESEARCH MILESTONES ON BRIGHTFOCUSBOLD.ORG.)

BRIGHTFOCUS ALSO INCREASES PUBLIC AWARENESS OF ALZHEIMER'S, MACULAR DEGENERATION, AND GLAUCOMA, AND COMMUNICATES WITH THOUGHT LEADERS AND ELECTED OFFICIALS ABOUT THE IMPORTANCE OF SCIENTIFIC RESEARCH IN THESE AREAS.

BRIGHTFOCUS' AWARD-WINNING PUBLIC SERVICE ANNOUNCEMENTS (PSAS) HAVE APPEARED ON TELEVISION, RADIO, AND IN PRINT THROUGHOUT THE NATION. THE IMPACT OF ALZHEIMER'S, MAKE A PLAN TODAY: GET YOUR EYES CHECKED, AND NOW IS THE MOMENT TO STOP ALZHEIMER'S DISEASE POWERFULLY SEEKS TO RAISE AWARENESS AND EARLY DETECTION, AND SIMILAR MESSAGES HAVE BEEN DELIVERED THROUGH DONATED PRINT PSA SPACE IN AIRPORTS AND TRAIN STATIONS, AS WELL AS AT PHARMACIES, SUPERMARKETS AND DIGITALLY. IN FISCAL YEAR 2023, THESE PSA MESSAGES GENERATED \$25,308,680 IN DONATED MEDIA SERVICES AND

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
--	--

GARNERED OVER 532 MILLION IMPRESSIONS.

WE CONTINUE TO INCREASE OUR PRINT PUBLICATIONS, MANY IN SPANISH, THAT PROVIDE HELPFUL INFORMATION TO PATIENTS AND CAREGIVERS, AND REGULARLY UNVEIL NEW VIDEO AND AUDIO RESOURCES IN CONJUNCTION WITH ALLIES IN THE MEDICAL AND SCIENTIFIC COMMUNITIES.

PARTNERING WITH SEVERAL HIGH-PROFILE PUBLIC AND PRIVATE ORGANIZATIONS, BRIGHTFOCUS IS HELPING TO BETTER EDUCATE THE PUBLIC ON THE LATEST RESEARCH DEVELOPMENTS PERTAINING TO ALZHEIMER'S, MACULAR DEGENERATION, AND GLAUCOMA, AS WELL AS THE IMPORTANCE OF EQUITABLE PARTICIPATION IN CLINICAL RESEARCH TO ACCELERATE THE PATH TO CURES FOR NEURODEGENERATIVE DISEASES.

SPECIFICALLY, BRIGHTFOCUS IS PRODUCING AND DISSEMINATING FREE PROGRAMS INCLUDING:

- BRIGHTFOCUS CHATS, SINCE 2014, THESE AUDIO DISCUSSIONS HAVE BROUGHT TOGETHER PATIENTS AND CAREGIVERS FOR INTERACTIVE MONTHLY TELEPHONE FORUMS TO LEARN FROM AND ASK QUESTIONS OF LEADING VISION DISEASE EXPERTS. THE CHATS ARE ARCHIVED ON OUR WEBSITE, WITH AUDIO AND PRINT TRANSCRIPTS AVAILABLE IN SEVERAL ACCESSIBLE FORMATS ONLINE, INCLUDING AS PODCASTS ON SPOTIFY AND APPLE ITUNES.

- ZOOM IN ON DEMENTIA AND ALZHEIMER'S, A MONTHLY VIRTUAL DISCUSSION OPEN TO THE PUBLIC FEATURING TOPIC EXPERTS.

- BRAIN INFO LIVE, A SUSTAINED, EPISODIC VIRTUAL EDUCATION SERIES TAILORED TO DIVERSE COMMUNITIES ACROSS THE US PRODUCED IN ENGLISH, SPANISH, AND HAITIAN CREOLE.

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
---	---

BRIGHTFOCUS IS A PRESENTING PARTNER OF AN UPCOMING DOCUMENTARY, REMEMBERING GENE WILDER, AS WELL AS A DOCUMENTARY REMEMBERING ADELE, AND WILL EXECUTE ASSOCIATED EDUCATIONAL IMPACT CAMPAIGNS. THESE FILMS WILL BE SHOWN IN COMMUNITY SETTINGS ACROSS THE COUNTRY TO INCREASE AWARENESS OF, AND PARTICIPATION IN, ALZHEIMER'S CLINICAL RESEARCH.

WE HAVE EXPANDED OUR WRITTEN AND MULTIMEDIA CONTENT OF KEY RESEARCH FINDINGS, PROMOTING AND SHARING THIS INFORMATION THROUGH OUR WEBSITE AND SOCIAL MEDIA PLATFORMS, INCLUDING VIDEO AND YOUTUBE. BRIGHTFOCUS INFOGRAPHICS VISUALLY COMMUNICATE INFORMATION ON ALZHEIMER'S, MACULAR DEGENERATION, AND GLAUCOMA, AND WE PROVIDE ACCESSIBLE CONTENT TRANSCRIPTS AND RESOURCES. IN THE SPRING OF 2020, WE LAUNCHED A FULL SECTION OF OUR WEBSITE DEDICATED TO SHARING EXCLUSIVE CONTENT ON COVID-19 FOR FAMILIES IMPACTED BY DISEASES OF MIND AND SIGHT.

MORE SPECIFICALLY, EACH OF BRIGHTFOCUS' THREE PROGRAM AREAS MAILS AWARENESS-RAISING MATERIALS TO HUNDREDS OF THOUSANDS OF NATIONAL HOUSEHOLDS, WITH MESSAGES FOCUSING ON:

- RISK FACTORS AND SYMPTOM RECOGNITION THROUGH PUBLIC AWARENESS AND STEPS THE PUBLIC SHOULD TAKE THAT MAY HELP REDUCE THEIR RISK.
- LIFESTYLE CHOICES THAT PROMOTE GOOD HEALTH, ENCOURAGING READERS TO TAKE ACTION TO REDUCE THE LIKELIHOOD OF THE ONSET OF THE DISEASE.
- RESEARCH RESULTS AND TREATMENTS AVAILABLE TO ADDRESS THE DISEASE.

BRIGHTFOCUS REGULARLY INTERACTS WITH ADVOCACY ORGANIZATIONS, GOVERNMENTS AT ALL LEVELS, AND MEMBERS OF THE MEDIA, TO CALL GREATER

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
---	---

ATTENTION TO DISEASES OF MIND AND SIGHT AND SHARE THE LATEST RESEARCH AND BEST PRACTICES WITH PUBLIC FIGURES AND KEY STAKEHOLDERS. THROUGH OUR OWN OUTREACH EFFORTS, AS WELL AS VIA ACTIVE ROLES IN ADVOCACY COALITIONS, WE HELP ADVANCE THE CAUSE OF PIONEERING SCIENCE AND BETTER POSITION BRIGHTFOCUS AS A RESOURCE FOR THOSE STRUGGLING WITH AND SEARCHING FOR CURES FOR THESE TERRIBLE DISEASES.

BRIGHTFOCUS IS THE PRESENTING SPONSOR OF THE HELEN KELLER PRIZE FOR VISION RESEARCH, ONE OF THE MOST PRESTIGIOUS RECOGNITIONS IN THE FIELD. SELECTED BY A PANEL OF THE WORLD'S FOREMOST VISION SCIENTISTS, EACH YEAR'S LAUREATE IS HONORED FOR A GROUNDBREAKING CONTRIBUTION OR DISCOVERY TO SAVE SIGHT. BRIGHTFOCUS BEGAN ITS SPONSORSHIP IN 2015 TO CALL GREATER ATTENTION TO VISION RESEARCH ACROSS THE PRIVATE AND PUBLIC SECTORS. BRIGHTFOCUS WAS HONORED IN 2023 FOR ITS CONTRIBUTIONS TO ADVANCING GLOBAL VISION RESEARCH BY THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY (ARVO) FOUNDATION.

FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE:

ALZHEIMER'S DISEASE RESEARCH (ADR) -

ALZHEIMER'S DISEASE IS THE ONLY CAUSE OF DEATH AMONG THE TOP 10 IN AMERICA WITHOUT A WAY TO PREVENT, CURE, OR EVEN SLOW ITS PROGRESSION. IT IS AN IRREVERSIBLE DEGENERATION OF THE BRAIN THAT CAUSES DISRUPTIONS IN MEMORY, COGNITION, PERSONALITY, AND OTHER FUNCTIONS AND INEVITABLY LEADS TO DEATH. AN ESTIMATED 55 MILLION PEOPLE WORLDWIDE HAVE ALZHEIMER'S DISEASE OR OTHER DEMENTIAS, WITH WOMEN AND OTHER MINORITY GROUPS MOST AT-RISK.

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
---	---

BRIGHTFOCUS' ALZHEIMER'S DISEASE RESEARCH (ADR) PROGRAM FUNDS RESEARCH FOCUSED ON UNDERSTANDING THE CAUSES OF ALZHEIMER'S DISEASE, ITS EARLY DETECTION, AND TREATMENTS TO HELP SLOW OR STOP ITS PROGRESSION, AND ULTIMATELY TO PREVENT THE DISEASE ALTOGETHER. ADR ANNUALLY AWARDS PEER-REVIEWED GRANTS TO SCIENTISTS FROM INSTITUTIONS WORLDWIDE WHO ARE CONDUCTING BIOMEDICAL AND CLINICAL RESEARCH ON ALZHEIMER'S DISEASE.

SINCE ITS INCEPTION, BRIGHTFOCUS HAS CONTRIBUTED MORE THAN \$175 MILLION TO THE CONQUERING OF ALZHEIMER'S DISEASE. DURING THE FISCAL YEAR THAT ENDED MARCH 31, 2023, ADR AWARDED \$6,394,521 IN PEER-REVIEWED GRANT AWARDS TO 26 NEW RESEARCH PROJECTS AND 8 OTHER AWARDS TO MAKE A TOTAL OF 34 GRANTS AT \$7,755,537 TOTAL IN FUNDING.

NOTABLE PROJECTS INCLUDE: HYPERTENSION AND LIFESTYLE EFFECTS ON RISK OF ALZHEIMER'S (INCLUDING LIPIDS); DRUG DISCOVERY AND BIOMARKERS; THE ROLE OF INFLAMMATION, MICROGLIA, AND VASCULAR HEALTH IN DISEASE RISK; LOOKING AT THE MITOCHONDRIA AND CELL ENERGY DEFICIENCIES; THE ROLE OF SLEEP DISTURBANCES CAUSING AN INCREASED RISK OF COGNITIVE ISSUES; DIFFERENCES IN GENETICS AND DISEASE RISK FOR UNDERREPRESENTED POPULATIONS; AND BETTER USE OF MODERN TECHNOLOGIES, INCLUDING BIG DATA/AI AND SYSTEMS GENETICS ANALYSIS FOR INCREASED AND DECREASED RISKS. ADDITIONAL INFORMATION ABOUT SPECIFIC PROJECTS IS INCLUDED IN SCHEDULES F & I.

BRIGHTFOCUS IS HONORED TO HAVE SUPPORTED THE EARLY RESEARCH OF TWO NOBEL PRIZE WINNERS, DR. STANLEY PRUSINER AND DR. PAUL GREENGARD, WHOSE WORK HAS BEEN INSTRUMENTAL TO OUR CURRENT UNDERSTANDING OF ALZHEIMER'S

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
---	---

DISEASE.

BRIGHTFOCUS CONTINUES ITS PARTNERSHIP WITH THE ACADEMIC JOURNAL "MOLECULAR NEURODEGENERATION," THE OFFICIAL JOURNAL OF BRIGHTFOCUS FOUNDATION AND THE NUMBER ONE OPEN-ACCESS JOURNAL IN NEUROSCIENCE. THE JOURNAL PUBLISHES TECHNICAL PAPERS RELATED TO NEURODEGENERATION IN THE THREE DISEASE AREAS. TO ACCELERATE SCIENTIFIC PROGRESS, IT IS AN "OPEN ACCESS" JOURNAL, AND ALL CONTENT IS AVAILABLE FREE OF CHARGE. THIS OPEN ACCESS ENSURES MAXIMUM REACH OF JOURNAL CONTENT TO SCIENTISTS AND HEALTH CARE PROVIDERS WORLDWIDE.

IN ADDITION TO SUPPORTING CUTTING-EDGE RESEARCH, ADR PROVIDES EXCELLENT RESOURCES ON DETECTING, TREATING, AND LIVING WITH THE DISEASE. THESE ARE AVAILABLE IN BOTH PRINT AS WELL AS ON OUR WEBSITE, WWW.BRIGHTFOCUS.ORG.

FORM 990, PART III, LINE 4B, DESCRIPTION OF PROGRAM SERVICE:

MACULAR DEGENERATION RESEARCH (MDR) -

AGE-RELATED MACULAR DEGENERATION IS A LEADING CAUSE OF VISION LOSS IN THE UNITED STATES. IT DESTROYS THE MACULA, THE PART OF THE EYE THAT PROVIDES SHARP, CENTRAL VISION NEEDED FOR SEEING OBJECTS CLEARLY. THE MOST COMMON EYE CONDITION IN PEOPLE AGE 60 AND OLDER, IT CAN LEAD TO VISION LOSS IN ONE OR BOTH EYES, MAKING IT DIFFICULT TO RECOGNIZE FACES, DRIVE A CAR, OR READ. AT LEAST 20 MILLION AMERICANS HAVE SOME TYPE OF MACULAR DEGENERATION, INCLUDING BOTH THE EARLY AND LATER STAGES OF THE WET AND DRY TYPES.

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

MACULAR DEGENERATION RESEARCH (MDR), A PROGRAM OF BRIGHTFOCUS, HAS AWARDED NEARLY \$50 MILLION TO SCIENTISTS STUDYING THE DISEASE. THE LATEST RESEARCH IS FOCUSED ON NOVEL TREATMENTS FOR THE DISEASE, UNDERSTANDING ITS CAUSES AND PROGRESSION, PREDICTION METHODS AND DISEASE MODELING, DRUG THERAPIES, THE ROLE OF THE METABOLISM IN DISEASE RISK, GENES, THE ROLE OF THE IMMUNE RESPONSE IN DISEASE RISK, AND NEW IMAGING, MACHINE LEARNING AND SCREENING TECHNIQUES.

MDR GRANTS ARE AVAILABLE TO MACULAR DEGENERATION RESEARCHERS WORLDWIDE. MDR PLACES SPECIAL EMPHASIS ON ENCOURAGING APPLICATIONS FROM YOUNG SCIENTISTS AND THOSE WITH CUTTING-EDGE IDEAS. ANNUAL GRANT APPLICATIONS ARE PEER-REVIEWED, AND RECIPIENT SELECTIONS ARE BASED ON SCIENTIFIC MERIT.

DURING THE FISCAL YEAR ENDING MARCH 31, 2023, MDR AWARDED \$3,839,035 IN PEER-REVIEWED GRANT AWARDS TO 13 NEW RESEARCH PROJECTS, WITH 5 ADDITIONAL PROJECTS THAT TAKE THE TOTAL FUNDING TO 18 GRANTS AT \$4,039,275. DETAILS ABOUT SPECIFIC PROJECTS ARE INCLUDED IN SCHEDULES F & I.

IN ADDITION TO SUPPORTING CUTTING-EDGE RESEARCH, MDR PROVIDES EXCELLENT RESOURCES ON DETECTING, TREATING, AND LIVING WITH THIS DISEASE. THESE ARE AVAILABLE IN BOTH PRINT AS WELL AS ON OUR WEBSITE, WWW.BRIGHTFOCUS.ORG

FORM 990, PART III, LINE 4C, DESCRIPTION OF PROGRAM SERVICE:

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

NATIONAL GLAUCOMA RESEARCH (NGR) -

GLAUCOMA IS THE SECOND LEADING CAUSE OF BLINDNESS WORLDWIDE. ACCORDING TO A RECENT REPORT FROM THE WORLD HEALTH ORGANIZATION, APPROXIMATELY 80 MILLION PEOPLE AROUND THE WORLD HAVE GLAUCOMA. MORE THAN THREE MILLION AMERICANS OVER THE AGE OF 40 ARE LIVING WITH GLAUCOMA, WITH AN ESTIMATED 2.7 MILLION HAVE OPEN-ANGLE GLAUCOMA, THE MOST COMMON TYPE. IN THE UNITED STATES, GLAUCOMA IS A LEADING CAUSE OF BLINDNESS AMONG BLACK AND HISPANIC AMERICANS. WITH EARLY DETECTION AND TREATMENT, GLAUCOMA OFTEN CAN BE MANAGED TO PROTECT EYES FROM MORE SERIOUS VISION LOSS. IT IS ESTIMATED THAT ONLY HALF OF THE PEOPLE LIVING WITH GLAUCOMA ARE AWARE THAT THEY HAVE THE DISEASE.

BRIGHTFOCUS' NGR PROGRAM HAS AWARDED MORE THAN \$49 MILLION WORLDWIDE FOR THE STUDY OF GLAUCOMA. NGR-SUPPORTED RESEARCH HAS BEEN FOCUSED ON THE EYE-BRAIN CONNECTION, HOW PRESSURE BUILDUP IN THE EYE CAN AFFECT SYNAPTIC NERVE COMMUNICATIONS, NEUROPROTECTION, AND OPTIC NERVE REGENERATION, DISCOVERING GLAUCOMA RISK GENES, AI/DEEP LEARNING AND ADAPTIVE OPTICS, SLEEP DISTURBANCE AND RISK OF DEVELOPING GLAUCOMA, DEVELOPING EARLY GLAUCOMA SCREENING, AND PURSUING NOVEL GENETIC COUNSELING AND COMMUNICATION STRATEGIES, AMONGST OTHER INNOVATIVE PURSUITS.

BRIGHTFOCUS' NATIONAL GLAUCOMA RESEARCH (NGR) GRANTS ARE AVAILABLE TO GLAUCOMA RESEARCHERS WORLDWIDE. NGR PLACES SPECIAL EMPHASIS ON ENCOURAGING APPLICATIONS FROM YOUNG SCIENTISTS AND THOSE WITH CUTTING-EDGE IDEAS. ANNUAL GRANT APPLICATIONS ARE PEER-REVIEWED, AND RECIPIENT SELECTIONS ARE BASED ON SCIENTIFIC MERIT.

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

DURING THE FISCAL YEAR ENDING MARCH 31, 2023, NGR AWARDED \$2,034,241 IN PEER-REVIEWED GRANT AWARDS FOR 11 NEW PROJECTS AND 2 OTHER AWARDS TO MAKE A TOTAL OF 13 GRANTS AT \$2,526,791 IN FUNDING. DETAILS ABOUT SPECIFIC PROJECTS ARE INCLUDED IN SCHEDULES F & I.

IN ADDITION TO SUPPORTING CUTTING-EDGE RESEARCH, BRIGHTFOCUS' NGR PROGRAM PROVIDES EXCELLENT RESOURCES ON DETECTING, TREATING, AND LIVING WITH THE DISEASE. THESE ARE AVAILABLE IN BOTH PRINT AS WELL AS ON OUR WEBSITE, WWW.BRIGHTFOCUS.ORG.

FORM 990, PART VI, SECTION B, LINE 11B:

A DRAFT OF THE FEDERAL FORM 990 IS DISTRIBUTED TO THE AUDIT COMMITTEE FOR REVIEW PRIOR TO BEING SUBMITTED TO THE INTERNAL REVENUE SERVICE. THE DRAFT FEDERAL FORM 990 IS DISTRIBUTED EARLY ENOUGH TO PROVIDE EACH COMMITTEE MEMBER WITH A REASONABLE AMOUNT OF TIME FOR REVIEW AND SUBMISSION OF QUESTIONS OR COMMENTS PRIOR TO THE FILING DEADLINE. THE FINAL FEDERAL FORM 990 IS DISTRIBUTED TO EACH MEMBER OF THE FULL BOARD OF DIRECTORS PRIOR TO BEING FILED WITH THE INTERNAL REVENUE SERVICE. THE DRAFT OR FINAL FEDERAL FORM 990 MAY BE DISTRIBUTED IN PERSON, BY REGULAR MAIL, E-MAIL, OR FAX.

FORM 990, PART VI, SECTION B, LINE 12C:

BRIGHTFOCUS HAS ALL EMPLOYEES, OFFICERS, AND DIRECTORS AGREE TO THE CODE OF CONDUCT THAT INCLUDES ADHERENCE TO THE CONFLICT OF INTEREST AND IMPLEMENTATION POLICY. EACH BOARD DIRECTOR, OFFICER, AND EMPLOYEE IS REQUIRED TO COMPLETE A CONFLICT OF INTEREST DISCLOSURE STATEMENT ANNUALLY.

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
--	--

EMPLOYEES MEET ANNUALLY WITH THE BRIGHTFOCUS' CHIEF COMPLIANCE OFFICER TO REVIEW THEIR CONFLICT OF INTEREST STATEMENTS, AND GIVE AN ANNUAL CONFLICT OF INTEREST COMPLIANCE REPORT TO THE BOARD CHAIR AND VICE CHAIR. IF A CONFLICT IS REPORTED, IT IS THEN REFERRED TO THE PRESIDENT/CEO AND/OR BRIGHTFOCUS' LEGAL COUNSEL AND, IF APPROPRIATE AND NECESSARY, THEN TO THE BOARD OF DIRECTORS OR ITS APPOINTED COMMITTEE FOR FURTHER ACTION.

THE DIRECTOR'S AND OFFICER'S STATEMENTS ARE REVIEWED BY THE BRIGHTFOCUS LEGAL COUNSEL. IF A CONFLICT IS REPORTED, IT IS THEN REFERRED TO THE BOARD OF DIRECTORS OR ITS APPOINTED COMMITTEE FOR FURTHER ACTION.

AT THE TIME OF THE BRIGHTFOCUS DISCUSSION AND DECISION CONCERNING A CONFLICT OF INTEREST, THE CONFLICTED PARTY IS NOT PRESENT IN THE MEETING.

FORM 990, PART VI, SECTION B, LINE 15:
BRIGHTFOCUS' BOARD OF DIRECTORS HAS OVERALL AUTHORITY AND RESPONSIBILITY FOR APPROVING THE ANNUAL BUDGET WHICH INCLUDES SALARY AND BENEFITS FOR ALL EMPLOYEES AT EVERY LEVEL INCLUDING NON-DIRECTOR OFFICERS AND KEY EMPLOYEES. ALL PAY ADJUSTMENTS ARE MADE ON A YEARLY BASIS EFFECTIVE APRIL 1ST, THE BEGINNING OF THE BRIGHTFOCUS FISCAL YEAR.

BEFORE APPROVING THE COMPENSATION OF THE PRESIDENT/CEO, THE BOARD DETERMINES THE TOTAL COMPENSATION TO BE PROVIDED BY BRIGHTFOCUS TO THE PRESIDENT/CEO IS REASONABLE IN LIGHT OF THE POSITION, RESPONSIBILITY AND QUALIFICATION OF THE POSITION HELD INCLUDING THE RESULT OF AN EVALUATION OF PRIOR PERFORMANCE FOR BRIGHTFOCUS, IF APPLICABLE. THE PRESIDENT/CEO IS EVALUATED ANNUALLY BY THE BOARD OF DIRECTORS THROUGH THE USE OF AN IN-DEPTH GOAL ATTAINMENT STRUCTURE, (DEVELOPED WITH ADVICE FROM BOARD SOURCE) THAT

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
---	---

INCLUDES A SELF ASSESSMENT AND A BOARD OF DIRECTORS ASSESSMENT AND EVALUATION AGAINST SET GOALS, OUTCOMES AND DELIVERABLES. IN ADDITION, THE BOARD OF DIRECTORS PERIODICALLY ENGAGES AN OUTSIDE CONSULTANT TO OBTAIN AND CONSIDER APPROPRIATE DATA, INCLUDING A SALARY SURVEY, WHICH INCLUDES INFORMATION COMPILED FROM THE FEDERAL FORM 990 OF OTHER ORGANIZATIONS, CONCERNING COMPENSATION PAID TO CEOS IN LIKE CIRCUMSTANCES. IN MAKING THE DETERMINATION, THE BOARD OF DIRECTORS SHALL CONSIDER TOTAL COMPENSATION TO INCLUDE THE SALARY AND VALUE OF ALL BENEFITS PROVIDED BY BRIGHTFOCUS TO THE INDIVIDUAL IN PAYMENT FOR SERVICES. AT THE TIME OF THE BRIGHTFOCUS BOARD DISCUSSION AND DECISION CONCERNING THE PRESIDENT/CEO'S COMPENSATION, THE PRESIDENT/CEO IS NOT PRESENT IN THE MEETING.

THE BOARD SHALL SET FORTH THE BASIS FOR ITS DECISIONS WITH RESPECT TO COMPENSATION IN THE MINUTES OF THE MEETING AT WHICH THE DECISIONS ARE MADE, INCLUDING THE CONCLUSIONS OF THE EVALUATION AND THE BASIS FOR DETERMINING THAT THE INDIVIDUAL'S COMPENSATION WAS REASONABLE IN LIGHT OF THE EVALUATION AND COMPARABILITY DATA.

THE PRESIDENT/CEO IS CHARGED WITH THE SETTING OF SALARIES OF ALL OTHER EMPLOYEES IN ACCORDANCE WITH A COMPENSATION STRUCTURE AND BUDGET APPROVED BY THE BOARD OF DIRECTORS. THE PRESIDENT/CEO AND HUMAN RESOURCES REVIEW EMPLOYEE COMPENSATION AND BENEFITS THAT INCLUDE KEY EMPLOYEES, BY PERIODICALLY ENGAGING AN OUTSIDE CONSULTANT TO CONDUCT COMPENSATION AND BENEFIT BENCHMARKING STUDIES THAT INCLUDE VARIOUS REGIONAL AND NATIONAL NON-PROFIT COMPENSATION REPORTS AND SURVEYS. COMPENSATION DELIBERATIONS AND DECISIONS INCLUDE THE REVIEW OF SELF AND SUPERVISORY EVALUATIONS OF EMPLOYEE PERFORMANCE COMPARED TO SET INDIVIDUAL AND ORGANIZATIONAL GOALS.

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

FORM 990, PART VI, LINE 17, LIST OF STATES RECEIVING COPY OF FORM 990:

AK, AL, AR, CA, CT, FL, GA, HI, IL, KS, KY, ME, MD, MA, MI, MN, MO, MS, NC, ND, NH, NJ, NM, NY, OH
 OK, OR, PA, RI, SC, TN, UT, VA, WA, WI, WV

FORM 990, PART VI, SECTION C, LINE 19:

BRIGHTFOCUS MAKES ITS GOVERNING DOCUMENTS INCLUDING ITS ARTICLES OF
 INCORPORATION AND BYLAWS, THE FEDERAL FORM 1023, THE 501(C)(3) LETTER OF
 DETERMINATION FROM THE INTERNAL REVENUE SERVICE, CONFLICT OF INTEREST
 POLICY, AUDITED FINANCIAL STATEMENTS AND FEDERAL FORM 990 AVAILABLE TO THE
 PUBLIC UPON REQUEST. IN ADDITION, THE PUBLIC ALSO HAS ACCESS TO THE ANNUAL
 REPORT, AUDITED FINANCIAL STATEMENTS, THE 501(C)(3) LETTER OF DETERMINATION
 FROM THE INTERNAL REVENUE SERVICE, AND FEDERAL FORM 990 ON OUR WEBSITE.

FORM 990, PART XI, LINE 9, CHANGES IN NET ASSETS:

RECOVERIES OF PRIOR YEAR GRANTS	1,028,552.
CHANGE IN PRESENT VALUE OF GRANTS	267,164.
TOTAL TO FORM 990, PART XI, LINE 9	1,295,716.

SCHEDULE F, PART II, LINE 1, COLUMN D:

REGION: EUROPE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY
 LUCIA CHAVEZ-GUTIERREZ, PHD, ENTITLED: (A2023005S) ELUCIDATING THE
 MECHANISMS OF ACTION OF GAMMA-SECRETASE MODULATORS (GSMS) TO FACILITATE
 STRUCTURE-BASED DESIGN OF NEXT-GENERATION THERAPEUTICS. INVESTIGATOR'S
 SUMMARY: ALZHEIMER'S DISEASE (AD) IS LINKED TO THE BUILD-UP OF LONGER,
 AGGREGATION-PRONE AMYLOID-BETA (A-BETA) PEPTIDES IN THE BRAIN.
 GAMMA-SECRETASE DYSREGULATION LEADING TO ENHANCED PRODUCTION OF LONGER
 A-BETAS CAUSES AD. GAMMA-SECRETASE MODULATORS PROMOTE THE PRODUCTION OF
 SHORTER A-BETAS, WHILE SPARING CRITICAL (GAMMA-SECRETASE) BIOLOGICAL

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

ROLES. THESE MOLECULES ARE PROMISING AGENTS IN THE FIGHT AGAINST AD; HOWEVER, A LACK OF UNDERSTANDING OF THEIR MODES OF ACTION HAVE LIMITED THEIR DEVELOPMENT. HERE, WE WILL DEFINE THE MODE(S) OF ACTION OF GAMMA-SECRETASE MODULATORS AND FOSTER THERAPEUTIC DEVELOPMENT. GRANT AWARDED: \$300,000, FLANDERS INSTITUTE FOR BIOTECHNOLOGY, (VIB), GENT, BELGIUM. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023005S

REGION: EUROPE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY MARTA CASQUERO-VEIGA, PHD, ENTITLED: (A2023012F) DEVELOPMENT OF MULTIMODAL NEUROIMAGING BIOMARKERS OF THE PRO-COAGULANT STATE IN ALZHEIMER'S DISEASE (NIPAD). INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE (AD) PATHOPHYSIOLOGY INCLUDES AN EARLY HEMOSTATIC DYSREGULATION, INDUCING A PRO-THROMBOTIC MILIEU. CONSEQUENTLY, AD-PATIENTS' BRAINS SHOW INCREASED FIBRIN LEVELS AND DEGRADATION-RESISTANT CLOTS, WHICH CONTRIBUTES TO NEURONAL DEATH. THESE PROCESSES APPEAR EARLY IN AD'S COURSE, BUT NOT IN ALL PATIENTS. THIS STUDY AIMS TO DEVELOP NEW GENERATION PROBES TO VISUALIZE THE PRO-COAGULANT COMPONENTS ACCUMULATED IN THE AD BRAIN, BY IN VIVO NON-INVASIVE MULTIMODAL IMAGING. ULTIMATELY, OUTCOMES WILL ENABLE CLINICIANS TO PRESCRIBE A SUITABLE TREATMENT TO AMELIORATE AD'S PROGRESSION. GRANT AWARDED: \$200,000, INSTITUTO DE INVESTIGACION SANITARIA - FUNDACION JIMENEZ DIAZ, MADRID, SPAIN. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023012F

REGION: EUROPE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY QI WANG, PHD, ENTITLED: (A2023018F) RESTORING MITOCHONDRIAL HOMEOSTASIS AS

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
--	--

A THERAPY OF ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: DEFECTS IN MITOCHONDRIA PRECEDE THE ONSET OF DEMENTIA BY DECADES AND ARE INVOLVED IN MULTIPLE ASPECTS OF ALZHEIMER'S DISEASE (AD) PATHOGENESIS. I AIM TO TEST WHETHER ACTIVATING THE BENEFICIAL MITOCHONDRIAL STRESS RESPONSES WITH A COMPOUND NAMED 9-TB COULD IMPROVE AD PATHOLOGIES. I WILL INVESTIGATE 9-TB'S EFFECTS ON MITOCHONDRIAL FUNCTION, MAIN COGNITIVE AND BIOMEDICAL MANIFESTATIONS OF AD IN A MOUSE MODEL. I WILL USE ADVANCED MULTI-OMICS APPROACH TO FULLY REVEAL 9-TB'S MECHANISMS OF ACTION AND VALIDATE ITS MECHANISM USING IN VITRO, EX VIVO AND IN SILICO SYSTEMS, FULFILLING THE REQUIREMENTS FOR CLINICAL TRIALS. GRANT AWARDED: \$200,000, SWISS FEDERAL INSTITUTE OF TECHNOLOGY LAUSANNE, SWITZERLAND. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023018F

REGION: MIDDLE EAST (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ARIEL GILAD, PHD, ENTITLED: (A2023024S) BRAIN-WIDE NETWORK DYSFUNCTIONS IN ALZHEIMER'S DISEASE OF INDIVIDUAL MICE. INVESTIGATOR'S SUMMARY: A HALLMARK OF ALZHEIMER'S DISEASE (AD) IS ABNORMAL BRAIN-WIDE NETWORKS THAT DIFFER ACROSS AND WITHIN PATIENTS. HERE, WE AIM TO USE AN AD MOUSE MODEL TO RECORD BRAIN-WIDE NETWORKS IN MICE DURING AD-RELATED COGNITIVE TASKS. BY USING AN INDIVIDUAL APPROACH AND TRACK EACH MOUSE THROUGHOUT ITS LIFESPAN, WE BELIEVE THAT EACH MOUSE WILL DISPLAY BRAIN-WIDE DYSFUNCTION THAT IS MODULATED BASED ON AD PROGRESSION AND INDIVIDUAL TRAITS. WE AIM TO OUTLINE KEY BRAIN AREAS THAT MAY BE TARGETED IN INDIVIDUAL HUMAN PATIENTS USING DEEP-BRAIN STIMULATION, THUS INCREASING THE QUALITY OF LIFE FOR MILLIONS OF PEOPLE GRANT AWARDED: \$300,000, HEBREW UNIVERSITY OF JERUSALEM, ISRAEL. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
---	---

WWW.BRIGHTFOCUS.ORG/GRANT/A2023024S

REGION: EUROPE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY LOUISE VAN DER WEERD, PHD, ENTITLED: (A2023026S) IRON SPREADING PATTERNS IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: WE KNOW THAT IRON ACCUMULATES IN THE BRAINS OF PATIENTS WITH ALZHEIMER'S DISEASE (AD). THIS PROCESS STRONGLY PREDICTS HOW FAST A PATIENT'S COGNITIVE FUNCTION WILL DECLINE. HOWEVER, WE DO NOT YET KNOW WHERE IN THE BRAIN THE ACCUMULATION STARTS, AND HOW THE ACCUMULATION SPREADS. THAT MAKES IT DIFFICULT TO DEVELOP MEASUREMENTS THAT CAN HELP TO PREDICT THE DISEASE COURSE FOR INDIVIDUAL PATIENTS. IN THIS PROJECT WE WILL DEVELOP AN ATLAS OF THE BRAIN THAT SHOWS HOW IRON ACCUMULATES AS AD PROGRESSES OVER TIME. WE DO THAT BY STUDYING HUNDREDS OF BRAIN DONORS WITH VARYING DEGREES OF AD. GRANT AWARDED: \$299,354, LEIDEN UNIVERSITY MEDICAL CENTER, LEIDEN, NETHERLANDS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023024S

REGION: EUROPE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH CONFERENCE SUPPORT. GRANT AWARDED: \$99,353, THE 2023 INTERNATIONAL CONFERENCE ON ALZHEIMER'S & PARKINSON'S DISEASES, GOTHENBURG, SWEDEN.

REGION: EUROPE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH TRAVEL GRANTS FOR CONFERENCE ATTENDANCE. GRANT AWARDED: \$10,000, FINGERS BRAIN HEALTH INSTITUTE, STOCKHOLM, SWEDEN.

REGION: EUROPE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY DR. GAELLE CHETELAT ENTITLED: (CA2021013) SEX DIFFERENCES IN RISK PROFILES ACROSS THE ALZHEIMER'S DISEASE CONTINUUM. INVESTIGATOR'S

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
--	--

SUMMARY: THIS PROJECT WILL AIM TO MODEL COGNITIVE RESILIENCE IN RODENTS BY COMBINING A RAT MODEL OF SUCCESSFUL AGING WITH A MODEL OF EARLY ALZHEIMER'S DISEASE (AD). THE HYPOTHESIS TESTS WHETHER THESE RATS ARE RESILIENT TO AD PATHOLOGY, RESULTING IN INTACT COGNITION COMPARED TO AD RATS. THE INVOLVEMENT OF THE SEROTONERGIC SYSTEM WILL BE EVALUATED TO DETERMINE POTENTIAL THERAPEUTIC TARGETS THAT MAY PROMOTE RESILIENCE TO AD. GRANT AWARDED: \$25,000, FONDATION VAINCRE ALZHEIMER, PARIS, FRANCE. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/CA2021013

SCHEDULE F, PART II, LINE 1, COLUMN D, CONTINUED:

REGION: EUROPE (D) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY KAREN PEYNSHAERT, PHD, ENTITLED: (G2023002F) EXPLORING ICG-MEDIATED ILM PHOTODISRUPTION AS A TOOL TO BOOST RETINAL GANGLION CELL ENGRAFTMENT. INVESTIGATOR'S SUMMARY: THIS PROJECT EXPLORES AN INNOVATIVE BIOPHOTONIC APPROACH TO MANIPULATE THE INNER LIMITING MEMBRANE (ILM), A BARRIER WHICH GREATLY HINDERS THE RETINAL ENTRY OF DONOR RGCS FOLLOWING INTRAVITREAL INJECTION. BY CONTROLLED PERFORATION OF THE ILM, WE AIM TO ENHANCE THE MIGRATION OF RGCS INTO THE RETINA WHILE MAINTAINING ILM'S CUES NECESSARY FOR THEIR SUBSEQUENT DEVELOPMENT. GRANT AWARDED: \$150,000, GHENT UNIVERSITY, GENT, BELGIUM. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2023002F

REGION: NORTH AMERICA (D) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY ADRIANA DI POLO, PHD, ENTITLED: (G2023005S) DISEASE-MODIFYING MITOCHONDRIAL UNCOUPLERS: A NEW THERAPEUTIC STRATEGY FOR GLAUCOMA. INVESTIGATOR'S SUMMARY: MITOCHONDRIAL DYSFUNCTION IS A KEY FEATURE OF NEURONAL DAMAGE IN GLAUCOMA. THIS PROPOSAL WILL TEST THE POTENTIAL OF

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
--	--

MILD MITOCHONDRIA UNCOUPLERS AS DISEASE-MODIFYING AGENTS TO REDUCE
OXIDATIVE STRESS, IMPROVE CALCIUM HOMEOSTASIS, AND PROMOTE REPAIR
PATHWAYS. THE OUTCOME OF THIS STUDY WILL PROVIDE ROBUST
PROOF-OF-PRINCIPLE DATA AND OPEN NEW OPPORTUNITIES FOR CLINICAL TESTING
IN GLAUCOMA PATIENTS. GRANT AWARDED: \$200,000, UNIVERSITY OF MONTREAL,
CANADA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:
WWW.BRIGHTFOCUS.ORG/GRANT/G2023005S

REGION: EUROPE (D) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY
SILVIA MARINELLI, PHD, ENTITLED: (G2023006S) A NEW OPTIMIZED FORM OF
NERVE GROWTH FACTOR: AN ANTI-INFLAMMATORY AND NEUROPROTECTIVE DRUG
CANDIDATE FOR GLAUCOMA. INVESTIGATOR'S SUMMARY: WE DEVELOPED AN
OPTIMIZED NERVE GROWTH FACTOR, PAINLESS NGF (NGFP), THAT HAS THE SAME
NEUROPROTECTIVE PROPERTIES AS NATURAL NGF BUT LACKS ADVERSE EFFECTS,
SUCH AS PAIN AND CELL DEATH SIGNALLING. NGFP, WITHOUT THE PITFALLS OF
NATURAL NGF, IS A PROMISING THERAPEUTIC CANDIDATE FOR GLAUCOMA, ABLE TO
RESCUE RGC DEGENERATION THROUGH A SYNERGISTIC ACTION OF NEUROPROTECTION
AND INFLAMMATORY MODULATION GRANT AWARDED: \$200,000, FONDAZIONE EBRI
"RITA LEVI-MONTALCINI", ROME, ITALY. FOR MORE INFORMATION, VISIT THE
BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2023006S

REGION: EUROPE (D) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY
DARRYL OVERBY, PHD, ENTITLED: (G2023011S) MICROENVIRONMENTAL REGULATION
OF BARRIER FUNCTION IN SCHLEMM'S CANAL ENDOTHELIAL CELLS.
INVESTIGATOR'S SUMMARY: THE ONLY WAY TO TREAT GLAUCOMA IS TO REDUCE EYE
PRESSURE, BUT THE FACTORS CONTROLLING EYE PRESSURE ARE NOT UNDERSTOOD.
OUR LAB HAS SHOWN THAT EYE PRESSURE IS PARTLY REGULATED BY A LAYER OF
SPECIALISED CELLS THAT CREATE A BARRIER AGAINST FLUID DRAINAGE FROM THE

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
--	--

EYE. WE AIM TO RECREATE THIS CELLULAR BARRIER IN THE LAB, WHICH WILL
OPEN NEW AVENUES FOR RESEARCH AND DEVELOPMENT TARGETING THIS BARRIER.

GRANT AWARDED: \$184,242, IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND
MEDICINE, LONDON, UNITED KINGDOM. FOR MORE INFORMATION, VISIT THE
BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2023011S

REGION: EUROPE (D) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY
DARRYL OVERBY, PHD, ENTITLED: (CG2020003) DEVELOPING NEW DRUGS TO LOWER
EYE PRESSURE IN GLAUCOMA. INVESTIGATOR'S SUMMARY: OUR RESEARCH HAS
IDENTIFIED A PARTICULAR CELL TYPE (SCHLEMM'S CANAL CELLS) THAT REGULATE
EYE PRESSURE BY CONTROLLING THE DRAINAGE OF AQUEOUS HUMOR FROM THE EYE.
IN THIS PROJECT, WE WILL DEVELOP AND APPLY NOVEL SCREENING TECHNOLOGIES
TO IDENTIFY NEW DRUGS TO LOWER EYE PRESSURE BY IMPROVING AQUEOUS HUMOR
DRAINAGE ACROSS SCHLEMM'S CANAL CELLS. GRANT AWARDED: \$97,975, IMPERIAL
COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE, LONDON, UNITED KINGDOM.
FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:
WWW.BRIGHTFOCUS.ORG/GRANT/CG2020003

REGION: EAST ASIA & PACIFIC (D) PURPOSE OF GRANT: MACULAR DEGENERATION
RESEARCH BY MATTHEW RUTAR, PHD, ENTITLED: (M2023009N) INVESTIGATING THE
ROLE OF NEUTROPHIL EXTRACELLULAR TRAPS IN NEOVASCULAR AMD.
INVESTIGATOR'S SUMMARY: NEOVASCULAR AMD (NAMD) IS A MAJOR CAUSE OF
BLINDNESS WITH FEW AVAILABLE TREATMENTS. OUR CENTRAL HYPOTHESIS IS THAT
DYSREGULATION OF NEUTROPHIL EXTRACELLULAR TRAPS (NETS) PROMOTES
INFLAMMATION AND DEGENERATION IN NAMD, THUS REPRESENTING A NOVEL TARGET
FOR DIAGNOSTIC BIOMARKERS AND THERAPEUTIC INTERVENTIONS. WE DETERMINE A
ROLE FOR NETS USING EXPERIMENTAL MODELS AND AMD DONOR TISSUE, AND
EVALUATE THE POTENTIAL OF FIRST-GENERATION INHIBITORS OF NET ACTIVITY

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

IN CURTAILING INFLAMMATION AND PATHOLOGY IN CNV. GRANT AWARDED:

\$334,938, UNIVERSITY OF CANBERRA, BRUCE, AUSTRALIA. FOR MORE

INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

WWW.BRIGHTFOCUS.ORG/GRANT/M2023009N

SCHEDULE I, PART II, LINE 1, COLUMN (H):

NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS GENERAL HOSPITAL. (H)

PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ZAHRA SHIRZADI, PHD,

ENTITLED: (A2023001F) NOVEL TOOLS TO DISSECT THE MULTI-FACTORIAL

ETIOLOGIES OF WHITE MATTER INJURY IN AGING AND ALZHEIMER'S DISEASE.

INVESTIGATOR'S SUMMARY: THE BRAIN'S WHITE MATTER IS COMPOSED OF

MILLIONS OF BUNDLES OF NERVE FIBERS THAT CONNECT NEURONS IN DIFFERENT

BRAIN REGIONS INTO FUNCTIONAL CIRCUITS. THEREFORE, ANY DAMAGE TO THESE

FIBERS CAN AFFECT NORMAL BRAIN FUNCTION. IT IS VERY COMMON TO OBSERVE

SIGNS OF WHITE MATTER INJURY IN BRAIN IMAGES OF PRECLINICAL AND

SYMPTOMATIC ALZHEIMER'S DISEASE (AD) PATIENTS, YET IT IS UNCLEAR WHY

THIS INJURY OCCURS. FOLLOWING UP ON OUR RECENT STUDIES IN FAMILIAL AD,

WE WILL INVESTIGATE WHETHER AD MARKERS INCLUDING AMYLOID ACCUMULATION

AND BRAIN TISSUE LOSS CAN DESCRIBE WHITE MATTER INJURY IN AD. FOR MORE

INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

WWW.BRIGHTFOCUS.ORG/GRANT/A2023001F

NAME OF ORGANIZATION OR GOVERNMENT: BAYLOR COLLEGE OF MEDICINE. (H)

PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY DAHEUN CHUNG, PHD,

ENTITLED: (A2023002F) EXPLORING THE PROTECTIVE ROLE OF THE BIG TAU

ISOFORM IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: AS COGNITIVE

DECLINE IS HIGHLY CORRELATED WITH THE SEVERITY OF TAU PATHOLOGY IN

ALZHEIMER'S DISEASE, PROTECTING TAU FROM ABNORMAL CHANGES MAY BRING

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
--	--

THERAPEUTIC BENEFITS. WHILE THERE IS NO EFFECTIVE TAU-TARGETING TREATMENT, I RECENTLY DISCOVERED THAT AN UNDERSTUDIED TAU ISOFORM, ABUNDANT IN THE BRAIN REGION SPARED FROM TAU PATHOLOGY, IS LESS LIKELY TO BECOME PATHOLOGICALLY ALTERED. AS SUCH, I PROPOSE TO EXAMINE IF THIS TAU ISOFORM IS CRUCIAL IN PREVENTING THE DEVELOPMENT OF TAU PATHOLOGY IN THE BRAIN, AND IF IT HAS ANY UNIQUE INTERACTING PROTEIN PARTNERS THAT FACILITATE SUCH A PHENOMENON. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023002F

NAME OF ORGANIZATION OR GOVERNMENT: NORTHWESTERN UNIVERSITY FEINBERG SCHOOL OF MEDICINE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY DAVID GATE, PHD, ENTITLED: (A2023003S) PROTEOGENOMICS TO STUDY ADAPTIVE IMMUNITY IN NEURODEGENERATIVE DISEASE. INVESTIGATOR'S SUMMARY: THIS PROPOSAL WILL UTILIZE A NOVEL PROTEOGENOMICS APPROACH TO EXPLORE THE ROLE OF ADAPTIVE IMMUNE T CELLS IN THE PATHOPHYSIOLOGY OF AGE-RELATED NEURODEGENERATION. THIS APPROACH AIMS TO IDENTIFY NEUROIMMUNOLOGIC DISEASE MECHANISMS AND THERAPEUTIC TARGETS FOR THESE DEVASTATING DISEASES. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023003S

NAME OF ORGANIZATION OR GOVERNMENT: JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY MEAGHAN MORRIS, MD, PHD, ENTITLED: (A2023004S) EXPLORING THE ORIGINS OF TAU PATHOLOGY IN HUMAN BRAIN: MOLECULAR SIGNATURES OF AGING AND NEURODEGENERATION IN THE LOCUS CERULEUS. INVESTIGATOR'S SUMMARY: THE SPREAD OF TAU PATHOLOGY IN ALZHEIMER'S DISEASE IS ASSOCIATED WITH PROGRESSIVE COGNITIVE DECLINE. HOWEVER, THE MOLECULAR EVENTS SURROUNDING THE EARLIEST FORMATION AND SPREAD OF TAU PATHOLOGY IN THE

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
--	--

HUMAN BRAIN ARE LARGELY UNEXPLORED. THIS STUDY WILL EXAMINE THE MOLECULAR ENVIRONMENT ASSOCIATED WITH AGING AND EARLY ACCUMULATION OF TAU PATHOLOGY IN HUMAN BRAIN, AS WELL AS THE EARLIEST SPREAD OF TAU PATHOLOGY IN AGING AND ALZHEIMER'S DISEASE. INSIGHT INTO THIS EARLY TAU FORMATION COULD PROVIDE TARGETABLE PATHWAYS TO PREVENT THE FORMATION OR SPREAD OF TAU PATHOLOGY IN THE BRAIN. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023004S

NAME OF ORGANIZATION OR GOVERNMENT: CORNELL UNIVERSITY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY MATTHEW ISAACSON, PHD, ENTITLED: (A2023006F) IMAGING NEURAL ACTIVITY CHANGES UNDERLYING THE ACUTE RESCUE OF MEMORY FUNCTION AFTER IMPROVING CEREBRAL BLOOD FLOW IN ALZHEIMER'S DISEASE MOUSE MODELS. INVESTIGATOR'S SUMMARY: USING VISUAL AND SPATIAL BEHAVIORAL TASKS DURING FUNCTIONAL BRAIN IMAGING, WE WILL CHARACTERIZE LEARNING AND MEMORY DEFICITS AND THEIR NEURAL CORRELATES IN AN ALZHEIMER'S DISEASE MOUSE MODEL. WITH A PREVIOUSLY ESTABLISHED ACUTE TREATMENT TO IMPROVE BLOOD FLOW IN THE BRAIN THAT IMPROVES MEMORY, WE WILL GAIN NEW INSIGHT INTO HOW IMPROVED COGNITIVE ABILITY MANIFESTS IN NEURAL ACTIVITY CHANGES AND UNCOVER DISEASE-RELEVANT FAILURE MODES OF NEURAL CIRCUITRY THAT WILL INFORM HOW THESE CIRCUITS COULD BE THERAPEUTICALLY MANIPULATED TO RESTORE COGNITIVE ABILITY IN NEURODEGENERATIVE DISORDERS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023006F

NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS GENERAL HOSPITAL. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JOOST RIPHAGEN, MD, PHD, ENTITLED: (A2023007F) MEYNERT TO MAYHEM? THE TEMPORAL-SPATIAL EVOLUTION OF EARLY TAU PATHOLOGY IN ALZHEIMER'S DISEASE. INVESTIGATOR'S

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
--	--

SUMMARY: FOR OPTIMAL TREATMENT OF ALZHEIMER'S DISEASE (AD) IT IS CRUCIAL TO IDENTIFY PEOPLE AT RISK OF AD EARLY, BEFORE IRREVERSIBLE BRAIN DAMAGE OCCURS. A SMALL REGION AT THE BOTTOM OF THE BRAIN (BASAL FOREBRAIN) IS ONE OF THE FIRST REGIONS TO ACCUMULATE MISFOLDED AD TAU PROTEINS AND IS CRITICAL FOR MEMORY FUNCTION. WE WILL USE ADVANCED BRAIN IMAGING METHODS (MRI AND PET) TO DETECT SUBTLE CHANGES IN THIS REGION AND PREDICT DISEASE PROGRESSION. FINDINGS FROM THIS STUDY HAVE THE POTENTIAL TO UNDERSTAND MECHANISMS OF DISEASE PROGRESSION AND MOVE DETECTION AND TREATMENT TO EARLIER STAGES OF THE DISEASE. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:
WWW.BRIGHTFOCUS.ORG/GRANT/A2023007F

NAME OF ORGANIZATION OR GOVERNMENT: WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY TILL ZIMMER, PHD, ENTITLED: (A2023008F) MOLECULAR MECHANISMS AND EFFECTS OF ALZHEIMER'S-RELATED LIPID DYSREGULATION IN ASTROCYTES. INVESTIGATOR'S SUMMARY: THE BRAIN IS FULL OF FATS, ALSO CALLED LIPIDS, WHICH ARE DYSREGULATED IN ALZHEIMER'S DISEASE (AD). LIPID SUPPLY BY ASTROCYTES IS VITAL TO THE FUNCTION AND SURVIVAL OF NEURONS AND NEURONAL DEGENERATION IS THOUGHT TO CAUSE AD-RELATED SYMPTOMS. IMPROPER LIPID SUPPORT BY ASTROCYTES IN AD COULD CAUSE NEURONS TO BE DYSFUNCTIONAL OR DEGENERATE. TO BETTER UNDERSTAND THESE MECHANISMS, WE WILL STUDY HOW ALZHEIMER'S-ASSOCIATED DISEASE MECHANISMS LIKE NEUROINFLAMMATION AND ACCUMULATION OF A-BETA PROTEIN AFFECT LIPID METABOLISM IN ASTROCYTES AND HOW THESE ASTROCYTE LIPIDS ALTER NEURONAL FUNCTION. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:
WWW.BRIGHTFOCUS.ORG/GRANT/A2023008F

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
---	---

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF SOUTH FLORIDA. (H)

PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ARI SUDWARTS, PHD,

ENTITLED: (A2023009F) IDENTIFYING THE INTERACTOME AND NON-AUTONOMOUS

SIGNALLING OF RISK-GENE BIN1 IN AMYLOID-RESPONSIVE MICROGLIA.

INVESTIGATOR'S SUMMARY: GENES EXPRESSED IN MICROGLIA - THE IMMUNE CELL

OF THE BRAIN - HAVE COME TO LIGHT AS KEY RISK FACTORS FOR LATE-ONSET

ALZHEIMER'S DISEASE (LOAD). THE BIN1 GENE CONTAINS THE SECOND-MOST

COMMON RISK FOR LOAD, AND BIN1 IS INTEGRAL FOR MICROGLIAL RESPONSES TO

INFLAMMATION AND DISEASE. MY PROJECT WILL IDENTIFY WHICH GENES BIN1

INTERACTS WITH IN MICROGLIA, PROVIDING CRUCIAL INSIGHT INTO BIN1

FUNCTION. ADDITIONALLY, I FOUND BIN1 IS INVOLVED IN MICROGLIA

SIGNALLING TO OTHER CELLS. THIS WILL BE EXPLORED USING A COMBINATION OF

CUTTING-EDGE TECHNOLOGIES TO IDENTIFY CELL RECIPIENTS OF MICROGLIAL

SIGNALS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

WWW.BRIGHTFOCUS.ORG/GRANT/A2023009F

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, LOS

ANGELES. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY DAVID

BOYER, PHD, ENTITLED: (A2023010F) ATOMIC STRUCTURE DETERMINATION OF

A-BETA OLIGOMERS ASSOCIATED WITH ALZHEIMER'S DISEASE. INVESTIGATOR'S

SUMMARY: THE FORMATION OF AMYLOID FIBRILS IN THE BRAINS OF PATIENTS IS

THE DEFINING CHARACTERISTIC OF ALZHEIMER'S DISEASE AND RELATED DEMENTIA

(ADRD). EXPERIMENTS DETAILING THE STRUCTURES OF AMYLOID FIBRILS HAVE

GREATLY ADVANCED OUR UNDERSTANDING OF ADRD AND OFFER ROUTES TO

THERAPEUTIC DEVELOPMENT; HOWEVER, WE ARE CURRENTLY HINDERED IN THE

FIGHT TO CURE ADRD DUE TO THE LACK OF STRUCTURES OF INTERMEDIATES ON

THE PATHWAY TO FIBRILS - TERMED AMYLOID OLIGOMERS. HERE I PROPOSE TO

OBTAIN THE STRUCTURES OF AMYLOID OLIGOMERS USING CRYO-ELECTRON

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
---	---

MICROSCOPY TO DEEPEN OUR KNOWLEDGE OF THE MOLECULAR BASIS OF ADRD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023010F

SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED:

NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS GENERAL HOSPITAL. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JINGYUAN CHEN, PHD, ENTITLED: (A2023011S) WHOLE-BRAIN SLEEP-WAKE ENERGETICS IN SUBJECTS AT GENETIC RISK FOR ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: RECENT RODENT STUDIES HAVE SUGGESTED THAT DISRUPTED SYNAPTIC ACTIVITY ACROSS SLEEP-WAKE CYCLES PLAYS AN IMPORTANT ROLE IN CAUSING ALZHEIMER'S DISEASE (AD). IN THIS PROPOSAL, WE WILL LEVERAGE CUTTING-EDGE HUMAN IMAGING TECHNIQUES TO TEST WHETHER SUCH ABNORMALITIES OF CYCLIC NEURONAL ACTIVITY ACROSS SLEEP-WAKE CYCLES CAN BE IDENTIFIED IN SUBJECTS AT GENETIC RISK FOR AD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023011S

NAME OF ORGANIZATION OR GOVERNMENT: NORTHWESTERN UNIVERSITY FEINBERG SCHOOL OF MEDICINE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ARUN UPADHYAY, PHD, ENTITLED: (A2023013F) STABLE ISOTOPE-BASED DATING OF THE AMYLOID FIBRIL PROTEOME. INVESTIGATOR'S SUMMARY: THE RECENT SUCCESS OF ANTIBODY-BASED THERAPEUTICS TARGETING VARIOUS FORMS OF A-BETA PEPTIDES HIGHLIGHTS THE IMPORTANCE OF AMYLOID FIBRILS IN AD PATHOLOGY. NOTABLY, FIBRIL DYNAMICS IS ONE OF THE MOST CRUCIAL FACTORS AFFECTING AMYLOID DEPOSITION DURING AD PROGRESSION. IN THIS APPLICATION, I PROPOSE TO (1) IDENTIFY PROTEINS ASSOCIATED WITH NEWLY FORMED AMYLOID FIBRILS IN THE BRAIN; (2) INVESTIGATE IF MANIPULATING THESE PROTEINS INFLUENCES THE ONSET OF AMYLOID PATHOLOGY. ULTIMATELY,

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
---	---

THIS PROJECT WILL UNCOVER NEW ASPECTS OF AMYLOID KINETICS AND MAY PROVIDE NEW TARGETS FOR REDUCING AMYLOID PATHOLOGY. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023013F

NAME OF ORGANIZATION OR GOVERNMENT: WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY SUNG JI AHN, PHD, ENTITLED: (A2023014F) NEUROVASCULAR AND NEURONAL NETWORK DYSFUNCTION IN TAUOPATHY MOUSE MODELS. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE (AD) IS THE LEADING CAUSES OF DEMENTIA, CURRENTLY UNTREATABLE. A MAJOR CULPRIT THAT DAMAGES THE BRAIN IN AD IS THE PROTEIN "TAU." TAU MOLECULES ARE NORMAL CONSTITUENTS OF BRAIN CELLS BUT WHEN CHEMICALLY ALTERED FORM CLUMPS THAT CLOG UP IN THE CELLS. WE SEEK TO FIND OUT IF TAU CLUMPS ARE DAMAGING BY STARVING THE BRAIN OF ITS BLOOD SUPPLY, WHICH CARRIES VITAL OXYGEN AND NUTRIENTS NECESSARY FOR NORMAL BRAIN FUNCTION AND SURVIVAL. WE WILL ALSO TEST IF PROVIDING EXTRA OXYGEN TO THE BRAIN CAN OVERCOME THE BRAIN DYSFUNCTION CAUSED BY TAU, WHICH COULD HAVE THERAPEUTIC IMPLICATIONS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023014F

NAME OF ORGANIZATION OR GOVERNMENT: JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ALYSSA COYNE, PHD, ENTITLED: (A2023015S) ESCRT-III NUCLEAR SURVEILLANCE IN CHMP2B FTD. INVESTIGATOR'S SUMMARY: MAINTENANCE OF THE PROTEIN COMPLEXES THAT CONTROL COMMUNICATION BETWEEN THE NUCLEAR AND CYTOPLASMIC COMPARTMENTS OF CELLS IS ESSENTIAL FOR PROPER NEURONAL FUNCTION AND SURVIVAL. RECENT WORK HAS DEMONSTRATED THAT DEFECTS IN A NUCLEAR SURVEILLANCE PATHWAY INITIATE DAMAGE TO THESE CELLULAR

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
---	---

COMMUNICATION CHANNELS AS AN EARLY AND SIGNIFICANT EVENT IN LOU GEHRIG'S DISEASE. THIS PROPOSAL WILL EXAMINE THE CONTRIBUTION OF IMPAIRED NUCLEAR SURVEILLANCE AND NUCLEAR-CYTOPLASMIC COMPARTMENTALIZATION TO A GENETICALLY LINKED FORM OF DEMENTIA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:
WWW.BRIGHTFOCUS.ORG/GRANT/A2023015S

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF SOUTHERN CALIFORNIA.
(H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY PAUL SEIDLER, PHD, ENTITLED: (A2023016S) UNFOLDING ALZHEIMER'S TAU THERAPIES: APPROACHES FOR THE NEAR- AND LONG-TERM. INVESTIGATOR'S SUMMARY: BY NO MISTAKE, NATURAL PRODUCT CHEMICALS IN THE FORMS OF VITAMINS AND DIETARY SUPPLEMENTS HAVE LONG PLAYED A ROLE IN SUPPORTING HUMAN HEALTH. IN THE CONTEXT OF AGING, PLANT NATURAL PRODUCTS EVOLVED ALONGSIDE MICROBIAL PROTEINS THAT BEAR STRUCTURAL SIMILARITY TO PROTEINS FROM THE HUMAN BRAIN THAT BECOME TANGLED WITH AGE. WE LEVERAGE THESE REALIZED STRUCTURAL AND CHEMICAL SIMILARITIES TO DEVELOP DIETARY SUPPLEMENTS AND PHARMACEUTICAL-GRADE MEDICINES TO SUPPORT HEALTHIER AGING AND TO TREAT AD, RESPECTIVELY. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:
WWW.BRIGHTFOCUS.ORG/GRANT/A2023016S

NAME OF ORGANIZATION OR GOVERNMENT: SHRINERS HOSPITALS FOR CHILDREN - NORTHERN CALIFORNIA. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY OLGA CHECHNEVA, PHD, ENTITLED: (A2023017S) NUCLEAR MATERIAL TRANSFER IN PATHOGENIC PROTEIN SPREADING. INVESTIGATOR'S SUMMARY: SPREADING OF PATHOGENIC PROTEIN AGGREGATES IN NEURONS CAUSES PROGRESSION OF ALZHEIMER'S DISEASE AND MANY GENETIC AND AGE-RELATED NEUROLOGICAL DISORDERS. THIS PROJECT WILL INVESTIGATE A PREVIOUSLY UNRECOGNIZED

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
---	---

POPULATION OF SOX-10 LINEAGE CELLS THAT TRANSFER NUCLEAR AND RIBOSOMAL MATERIAL TO NEURONS AND THEIR ROLE IN PATHOGENIC PROTEIN SPREADING. OUR RESEARCH WILL ADVANCE OUR UNDERSTANDING OF THE MECHANISMS UNDERLYING PATHOGENIC PROTEIN SPREADING WITH THE AIM TO DEVELOP NOVEL THERAPIES TO TREAT ALZHEIMER'S DISEASE AND OTHER DEVASTATING DISORDERS OF THE NERVOUS SYSTEM. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023017S

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY HENRY PAN, PHD, ENTITLED: (A2023019F) FIDELITY OF TAU STRAIN TRANSMISSION: A FLUORESCENCE IN SITU AND CRYO-EM STRUCTURAL CHARACTERIZATION STUDY. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE AND ALZHEIMER'S RELATED DISEASES (ADRD) ARE PROTEIN CONFORMATIONAL DISEASES, WHERE THE SAME PROTEIN SUCH AS TAU CAN TAKE ON A DIVERSE RANGE OF CONFORMATIONAL STRAINS EACH ONE ASSOCIATED WITH A DIFFERENT DISEASE. MODELING TAU STRAINS CORRECTLY IS IMPORTANT FOR MECHANISTIC BIOLOGICAL STUDIES AND PRECLINICAL DRUG DEVELOPMENT STUDIES. THIS PROPOSAL SEEKS TO DEVELOP METHODS THAT CAN RAPIDLY SCREEN FOR FIBRIL STRAINS IN CELL AND TRANSGENIC RODENT MODELS TO ISOLATE STRAINS OF INTEREST FROM HETEROGENEOUS SAMPLES FOR CRYO-EM STRUCTURAL CHARACTERIZATION. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023019F

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF KENTUCKY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY KATE FOLEY, PHD, ENTITLED: (A2023020F) DETERMINING THE MECHANISMS OF ANTI-A-BETA IMMUNOTHERAPY ON CEREBROVASCULAR DYSFUNCTION. INVESTIGATOR'S SUMMARY: WITH RECENT FDA

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
--	--

APPROVAL OF ANTI-A-BETA IMMUNOTHERAPIES TO TREAT ALZHEIMER'S DISEASE,
IT IS IMPERATIVE TO UNDERSTAND HOW TO MITIGATE THE CEREBROVASCULAR SIDE
EFFECTS CAUSED BY THESE THERAPIES. THIS PROPOSAL WILL CHARACTERIZE THE
CELLULAR RESPONSE TO ANTI-A-BETA ANTIBODY TREATMENT, AS WELL AS
DETERMINE THE ROLE OF A VASCULAR DAMAGING PROTEIN, MMP9, IN PREVENTING
THE CEREBROVASCULAR DEFICITS THAT RESULT FROM ANTI-A-BETA ANTIBODY
THERAPY. THIS PROJECT WILL IDENTIFY TARGETABLE PATHWAYS TO HELP REDUCE
CEREBROVASCULAR ADVERSE EVENTS ASSOCIATED WITH ANTI-A-BETA
IMMUNOTHERAPIES. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:
WWW.BRIGHTFOCUS.ORG/GRANT/A2023020F

NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS GENERAL HOSPITAL. (H)

PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY MARIA VIRTUDES
SANCHEZ MICO, PHD, ENTITLED: (A2023021F) IN VIVO IMAGING OF ASTROGLIAL
DYSFUNCTION IN A MOUSE MODEL OF ALZHEIMER'S DISEASE. INVESTIGATOR'S
SUMMARY: ASTROCYTES PLAY AN ESSENTIAL METABOLIC ROLE TO SUPPORT ENERGY
REQUIREMENTS OF BRAIN CELLS. IMPAIRMENT OF ASTROGLIAL METABOLISM IS
THOUGHT TO ACCELERATE NEURONAL DEGENERATION AND WORSEN ALZHEIMER'S
DISEASE (AD). THUS, THERE IS AN URGENT NEED TO FULLY UNDERSTAND
ASTROGLIAL METABOLIC DYSFUNCTION. HERE, WE WILL IMAGE THE ASTROGLIAL
METABOLISM IN THE BRAINS OF LIVING AD MOUSE MODEL USING FLUORESCENT
REPORTER MOLECULES AND MULTIPHOTON MICROSCOPY. THE OUTCOME OF OUR
EXPERIMENTS WOULD FACILITATE THE DEVELOPMENT OF NEW THERAPEUTIC
STRATEGIES TO PREVENT OR REVERSE THE PROGRESSION OF THIS DEVASTATING
DISEASE FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:
WWW.BRIGHTFOCUS.ORG/GRANT/A2023021F

SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED:

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
---	---

NAME OF ORGANIZATION OR GOVERNMENT: YALE UNIVERSITY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY CARLA ROTHLIN, PHD, ENTITLED: (A2023022S) FUNCTIONAL UNDERSTANDING OF AXL EFFECTOR ROLE(S) IN MICROGLIA TOWARDS DEVELOPING DISEASE MODIFYING THERAPIES IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: WE HAVE IDENTIFIED A PROTEIN EXPRESSED IN BRAIN IMMUNE CELLS THAT MAKES THESE CELLS BETTER AT PROTECTING AGAINST ALZHEIMER'S DISEASE (AD). HERE WE ENVISION TO UNDERSTAND EXACTLY HOW THIS PROTEIN FUNCTIONS BY ENGULFING AND REMOVING A-BETA PLAQUES OR BY DAMPENING INFLAMMATION TO PREVENT AD-ASSOCIATED NEUROINFLAMMATION. WE WILL ALSO BETTER UNDERSTAND THE SEQUENCE OF EVENTS LEADING TO THE IMPROVED ACTIVITY OF THIS PROTEIN THAT PROTECTS AGAINST COGNITIVE DECLINE. THIS KNOWLEDGE WILL ENABLE US TO DEVELOP THERAPEUTICS TO IMPROVE DISEASE OUTCOME IN AD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023022S

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN DIEGO. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY SUBHOJIT ROY, MD, PHD, ENTITLED: (A2023023S) THERAPEUTIC GENE-EDITING IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: OUR OVERALL GOAL IS TO TAKE A CRISPR BASED GENE THERAPY FOR ALZHEIMER'S DISEASE (AD) TO THE CLINIC. BROADLY SPEAKING, OUR APPROACH RESTORES THE PHYSIOLOGIC BALANCE OF THE AMYLOID PATHWAY DECREASING NEUROTOXIC PROTEIN FRAGMENTS, WHILE PROMOTING NEUROPROTECTIVE PROTEIN FRAGMENTS. THERE ARE OVER 100 ONGOING CLINICAL TRIALS WORLDWIDE USING CRISPRS, AND THE RESULTS SO FAR WITH NON-NEUROLOGIC DISORDERS HAVE SHOWN UNPRECEDENTED (ALMOST 100%) EFFICACY. OUR BROAD VISION IS TO APPLY CRISPRS FOR DEVASTATING NEUROLOGIC ILLNESSES LIKE AD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023023S

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
---	---

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF KENTUCKY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY DANIEL C. LEE, PHD, ENTITLED: (A2023025S) CITRULLINATED TAU AS A THERAPEUTIC TARGET IN TAUOPATHIES. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE (AD) CONTINUES TO IMPACT NEURONAL HEALTH. TAU PATHOLOGY IS DIVERSE DESPITE BEING A SINGLE PROTEIN AND ALSO REMAINS THE CLOSEST COROLLARY TO MEMORY LOSS AND NEURODEGENERATION. TAU DIVERSITY LIKELY COMES FROM DIFFERENT CELLULAR MODIFICATIONS ON THE TAU PROTEIN. WE DISCOVERED A NEW MODIFICATION ON TAU CALLED CITRULLINATION WHICH CHANGES THE AMINO ACID ARGININE TO A CITRULLINE. WE HYPOTHEZIZE THAT CITRULLINATION TO TAU CAUSES MORE TOXICITY IN THE BRAIN. WE WILL TEST CITRULLINATION INHIBITORS AND VACCINES AGAINST CITRULLINATED TAU IN MICE THAT DEVELOP HALLMARKS OF AD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023025S

NAME OF ORGANIZATION OR GOVERNMENT: MAYO CLINIC, JACKSONVILLE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ENTITLED: (CA2021010) MOLECULAR NEURODEGENERATION JOURNAL. INVESTIGATOR'S SUMMARY: THE AIM OF MOLECULAR NEURODEGENERATION (MN) JOURNAL (HTTPS://MOLECULARNEURODEGENERATION.BIOMEDCENTRAL.COM/) IS TO SERVE THE SCIENTIFIC COMMUNITY BY PUBLISHING HIGH-IMPACT, HIGH-QUALITY, AND FRONT-LINE RESEARCH DISCOVERIES IN DIVERSE AREAS OF NEURODEGENERATIVE DISEASES INCLUDING ALZHEIMER'S DISEASE AND EYE-RELATED DEGENERATIVE CONDITIONS. MN IS THE OFFICIAL JOURNAL OF THE BRIGHTFOCUS FOUNDATION. ALL ARTICLES ARE FREE AND PERMANENTLY ACCESSIBLE ONLINE, WITHOUT SUBSCRIPTION CHARGES OR REGISTRATION BARRIERS. THE JOURNAL HAS SEEN FURTHER GROWTH IN RECENT YEARS IN PARTICULAR IN THE AREA OF SCIENTIFIC

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
---	---

IMPACT AND REPUTATION. SOME OF THESE ARE REFLECTED IN THE FOLLOWING METRICS: 1) THE IMPACT FACTOR OF MOLECULAR NEURODEGENERATION, THE OFFICIAL SCIENTIFIC JOURNAL OF BRIGHTFOCUS FOUNDATION, HAS RISEN TO 18.879, ACCORDING TO ITS PUBLISHER, UP FROM 14.195 A YEAR AGO (33% INCREASE).; 2) IT IS NOW THE TOP-RANKED OPEN-ACCESS PUBLICATION IN ITS FIELD, ON PAR WITH OTHER HIGH-IMPACT JOURNALS INCLUDING NEURON, JOURNAL OF EXPERIMENTAL MEDICINE AND NATURE COMMUNICATIONS. A SCIENTIFIC JOURNAL'S IMPACT FACTOR IS DERIVED FROM HOW OFTEN ITS ARTICLES ARE CITED IN SCIENTIFIC LITERATURE DURING A PARTICULAR TIME PERIOD AND REFLECTS THE JOURNAL'S INFLUENCE IN SHAPING AND LEADING SCIENTIFIC PROGRESS. JOURNALS WITH HIGHER IMPACT FACTORS ARE CONSIDERED MORE PRESTIGIOUS AND HAVE HIGHER STANDARDS FOR PUBLICATION.; 3) THE JOURNAL HAS BEEN RANKED AS THE NUMBER ONE OPEN-ACCESS JOURNAL IN THE NEUROSCIENCE CATEGORY FOR NINE YEARS IN A ROW (2013 PRESENT) AND IS RANKED NO. 7 AMONG ALL 274 NEUROSCIENCE JOURNALS. AMONG THE TOP 10, MOLECULAR NEURODEGENERATION IS THE ONLY OPEN-ACCESS JOURNAL.

NAME OF ORGANIZATION OR GOVERNMENT: LUMIND IDSC. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH ENTITLED: MODELING THE IMPACT OF RESEARCH INVESTMENT ON ALZHEIMER'S DISEASE IN DOWN SYNDROME: CAREGIVING AND SOCIETAL COSTS.

NAME OF ORGANIZATION OR GOVERNMENT: INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH TRAVEL GRANTS FOR CONFERENCE ATTENDANCE.

NAME OF ORGANIZATION OR GOVERNMENT: INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
--	--

BY ENTITLED: (CA2021011) MOLECULAR NEURODEGENERATION JOURNAL.

INVESTIGATOR'S SUMMARY: THIS AWARD IS FOR THE CREATION, AND GROWTH OF, THE "INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION (ISMND) AND SUPPORT OF ITS BI-ANNUAL MEETINGS AND EDUCATIONAL AND SCIENTIFIC PURPOSES. IN ACCORDANCE WITH SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE AND THE PROVISIONS OF THE FLORIDA NOT FOR PROFIT CORPORATION ACT. THE INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION (ISMND) SHALL BE ORGANIZED AND OPERATED PRIMARILY AND EXCLUSIVELY FOR EDUCATIONAL AND SCIENTIFIC PURPOSES. THE INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION'S MISSION IS TO SERVE AS AN ACCELERATOR FOR THE CONTINUOUS IMPROVEMENT OF BRAIN AND EYE HEALTH AND WELL-BEING BY CREATING A MULTIDISCIPLINARY GLOBAL PLATFORM FOR SCIENTISTS, PHYSICIANS, AND THE PUBLIC FROM DIFFERENT FACETS AND SCIENTIFIC DISCIPLINES TO MORE READILY CONNECT, SHARE AND COMMUNICATE SCIENTIFIC DISCOVERIES, AND DEVELOP CURES FOR NEURODEGENERATIVE DISEASES, IN THE HOPES OF A WORLD FREE OF BRAIN AND EYE DISEASES.

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, IRVINE.

(H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH TRAVEL GRANTS FOR CONFERENCE ATTENDANCE.

NAME OF ORGANIZATION OR GOVERNMENT: FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY SJOERD FINNEMA, PHD, ENTITLED: (CA2021012) SV2A PET AS A BIOMARKER OF SYNAPTIC DENSITY. INVESTIGATOR'S SUMMARY: THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH (FNIH) BIOMARKERS CONSORTIUM (BC) HAS LAUNCHED A PROJECT THAT SIGNALS A PARADIGM SHIFT IN OUR METHODS TO IMAGE THE BRAIN. USING ADVANCES IN PET (POSITRON EMISSION TOPOGRAPHY)

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
---	---

TECHNOLOGY, THE PROJECT WILL FOCUS ON MEASURING THE INTEGRITY OF SYNAPSESTINY GAPS THAT CONNECT NEURONS AND COMMUNICATE INFORMATION TO THE BRAIN. LOSS OF THESE SYNAPSE CONNECTIONS STRONGLY CORRELATES WITH COGNITIVE DECLINE IN ALZHEIMER'S DISEASE (AD). A NEW IMAGING TOOL TO TRACK THIS BIOLOGICAL INDICATOR OF DISEASE PROGRESSION AND OF PATIENT RESPONSE TO THERAPEUTIC INTERVENTIONS WOULD BE A CATALYST IN THE DEVELOPMENT OF CLINICALLY EFFECTIVE TREATMENTS FOR AD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:
WWW.BRIGHTFOCUS.ORG/GRANT/CA2021012

SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED:

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF COLORADO. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY LOTTA GRANHOLM, PHD, ENTITLED: (CA2018010) INTERNATIONAL BRAIN BANK FOR DOWN SYNDROME-RELATED ALZHEIMER'S DISEASE. EMERGENCY RELIEF SUPPLEMENT DUE TO COVID-19. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:
WWW.BRIGHTFOCUS.ORG/GRANT/CA2018010

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF SOUTHERN CALIFORNIA. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JINKOOK LEE, PHD, ENTITLED: (CA2023001) EXPANDING AND ENHANCING LASI-DAD FOR BETTER UNDERSTANDING OF ALZHEIMER'S DISEASE AND DEMENTIA. INVESTIGATOR'S SUMMARY: THIS PROJECT WILL EXPAND AND ENHANCE THE ONGOING LONGITUDINAL AGING STUDY IN INDIA DIAGNOSTIC ASSESSMENT OF DEMENTIA (LASI-DAD) BY EXPLORING HOW DNA METHYLATION OF ALZHEIMER'S ASSOCIATED GENES IS ASSOCIATED WITH COGNITION AND DEMENTIA. IT WILL FURTHER VALIDATE PREVIOUS FINDINGS FROM THE LASI-DAD TO COMPARE THE ACCURACY OF FINDINGS WITH GOLD STANDARD MEASURES OF COGNITION AND BLOOD BIOMARKERS. FOR MORE

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
---	---

INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

WWW.BRIGHTFOCUS.ORG/GRANT/CA2023001

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, BERKELEY.

(H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY SHUBHAM MAURYA, PHD, ENTITLED: (G2023001F) REGULATION OF MICROGLIAL PHENOTYPE BY NEUROPROTECTIVE LXB4 IN OCULAR HYPERTENSION-INDUCED NEUROPATHY.

INVESTIGATOR'S SUMMARY: WE HAD IDENTIFIED A NOVEL WAY TO STOP THE DEATH OF RETINAL CELLS IN MICE GLAUCOMATOUS EYES USING SMALL MOLECULE LIPID MEDIATORS. THESE LIPID MEDIATORS HAVE BIOACTIONS IN MODULATING THE FUNCTIONS OF A RESIDENT IMMUNE CELL TYPE IN THE RETINA, I.E., MICROGLIA. THIS PROJECT INTENDS TO STUDY THE REGULATION OF MICROGLIA BY LIPIDS MEDIATORS DURING GLAUCOMA PROGRESSION TO STOP OR PREVENT THE DISEASE. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

WWW.BRIGHTFOCUS.ORG/GRANT/G2023001F

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF WISCONSIN-MADISON.

(H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY KAZUYA OIKAWA, PHD, BVSC, ENTITLED: (G2023003F) MODULATION OF NEUROINFLAMMATION IN GLAUCOMA BY GLP-1R AGONIST. INVESTIGATOR'S SUMMARY: INFLAMMATION OF THE NERVOUS SYSTEM TISSUE CONTRIBUTES TO BLINDING LOSS OF NERVE CELLS IN THE EYE AND BRAIN IN GLAUCOMA. IN THIS PROJECT, WE AIM TO REPURPOSE AN EXISTING FDA-APPROVED DRUG TO MODIFY THIS INFLAMMATORY RESPONSE WITH THE GOAL OF IDENTIFYING A POTENTIAL NEW THERAPY TO HELP PRESERVE VISION IN PATIENTS WITH GLAUCOMA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

WWW.BRIGHTFOCUS.ORG/GRANT/G2023003F

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, BERKELEY.

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
---	---

(H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY KARTHIK SHEKHAR, PHD, ENTITLED: (G2023004S) A SPATIAL TRANSCRIPTOMICS APPROACH TO IDENTIFY MOLECULAR CHANGES AND MULTICELLULAR INTERACTIONS UNDERLYING RETINAL NEURODEGENERATION IN GLAUCOMA. INVESTIGATOR'S SUMMARY: TO IDENTIFY NOVEL MOLECULAR TARGETS THAT CAN SLOW DOWN RELENTLESS RETINAL GANGLION CELL (RGC) DEATH IN GLAUCOMA, WE NEED TO UNDERSTAND MOLECULAR PATHWAYS AND MULTI-CELLULAR INTERACTIONS THAT UNDERLIE RGC SUSCEPTIBILITY. WE WILL COMBINE INNOVATIVE SPATIAL PROFILING TECHNOLOGIES, MOUSE MODELS, AND MACHINE LEARNING TO UNDERSTAND RGC DEGENERATION AND THE ROLE OF THE MICROENVIRONMENT IN GLAUCOMA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2023004S

NAME OF ORGANIZATION OR GOVERNMENT: GEORGIA TECH RESEARCH CORPORATION.

(H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY MARK PRAUSNITZ, PHD, ENTITLED: (G2023007S) NON-DRUG, NON-SURGICAL HYDROGEL-BASED TREATMENT OF GLAUCOMA. INVESTIGATOR'S SUMMARY: REDUCING INTRAOCULAR PRESSURE (IOP) IS THE ONLY GLAUCOMA TREATMENT, BUT IS OFTEN INEFFECTIVE DUE TO POOR PATIENT COMPLIANCE AND SURGICAL COMPLICATIONS. WE DEVELOPED A NON-DRUG, NON-SURGICAL METHOD TO LOWER IOP BY INJECTING A HYDROGEL TO EXPAND THE SUPRACHOROIDAL SPACE OF THE EYE. HERE WE OPTIMIZE THE HYDROGEL TO PROLONG IOP LOWERING, EVALUATE ITS SAFETY AND EFFICACY AND STUDY MECHANISMS OF ACTION. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2023007S

NAME OF ORGANIZATION OR GOVERNMENT: DUKE UNIVERSITY SCHOOL OF MEDICINE.

(H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY RUPALATHA MADDALA, PHD, ENTITLED: (G2023008S) ROLE OF SEPTIN CYTOSKELETON IN TRABECULAR

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
--	--

MESHWORK, IOP AND GLAUCOMA. INVESTIGATOR'S SUMMARY: STUDIES DESCRIBED IN THIS PROPOSAL ARE FOCUSED ON INVESTIGATING THE ROLE OF SEPTINS WHICH ARE IDENTIFIED AS THE RISK LOCI FOR OCULAR HYPERTENSION AND GLAUCOMA IN THE HOMEOSTASIS OF AQUEOUS HUMOR OUTFLOW AND INTRAOCULAR PRESSURE. AS WE LACK AN UNDERSTANDING OF HOW SEPTINS MAY INFLUENCE OCULAR PRESSURE, COMPLETION OF THE STUDIES PLANNED IN THIS APPLICATION ARE EXPECTED TO SHED LIGHT ON THIS QUESTION. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2023008S

NAME OF ORGANIZATION OR GOVERNMENT: INDIANA UNIVERSITY, INDIANAPOLIS.

(H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY WEIMING MAO, PHD, ENTITLED: (G2023009S) A NOVEL MOUSE ANTERIOR SEGMENT PERFUSION CULTURE MODEL FOR MEASURING OUTFLOW FACILITY AND LONG-TERM PERFUSION CULTURE.

INVESTIGATOR'S SUMMARY: GLAUCOMA IS A LEADING CAUSE OF BLINDNESS. THE MOST IMPORTANT RISK FACTOR OF GLAUCOMA IS HIGH PRESSURE INSIDE THE EYE. THIS PRESSURE ELEVATION IS DUE TO HIGH DRAINAGE RESISTANCE OF THE FLUID THAT FILLS THE EYE. TO BETTER UNDERSTAND THIS PRESSURE ELEVATION, LAB MICE HAVE BEEN WIDELY USED AS A RESEARCH MODEL. WE WILL DEVELOP A NOVEL METHOD TO MEASURE THIS DRAINAGE RESISTANCE IN MOUSE EYES. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

WWW.BRIGHTFOCUS.ORG/GRANT/G2023009S

NAME OF ORGANIZATION OR GOVERNMENT: JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY JITHIN YOHANNAN, MD, ENTITLED: (G2023010S) DEVELOPING DEEP LEARNING APPROACHES TO REDUCE THE BURDEN OF GLAUCOMA CLINICAL TRIALS. INVESTIGATOR'S SUMMARY: CLINICAL TRIALS OF NEW GLAUCOMA DRUGS (NEUROPROTECTIVE AGENTS) ARE DIFFICULT BECAUSE THE WORSENING OF GLAUCOMA MUST BE TRACKED WITH

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
---	---

VISUAL FIELD TESTING, WHICH IS VARIABLE AND ONEROUS. IN THIS PROPOSAL, WE DEVELOP AI MODELS THAT WILL REDUCE TRIAL TIME, COST, AND BURDEN BY 1) IDENTIFYING THE BEST CANDIDATES TO ENROLL IN TRIALS AND 2) USING DATA BEYOND THE VISUAL FIELD TO DETECT WORSENING. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2023010S

SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED:

NAME OF ORGANIZATION OR GOVERNMENT: INTERNATIONAL SOCIETY FOR EYE RESEARCH. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH TRAVEL GRANTS FOR CONFERENCE ATTENDANCE.

NAME OF ORGANIZATION OR GOVERNMENT: GEORGIA INSTITUTE OF TECHNOLOGY. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY C. ROSS ETHIER, PHD, ENTITLED: (CG2020001) SELECTIVE TARGETING OF SCHLEMM'S CANAL INNER WALL FOR NEXT-GENERATION GLAUCOMA DRUGS: SUBPART A. INVESTIGATOR'S SUMMARY: ALL TREATMENTS FOR GLAUCOMA SEEK TO LOWER INTRAOCULAR PRESSURE (IOP), YET EXISTING APPROACHES ARE INSUFFICIENT. WE NOW UNDERSTAND THAT ENDOTHELIAL CELL OF THE INNER WALL OF SCHLEMM'S CANAL (SC) PLAY A KEY ROLE IN HOMEOSTATIC CONTROL MECHANISMS THAT MAINTAIN IOP WITHIN A TARGET RANGE. HOWEVER, TOOLS FOR DIRECTLY ASSESSING SC INNER WALL ENDOTHELIAL FUNCTION ARE LACKING, AS ARE MOLECULAR APPROACHES FOR DIRECTLY TARGETING AND INTERROGATING THESE CELLS. THE LONG-TERM GOAL OF THIS INTER-DEPENDENT, MULTIPLE PRINCIPAL INVESTIGATOR AND GRANTEE INSTITUTION-ASSOCIATED PROJECT IS TO DEVELOP NOVEL THERAPIES THAT DIRECTLY TARGET SC CELLS TO IMPROVE IOP CONTROL. THESE TARGETED THERAPIES WILL BE HIGHLY EFFECTIVE DUE THEIR SPECIFICITY, AND WILL THUS GREATLY BENEFIT GLAUCOMA PATIENTS. TO ACCOMPLISH THIS GOAL, WE HAVE ASSEMBLED AN OUTSTANDING TEAM THAT BRINGS TOGETHER ALL NECESSARY

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
---	---

EXPERTISE TO INTERVENE IN THIS COMPLEX SYSTEM. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/CG2020001

NAME OF ORGANIZATION OR GOVERNMENT: DUKE UNIVERSITY. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY W. DANIEL STAMER, PHD, ENTITLED: (CG2020002) SELECTIVE TARGETING OF SCHLEMM'S CANAL INNER WALL FOR NEXT-GENERATION GLAUCOMA DRUGS: SUBPART B. INVESTIGATOR'S SUMMARY: FOR THE PROJECT, WE WILL SCREEN CANDIDATE ADENO ASSOCIATED VIRUSES AND ENGINEERED PROMOTERS CLONED INTO LENTIVIRUSES OBTAINED FROM COLLABORATORS IN HUMAN SCHLEMM'S CANAL CELLS IN VITRO AND ANTERIOR SEGMENTS EX VIVO FOR SELECTIVE TROPISM TO/ACTIVITY IN TRABECULAR MESHWORK VERSUS SCHLEMM'S CANAL. WE WILL UTILIZE RECENTLY VALIDATED VIRUS TECHNOLOGY (ENOS PROMOTERS DRIVING XFP OR SEAP REPORTER PROTEINS) TO TRANSDUCE SCHLEMM'S CANAL IN HUMAN ANTERIOR SEGMENTS AND MONITOR SHEAR STRESS LEVELS AND LOCATION THROUGHOUT SCHLEMM'S CANAL. WE WILL PROVIDE A STEADY SUPPLY OF SCHLEMM'S CANAL CELLS FOR DEVELOPMENT AND TESTING OF DRUG SCREENING PLATFORMS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/CG2020002

NAME OF ORGANIZATION OR GOVERNMENT: COLUMBIA UNIVERSITY. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY SIMON JOHN, PHD, ENTITLED: (CG2020004) SELECTIVE TARGETING OF SCHLEMM'S CANAL INNER WALL FOR NEXT-GENERATION GLAUCOMA DRUGS: SUBPART D. INVESTIGATOR'S SUMMARY: THE PROJECT AIMS TO DEVELOP AND TEST RESOURCES FOR SCHLEMM'S CANAL SPECIFIC TARGETING AND EXPRESSION OF GENES FOR GENE THERAPY. SUCCESSFUL DEVELOPMENT OF THIS TARGETED THERAPY WILL HELP CONTROL EYE PRESSURE MORE EFFECTIVELY AND PROVIDE BETTER TREATMENT OPTIONS FOR GLAUCOMA PATIENTS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
---	---

WWW.BRIGHTFOCUS.ORG/GRANT/CG2020004

NAME OF ORGANIZATION OR GOVERNMENT: STANFORD UNIVERSITY. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY JEFFREY GOLDBERG, PHD, ENTITLED: (CG2022001) A RANDOMIZED, SHAM CONTROLLED, MASKED PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF DUAL INTRAVITREAL IMPLANTATION OF NEUROPROTECTIVE CELL THERAPY FOR THE TREATMENT OF GLAUCOMA.

INVESTIGATOR'S SUMMARY: THE PROPOSED PROJECT IS AN EXTENSION OF THE CURRENT PHASE 2 CLINICAL TRIAL, TO ASSESS AND VALIDATE THE USE OF DUAL NT-501 CNTF ENCAPSULATED CELL THERAPY (ECT) ON VISUAL IMPAIRMENT RELATED TO GLAUCOMA, IN HUMAN SUBJECTS. THE PROPOSED STUDY IS DESIGNED TO EXPAND OUR KNOWLEDGE OF THE DOSE-DEPENDENT EFFECT OF CNTF IN GLAUCOMA THROUGH DUAL IMPLANTATION OF NT-501 ECT. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/CG2022001

NAME OF ORGANIZATION OR GOVERNMENT: THE JACKSON LABORATORY. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY NAVDEEP GOGNA, PHD, ENTITLED: (M2023001F) MITOCHONDRIAL DYSFUNCTION AS A KEY MEDIATOR OF AMD-LIKE PHENOTYPES IN HUMANIZED ARMS2A69S MICE. INVESTIGATOR'S SUMMARY: VARIATIONS IN THE PRIMATE SPECIFIC GENE ARMS2 ARE IMPLICATED IN AGE-RELATED MACULAR DEGENERATION (AMD). HOWEVER, THE MECHANISMS BY WHICH ARMS2 INCREASES AMD RISK ARE NOT KNOWN. THE NISHINA LAB HAS DEVELOPED NEW HUMANIZED MOUSE MODELS TO STUDY THE ROLE OF ARMS2 IN AMD. PRELIMINARY RESULTS SUGGEST EARLY CHANGES IN MITOCHONDRIAL GENES, ALTERED LIPID METABOLISM AND AGE-ASSOCIATED AMD-LIKE PHENOTYPES IN THE MODEL. THIS STUDY WILL IDENTIFY ALTERATIONS IN MITOCHONDRIA AND LIPID METABOLISM DUE TO ARMS2A69S RISK VARIANT, IN AMD DEVELOPMENT, THAT COULD BE TARGETED FOR THERAPEUTIC BENEFIT. FOR MORE INFORMATION, VISIT

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
---	---

THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2023001F

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF PENNSYLVANIA. (H)

PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY CATHARINA GRUBAUGH, PHD, ENTITLED: (M2023002F) MICROSOMAL TRANSFER PROTEIN IN RETINAL LIPID HOMEOSTASIS, IMPLICATIONS FOR AMD. INVESTIGATOR'S SUMMARY: RECENT RESEARCH HAS INCREASINGLY LINKED AGE-RELATED MACULAR DEGENERATION (AMD) TO LIPID DYSREGULATION IN THE EYE. ONE OF THE MOST IMPORTANT ROLES OF THE RETINAL PIGMENT EPITHELIUM (RPE) IS THE PROCESSING AND TRANSPORT OF LIPIDS. MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP), ENCODED BY THE MTTP GENE, REGULATES LIPID PACKAGING IN THE RPE. WE HAVE GENERATED THE RPEDELMTTP MOUSE, IN WHICH MTTP IS KNOCKED OUT IN THE RPE BUT EXPRESSED NORMALLY IN OTHER TISSUES. WE WILL TEST THE HYPOTHESIS THAT MTP-MEDIATED LIPID PACKAGING IN THE RPE IS NECESSARY TO MAINTAIN RETINAL HEALTH AND VISUAL FUNCTION. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2023002F

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN

DIEGO. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY JACLYN SWAN, PHD, ENTITLED: (M2023003F) THE GLYCANS OF THE HUMAN RETINA AND THEIR INTERACTION WITH COMPLEMENT FACTOR H. INVESTIGATOR'S SUMMARY: ALL CELLS IN THE HUMAN BODY ARE COVERED IN A COMPLEX SUGAR COAT, THE GLYCOCALYX. THIS MOLECULAR COAT IS CRUCIAL FOR CELL-TO-CELL COMMUNICATION AND IMMUNE SURVEILLANCE. AN UNDERLYING MECHANISM OF AGE-RELATED MACULAR DEGENERATION (AMD) IS THE DYSREGULATION OF THE INNATE IMMUNE SYSTEM. THE GLYCOCALYX IS INVOLVED IN REGULATING THESE SYSTEMS. CURRENTLY, WE DON'T KNOW THE PRECISE COMPOSITION OF THE SUGAR COATS ON CELLS IN THE EYE AT THE SITE WHERE AMD OCCURS. WE WILL

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
---	---

CHARACTERIZE THE GLYCOCALYX OF DISEASED AND HEALTHY EYES TO TEST WHETHER DIFFERENCES CONTRIBUTE TO IMMUNOLOGICAL CONSEQUENCES. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2023003F

SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED:

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF WASHINGTON. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY RAYNE LIM, PHD, ENTITLED: (M2023004F) FACTOR H-LIKE PROTEIN 1 INSUFFICIENCY IN RETINAL PIGMENT EPITHELIUM. INVESTIGATOR'S SUMMARY: EARLY ONSET MACULAR DRUSEN (EOMD) IS AN INHERITED, SEVERE FORM OF AGE-RELATED MACULAR DEGENERATION (AMD). WE FOUND THAT RETINAL PIGMENTED EPITHELIUM (RPE) CELLS MADE FROM EOMD PATIENTS HAVE DECREASED (ABOUT 50%) EXPRESSION OF TWO IMPORTANT COMPLEMENT PROTEINS, CFH AND FHL-1. THIS SIGNIFICANT DECREASE MAY ALTER LOCAL COMPLEMENT ACTIVITY AND RPE METABOLISM. WE WILL STUDY EOMD PATIENT RPE, THEIR GENE-EDITED CONTROLS, AND DETERMINE WHETHER ADDING THE FHL-1 GENE BACK TO THE EOMD CELLS WILL HELP ATTENUATE THESE PATHOGENIC CHANGES. THIS PROJECT WILL HELP OUR UNDERSTANDING OF AMD DISEASE PATHOGENESIS AND TREATMENT. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2023004F

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY SANGEETHA KANDOI, PHD, ENTITLED: (M2023005F) PHOTORECEPTOR REMODELING IN THE HIBERNATING CONE-DOMINANT 13-LINED GROUND SQUIRREL AS A MODEL FOR MACULAR DEGENERATION IN HUMANS. INVESTIGATOR'S SUMMARY: THE CONE PHOTORECEPTORS EXCLUSIVELY POPULATE THE SMALL CENTRAL REGION WITHIN THE HUMAN RETINA AND PROVIDE HIGH ACUITY, AND COLOR VISION. THE LOSS OF

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
--	--

CONES IS AN ENDPOINT OF AGE-RELATED MACULAR DEGENERATION (AMD), THE LEADING CAUSE OF BLINDNESS IN INDIVIDUALS >50 YEARS OLD. OUR STUDY UTILIZES 13-LINED GROUND SQUIRREL (13-LGS), WHICH HAS 85% CONES OVERALL AND HIBERNATES IN WINTER. THE ABUNDANCE OF CONES, AND EVOLVED PROTECTION AGAINST HIBERNATION STRESS ON CONES SUGGEST THAT THE 13-LGS COULD BE A CLINICALLY RELEVANT MODEL FOR EXPLORING INNOVATIVE THERAPIES FOR CATASTROPHIC VISION LOSS IN AMD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2023005F

NAME OF ORGANIZATION OR GOVERNMENT: WASHINGTON UNIVERSITY IN ST. LOUIS.

(H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY JAMES WALSH, MD, PHD, ENTITLED: (M2023006F) DYSREGULATED CHOROIDAL ADAPTIVE IMMUNITY

EXACERBATES MACULAR DEGENERATION PATHOLOGY. INVESTIGATOR'S SUMMARY:

MACULAR DEGENERATION IS ONE OF THE LEADING CAUSES OF BLINDNESS IN THE US, YET THE EXACT DISEASE PROCESS THAT LEADS TO THE FINDINGS OF THIS DISEASE ARE NOT KNOWN. THERE HAVE BEEN CONSISTENT STUDIES THAT SHOW THAT THE ADAPTIVE IMMUNE SYSTEM IS ALTERED SYSTEMICALLY, BUT BECAUSE THE EYE HAS A REPUTATION FOR BEING IMMUNE PRIVILEGED, THE ROLE OF THE LOCAL ADAPTIVE IMMUNE SYSTEM IN THIS PROCESS HAS NOT BEEN EXPLORED. WE RECENTLY DISCOVERED THAT THERE IS A RICH ADAPTIVE LYMPHOID ENVIRONMENT IN THE CHOROID THAT COULD CONTRIBUTE TO THE DISEASE PROCESS, AND WILL EXPLORE THIS FURTHER IN THIS PROPOSAL. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2023006F

NAME OF ORGANIZATION OR GOVERNMENT: THE UNIVERSITY OF IOWA. (H) PURPOSE

OF GRANT: MACULAR DEGENERATION RESEARCH BY NARENDRA PANDALA, PHD,

ENTITLED: (M2023007F) AUTOLOGOUS CHOROIDAL ENDOTHELIAL CELL REPLACEMENT

FOR THE TREATMENT OF AMD. INVESTIGATOR'S SUMMARY: AGE RELATED MACULAR

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

DEGENERATION IS A LEADING CAUSE OF BLINDNESS IN THE U.S. IN THE DRY FORM OF THE DISEASE, THE MACULA, WHICH IS THE CENTRAL MOST PART OF THE RETINA THAT IS RESPONSIBLE FOR HIGH ACUITY VISION, DETERIORATES. RECENT STUDIES HAVE SHOWN THAT THE CAPILLARIES PRESENT UNDERNEATH THE RETINA IN THE CHOROID ARE LOST BEFORE RETINAL DEGENERATION. IN THIS PROJECT, WE PROPOSE TO DEVELOP AN EARLY INTERVENTION STRATEGY TO TRANSPLANT PATIENT-DERIVED CHOROIDAL STEM CELLS USING A BIOMATERIAL TO REPOPULATE THE LOST CAPILLARIES IN THE CHOROID AND THUS PREVENT FURTHER DAMAGE TO THE RETINA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2023007F

NAME OF ORGANIZATION OR GOVERNMENT: OREGON HEALTH & SCIENCE UNIVERSITY.

(H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY YALI JIA, PHD, ENTITLED: (M2023008I) IMAGING CHORIOCAPILLARIS HEMODYNAMIC DEFECTS IN AGE-RELATED MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: AGE-RELATED MACULAR DEGENERATION IS A LEADING CAUSE OF BLINDNESS. ADVANCED FORMS OF THE DISEASE THAT INCLUDE GEOGRAPHIC ATROPHY REMAIN WITHOUT TREATMENT OPTIONS. NEW THERAPIES ARE REQUIRED, BUT RESEARCH EFFORTS ARE STYMIED BY AN INABILITY TO ASSESS PRECURSOR PATHOLOGIES ADEQUATELY. IN PARTICULAR, METHODS FOR IMAGING THE HEALTH OF BLOOD VESSELS THAT SUPPLY REGIONS THREATENED BY DEGENERATION COULD PROVIDE A MEANS OF IDENTIFYING NEW THERAPEUTIC TARGETS. THIS PROPOSAL MEETS THIS NEED BY DEVELOPING A NEW INSTRUMENT THAT WILL BE ABLE TO CHARACTERIZE VASCULAR FUNCTION IN UNSURPASSED DETAIL. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2023008I

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF WISCONSIN-MADISON.

(H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY FREYA MOWAT,

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

PHD, ENTITLED: (M2023010N) RELEVANT GENE-DIET INTERACTIONS IN AMD: USE OF A MOUSE MODEL TO STUDY THE COMBINED EFFECTS OF AGE, HIGH GLYCEMIC DIET AND PGC1A INSUFFICIENCY. INVESTIGATOR'S SUMMARY: HUMAN AGE-RELATED MACULAR DEGENERATION (AMD) HAS MANY RISK FACTORS INCLUDING AGE, GENETICS, AND UNHEALTHY LIFESTYLE. COMBINING RISK FACTORS INCREASES THE CHANCE OF AMD. WE WILL STUDY THE COMBINED EFFECTS OF RISK FACTORS (AGING, GENETIC VARIANT IN A MITOCHONDRIAL REGULATOR, AND HIGH DIETARY GLUCOSE) IN AN ANIMAL MODEL. WE WILL DETERMINE THE EFFECT ON VISION, RETINAL STRUCTURE, DNA METHYLATION, GENE EXPRESSION, AND METABOLIC FUNCTION IN THE EYE. WE PREDICT THAT A COMBINATION OF ALL 3 RISK FACTORS WILL CAUSE THE DEVELOPMENT OF AMD-LIKE DISEASE, AND WE WILL DEFINE BIOLOGICAL PATHWAYS THAT ACT IN CONCERT TO INCREASE AMD RISK. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

WWW.BRIGHTFOCUS.ORG/GRANT/M2023010N

NAME OF ORGANIZATION OR GOVERNMENT: THE UNIVERSITY OF IOWA. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY KELLY MULFAUL, PHD, ENTITLED: (M2023011N) INVESTIGATING HUMAN CHOROIDAL MACROPHAGE RECRUITMENT AND ACTIVATION IN AGE-RELATED MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: AGE-RELATED MACULAR DEGENERATION (AMD) IS A LEADING CAUSE OF BLINDNESS WORLDWIDE. THE BACK OF THE EYE IS MADE UP OF CELL LAYERS THAT SUPPORT ONE ANOTHER SUPPLYING NUTRIENTS AND IMPORTANT MOLECULES THAT ARE REQUIRED FOR NORMAL VISION. IN AMD, THE OUTER SUPPORTING LAYER, THE CHOROID, IS DAMAGED. IMMUNE CELLS MOVE FROM THE CIRCULATION INTO CHOROID TISSUE IN RESPONSE TO DAMAGE TO PROTECT THE TISSUE. WE PREDICT THAT RECRUITED IMMUNE CELLS DO MORE DAMAGE THAN GOOD AND MAY BE INVOLVED IN THE DEATH OF THE CHOROID. WE AIM TO UNDERSTAND HOW THESE IMMUNE CELLS MOVE FROM THE CIRCULATION INTO THE TISSUE. FOR

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
---	---

MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

WWW.BRIGHTFOCUS.ORG/GRANT/M2023011N

NAME OF ORGANIZATION OR GOVERNMENT: THE UNIVERSITY OF TEXAS AT AUSTIN.

(H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY LYNDISAY LEACH,

PHD, ENTITLED: (M2023012N) TOWARD UNCOVERING THE INTRICACIES OF

INTRINSIC RPE REPAIR: IDENTIFYING IMMUNE-RELATED PRO-REGENERATIVE

FACTORS USING ZEBRAFISH RPE INJURY PARADIGMS. INVESTIGATOR'S SUMMARY:

MAMMALS, INCLUDING HUMANS, HAVE A LIMITED ABILITY TO REPAIR RPE TISSUE

LOST TO INJURY OR DEGENERATIVE DISEASES LIKE AGE-RELATED MACULAR

DEGENERATION. CONSEQUENTLY, LITTLE IS KNOWN ABOUT WHAT CELLULAR AND

MOLECULAR PROCESSES DRIVE RPE REGENERATION. THIS STUDY UTILIZES

ZEBRAFISH, A VERTEBRATE MODEL CAPABLE OF ROBUST TISSUE REPAIR, TO

BETTER UNDERSTAND THE IMMUNE-RELATED RESPONSES UNDERLYING RPE

REGENERATION AND CHRONIC RPE DAMAGE. THE PROPOSED RESEARCH WILL UNCOVER

NOVEL RPE PRO-REGENERATIVE FACTORS, WHICH HOLD POTENTIAL AS FUTURE

THERAPEUTIC TARGETS TO QUELL, OR EVEN REVERSE, RPE LOSS. FOR MORE

INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

WWW.BRIGHTFOCUS.ORG/GRANT/M2023012N

NAME OF ORGANIZATION OR GOVERNMENT: YALE UNIVERSITY. (H) PURPOSE OF

GRANT: MACULAR DEGENERATION RESEARCH BY ABDELILAH MAJDOUBI, PHD,

ENTITLED: (M2023013F) DECIPHERING THE INFLAMMATORY PATHWAYS TRIGGERING

AGE-RELATED MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: THE FACTORS

THAT LEAD TO CHRONIC INFLAMMATION AND VISION LOSS IN AGE-RELATED

MACULAR DEGENERATION ARE NOT WELL UNDERSTOOD. PREVIOUS GENETIC STUDIES

HIGHLIGHTED THE ROLE OF INFLAMMATORY MICROGLIA IN THE DISEASE. HOWEVER,

AS THESE CELLS ARE RARE IN THE RETINA, DEEP GENETIC ANALYSIS IS NEEDED

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
--	--

TO UNDERSTAND THE MECHANISM BY WHICH THESE CELLS CONTRIBUTE TO THE DISEASE. THE AIM OF THIS STUDY IS TO IDENTIFY DISTINCT SUBPOPULATIONS OF MICROGLIA AND DEFINE THE GENETIC FACTORS THAT REGULATE OR REINFORCE THEIR ROLE IN THE RETINAL INFLAMMATION, WHICH CAN HELP IDENTIFY POTENTIAL THERAPEUTIC TARGETS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2023013F

SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED:

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, IRVINE.
 (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY DOROTA SKOWRONSKA-KRAWCZYK, PHD, ENTITLED: (M2020271) ROLE OF ELOVL2 IN AGE RELATED CHANGES IN THE EYE. EMERGENCY RELIEF SUPPLEMENT DUE TO COVID-19. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2020271

NAME OF ORGANIZATION OR GOVERNMENT: HELEN KELLER FOUNDATION FOR RESEARCH & EDUCATION. (H) PURPOSE OF GRANT: 2022 HELEN KELLER PRIZE FOR VISION RESEARCH PARTNERSHIP. THE HELEN KELLER PRIZE FOR VISION RESEARCH RECOGNIZES SIGNIFICANT ACCOMPLISHMENTS IN VISION RESEARCH, AND PROVIDES FUNDS FOR CONTINUANCE OF THOSE STUDIES.

NAME OF ORGANIZATION OR GOVERNMENT: HELEN KELLER FOUNDATION FOR RESEARCH & EDUCATION. (H) PURPOSE OF GRANT: 2022 CONFERENCE SUPPORT.

NAME OF ORGANIZATION OR GOVERNMENT: ARVO FOUNDATION FOR EYE RESEARCH.
 (H) PURPOSE OF GRANT: 2022 EYEFIND RESEARCH GRANT SPONSORSHIP

NAME OF ORGANIZATION OR GOVERNMENT: ARVO FOUNDATION FOR EYE RESEARCH.

**SCHEDULE R
(Form 990)**

Department of the Treasury
Internal Revenue Service

Related Organizations and Unrelated Partnerships

Complete if the organization answered "Yes" on Form 990, Part IV, line 33, 34, 35b, 36, or 37.
Attach to Form 990.

Name of the organization

BRIGHTFOCUS FOUNDATION

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2022

Open to Public
Inspection

Employer identification number
23-7337229

Part I Identification of Disregarded Entities. Complete if the organization answered "Yes" on Form 990, Part IV, line 33.

(a) Name, address, and EIN (if applicable) of disregarded entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Total income	(e) End-of-year assets	(f) Direct controlling entity
NATIONAL DEVELOPMENT, LLC - 23-7337229 22512 GATEWAY CENTER DRIVE CLARKSBURG, MD 20871	PROPERTY RENTAL AND MANAGEMENT	MARYLAND	523,842.	3,820,008.	BRIGHTFOCUS FOUNDATION
AMERICAN HEALTH ASSISTANCE, LLC - 23-7337229 22512 GATEWAY CENTER DRIVE CLARKSBURG, MD 20871	OWNER OF BRIGHTFOCUS HEADQUARTERS	MARYLAND	0.	3,203,678.	BRIGHTFOCUS FOUNDATION

Part II Identification of Related Tax-Exempt Organizations. Complete if the organization answered "Yes" on Form 990, Part IV, line 34, because it had one or more related tax-exempt organizations during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Exempt Code section	(e) Public charity status (if section 501(c)(3))	(f) Direct controlling entity	(g) Section 512(b)(13) controlled entity?	
						Yes	No

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Schedule R (Form 990) 2022

Part V Transactions With Related Organizations. Complete if the organization answered "Yes" on Form 990, Part IV, line 34, 35b, or 36.

Note: Complete line 1 if any entity is listed in Parts II, III, or IV of this schedule.

1 During the tax year, did the organization engage in any of the following transactions with one or more related organizations listed in Parts II-IV?

	Yes	No
a Receipt of (i) interest, (ii) annuities, (iii) royalties, or (iv) rent from a controlled entity	1a	
b Gift, grant, or capital contribution to related organization(s)	1b	
c Gift, grant, or capital contribution from related organization(s)	1c	
d Loans or loan guarantees to or for related organization(s)	1d	
e Loans or loan guarantees by related organization(s)	1e	
f Dividends from related organization(s)	1f	
g Sale of assets to related organization(s)	1g	
h Purchase of assets from related organization(s)	1h	
i Exchange of assets with related organization(s)	1i	
j Lease of facilities, equipment, or other assets to related organization(s)	1j	
k Lease of facilities, equipment, or other assets from related organization(s)	1k	
l Performance of services or membership or fundraising solicitations for related organization(s)	1l	
m Performance of services or membership or fundraising solicitations by related organization(s)	1m	
n Sharing of facilities, equipment, mailing lists, or other assets with related organization(s)	1n	
o Sharing of paid employees with related organization(s)	1o	
p Reimbursement paid to related organization(s) for expenses	1p	
q Reimbursement paid by related organization(s) for expenses	1q	
r Other transfer of cash or property to related organization(s)	1r	
s Other transfer of cash or property from related organization(s)	1s	

2 If the answer to any of the above is "Yes," see the instructions for information on who must complete this line, including covered relationships and transaction thresholds.

	(a) Name of related organization	(b) Transaction type (a-s)	(c) Amount involved	(d) Method of determining amount involved
(1)				
(2)				
(3)				
(4)				
(5)				
(6)				

Part VII Supplemental Information

Provide additional information for responses to questions on Schedule R. See instructions.

Multiple horizontal lines for providing supplemental information.